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Systemic lupus erythematosus (SLE) is a chronic, rheumatic autoimmune disease 
in which pathogenic autoantibodies can cause inflammation throughout the whole body. 
Immunosuppressive drugs are often necessary to suppress this inflammation and to 
prevent tissue damage. Although immunosuppression is generally effective in controlling 
disease activity, these drugs can have numerous unpleasant and serious side effects. In 
addition, frequent exacerbations are characteristic of SLE, so that continuous treatment 
may be necessary. Although developments in immunosuppressive treatment have 
improved survival rates
1
, SLE remains a burdensome disease.  
An important contributor to the improved survival rates are advances in the 
treatment of one of the most serious and prevalent organ involvements of SLE, i.e., lupus 
nephritis.2 Although multiple pharmacological treatment regimens for lupus nephritis 
have been investigated over the last few decades, which treatment results in optimal 
renal outcome and the least side effects is still a matter of debate. Type and intensity of 
treatment are based on the results of renal biopsy3, which is a burdensome procedure for 
patients and gives risk of haemorrhages and infections.4 Therefore, it would be desirable 
to be able to keep the frequency of biopsies to a minimum. However, there is an ongoing 
discussion on whether repeat renal biopsies are necessary in the case of recurrent 
episodes of lupus nephritis. 
Studies investigating the preferred frequency of renal biopsies and optimal 
treatment for lupus nephritis focus on the effects on renal outcome. The impact of 
diagnosis and treatment on patients´ well-being has been given less attention. Quality of 
life (QoL) of SLE patients has been shown to be low5 and whether treatments that result in 
better renal outcome also lead to a better QoL is seldom investigated. In addition, even if 
there is a positive effect of improved renal outcome on QoL, this plausible relationship is 
not likely to be a unidirectional, straightforward cause-and-effect relationship. Besides 
disease and treatment characteristics, QoL of patients with a chronic illness is influenced 
by many other factors, such as demographics (e.g. age, culture) and psychological factors 
(e.g. emotions, coping). In addition, a patient’s level of QoL may in turn influence disease 
management through its effect on psychological determinants of treatment outcome, 
such as treatment adherence.
6
 The notion that the relationship between disease 
12 
characteristics and patients’ well-being is reciprocal and multifactorial and that therefore 
the patient and not the disease should be the centre of focus, is the key concept of the 
biopsychosocial model as proposed by Engel.
7
 This thesis reports on several studies aimed 
to describe a part of this complex interaction between disease- and patient-related factors 
from a biopsychosocial point of view. Hence, these studies do not only describe the results 
of optimization of diagnosis and treatment of lupus nephritis on renal outcome, but also 
the impact on patients’ well-being and its determinants. The theoretical background of 
the biopsychosocial and associated models will be discussed in the corresponding 
paragraphs.  
 
Repeat renal biopsies 
 At the first signs of lupus nephritis, a renal biopsy is necessary to define the 
classification of lupus nephritis. Lupus nephritis is divided into six different classes of 
varying severity and prognosis8, with an additional important distinction between 
proliferative and non-proliferative classes. Between 27% and 66% of patients who have 
once been treated for lupus nephritis experience a renal flare.9 In addition, third, fourth 
and fifth episodes of lupus nephritis have been reported. The role of a repeat renal biopsy 
in recurrent episodes of lupus nephritis has been subject of discussion. Several studies 
have proposed to perform repeat renal biopsies in the case of a lupus nephritis flare10-15, 
because a switch to another classification has been found in the majority of patients.16 
However the majority of these studies are based on protocol renal biopsies, whereas in 
clinical practice biopsies are performed on account of a clinical manifestation of a lupus 
nephritis flare. In addition, most earlier studies applied the old WHO classification for 
lupus nephritis. Because of this the clinical significance of the reported switches can be 
questioned, but also because the most frequent transformation occurred from one 
proliferative class to another, which has no consequences for type or intensity of 
treatment. Therefore, it has also been suggested that the choice for repeated biopsy 
should be based on the type of nephritis in the initial biopsy.9;17 The indication for a repeat 
biopsy could therefore be limited to cases where there is a reasonable chance to detect an 
important class switch. This would mean a great reduction in the number of repeated 
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biopsies, which will clearly lower discomfort and complication risk for patients. This thesis 
will report on a study which investigated how often a clinically relevant switch occurred 
when repeat biopsies were performed in the face of a renal flare. 
 
Therapeutic drug monitoring in lupus nephritis 
 The proliferative classes of lupus nephritis are the most prevalent (40 to 60% of 
lupus nephritis cases)
18
 and there is much debate on the optimal treatment. Treatment for 
proliferative lupus nephritis is divided in an induction and maintenance phase. The 
cornerstone of both phases is a chemotherapeutic drug in combination with 
glucocorticosteroids. There are three main immunosuppressive drugs in the treatment of 
lupus nephritis, i.e., cyclophosphamide (CYC), azathioprine (AZA), and mycophenolate 
mofetil (MMF). CYC has long been the golden standard for both induction and 
maintenance treatment of proliferative lupus nephritis19, but concerns about toxicity and 
varying results on renal outcome have led to comparisons with alternative treatments 
including AZA or MMF.19-21 Although AZA and MMF have not shown to be superior to CYC 
as induction treatment in terms of renal outcome and side effects20;22, preference for one 
or the other may exist because of ethnicity, disease severity or the need to avoid certain 
side effects (i.e., risk for ovarian failure after CYC treatment).22-24 In maintenance 
treatment, AZA and MMF do appear to be superior to CYC in terms of survival, relapse and 
side effects25, but results on the difference between MMF and AZA have been 
conflicting.26-28 It has been suggested that AZA would be most suitable as alternative if 
MMF is not tolerated or when women in remission on maintenance therapy have a desire 
to become pregnant24, as MMF has been associated with a higher risk for congenital 
malformations and spontaneous abortion.29 
An additional issue that arises on choosing MMF in the treatment of proliferative 
lupus nephritis is that it is a relatively new drug, which in the Netherlands is officially only 
registered for the use in patients with a kidney, heart or liver transplantation. Hence, 
formal dosage recommendations for MMF in the treatment of lupus nephritis are 
unavailable and therapeutic regimens are based on the results with renal transplantation 
patients. However, MMF has been shown to have complex pharmacokinetic and 
14 
pharmacodynamic characteristics with high inter- and intra-individual variability.
30;31
 The 
intra-individual variability in mycophenolic acid (MPA; the active metabolite of MMF) 
exposure in SLE patients with lupus nephritis has been shown to be influenced by renal 
function and serum albumin levels.
32-34
 In addition, MMF dose does not show a 
relationship with exposure35 or with measures of renal outcome.35;36 Instead, MPA 
exposure did show strong associations with therapeutic response
35
, disease recurrence
36
, 
and side effects.36  
Because of these characteristics of MPA exposure and its associations with clinical 
outcomes, therapeutic drug monitoring of MMF has been advised to improve 
management of patients with lupus nephritis.
33-37
 Therapeutic drug monitoring allows the 
detection and adjustment of too low or too high levels of MPA at an earlier phase in 
treatment. In this way, the beneficial effects on renal outcome may be optimized and the 
occurrence of side effects may be reduced to a minimum. However, studies on the 
implementation of therapeutic drug monitoring in patients with SLE and its influence on 
MPA exposure and renal outcome are still missing. This thesis will report on a study that 
investigated optimized dosing of MMF in maintenance treatment for proliferative lupus 
nephritis.  
 
Health-related quality of life 
 Quality of life (QoL) is defined in various ways, reflecting differences in theoretical 
background. One definition is `an individual’s perception of their position in life in the 
context of the culture and value systems in which they live and in relation to their goals, 
expectations, standards and concerns.38 This definition reflects a complex interaction 
between a person’s physical health, psychological state, level of independence, social 
relationships, personal beliefs, and the relationship to salient features of the 
environment.38 Health-related quality of life (HRQoL) reflects the extent to which an illness 
and its treatment influences a patient’s life, as perceived by that patient. There are many 
factors that influence HRQoL, including demographics (e.g., age, culture), the condition 
itself, treatment, and psychological and social factors (e.g., emotions, coping, support). To 
illustrate the relationships between these factors and level of HRQoL, Leventhal and 
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Colman (1997) have proposed a process model in which a distinction has been made 
between the determinants of HRQoL and patients’ judgments of HRQoL (Figure 1).39 In 
their model, six different determinants of quality of life are distinguished: physical 
function, symptoms, psychological function, mood, economic status, and social 
relationships. HRQoL is influenced by patients’ perceptions of these various domains of 
their life as well as by the importance they attach to their perceptions. Changes in any of 
the determinants may influence patients’ perceptions of these determinants and in turn 
result in a new level of HRQoL. In addition, determinants can be interpreted by one 
patient to have a negative impact on HRQoL, while another patient may view them as 
having a positive influence on HRQoL. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Process model of HRQoL by Leventhal & Collman (1997).
39
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Research into HRQoL in SLE patients has been scant until the late nineties, but has 
been rapidly increasing over the last decade. The need for HRQoL assessment has become 
more apparent as several studies have reported a discrepancy between physicians’ and 
patients’ perceptions of disease activity and global health.
40
 In addition, it has been 
proposed that behavioural outcomes such as HRQoL should obtain a central role in studies 
of health care and medicine because they are more important predictors of health 
outcome than biological variables.41 Studies of HRQoL in SLE patients have shown it to be 
significantly reduced compared with the general population.
5;42
 Assessment with the 
Medical Outcomes Study Short Form 36 (SF-36) has shown an impact across all eight 
domains of HRQoL (i.e., physical functioning, vitality, bodily pain, mental health, physical 
role functioning, social role functioning, emotional role functioning, and general 
health).40;43 HRQoL in SLE patients has been found to be less affected when compared with 
fibromyalgia patients, but worse in comparison with patients with Wegener’s 
granulomatosis44, diabetes, hypertension, congestive heart failure, and myocardial 
infarction.45  
 Studies investigating factors affecting HRQoL in SLE patients have largely focused 
on socio-demographic factors (e.g., age and educational status) and measures of disease 
activity. However, the attention for the relationship with psychological and social factors, 
such as emotions and support, has been increasing. Although studies on the relationship 
between disease activity and damage and HRQoL do not always use the same measure of 
disease activity, HRQoL does not seem to be correlated to disease activity or damage in 
SLE patients.5;46 Age appears one of the strongest socio-demographic determinants of 
HRQoL and especially seems to effect physical health.5 Important psychological and social 
factors that have been associated with reductions in HRQoL in SLE patients are social 
support47;48 and coping.49 Patients with SLE reported lower levels of HRQoL when they 
experienced little social support47;48 or when coping efforts were more task-oriented 
instead of emotion-oriented during active disease.49  
Treatment is another important determinant of HRQoL, which has not been 
widely studied in SLE patients. Especially with the rapid increase in new biological 
therapies for lupus, it will become more important to determine the impact of therapy not 
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only on disease activity but also on HRQoL. Previous studies have found a negative effect 
of glucocorticosteroids, immunosuppressants, and antimalarials on HRQoL in cohorts of 
SLE patients with varying levels of disease activity.
50-52
 Although SLE patients in general 
require some form of maintenance therapy, the intensity of therapeutic regimens is 
greatest during severe organ involvements of which lupus nephritis is one of the most 
common and serious. However, the effect of treatment for lupus nephritis on HRQoL has 
only been addressed by two studies.53;54 This thesis will report on a study that compared 
HRQoL in SLE patients with lupus nephritis who were treated with either a low or high 
dose CYC induction treatment.  
  
Sexual functioning 
Sexual functioning is one of the subdomains of HRQoL and has been shown to be 
important for SLE patients.5 Patients with SLE report a higher rate of problems with sexual 
functioning compared with healthy controls.55 Sexual functioning is a complex process 
which not only depends on physiological systems (neurologic, vascular, endocrine), but is 
also influenced by numerous psychological and social factors, such as self-esteem, body 
image and the relationship with the sexual partner.56 Chronic medical illnesses may 
influence every stage of the sexual response cycle.57  
Despite the significance of sexual functioning in SLE patients, it has not been 
frequently studied58 and findings have been inconclusive. The reported incidence rates of 
sexual problems among SLE patients range from 4% to 52.5%.59;60 The few previous 
studies that have investigated possible determinants of reductions in sexual functioning 
have focused on its associations with medical factors. Apart from the relation with 
symptoms of depression55;61;62, the association with other emotions or psychological 
parameters such as illness perceptions has not been investigated. Research in patients 
with other chronic medical illnesses has suggested that such psychological parameters 
may be more important determinants of sexual functioning than medical factors.
63
 This 
thesis includes a study on sexual functioning in SLE patients to define the problem and to 
investigate additional psychological associations that could be addressed to improve 
sexual function. 
18 
Illness perceptions 
The influence of medical conditions and their symptoms on HRQoL depends on 
how patients interpret these medical conditions and symptoms.
39
 In addition, these 
interpretations of disease and symptoms are guided by patients’ illness perceptions.64 
Illness perceptions are cognitive and emotional representations of one’s illness and are 
composed of one’s own implicit common-sense beliefs about illness.
64
 These illness beliefs 
can be grouped into nine different dimensions, i.e. identity (illness name and symptoms), 
causes, duration, consequences, personal control, the effectiveness of treatment, 
understanding, concerns, and emotional responses.65 Illness perceptions not only play a 
role in how patients make sense of their symptoms and illness, but they also guide 
behaviour to manage the illness. This process by which patients make sense and respond 
to illness is described by the self-regulatory model (SRM), also known as the Common 
Sense Model of self-regulation.65 The SRM states that patients create mental 
representations of their illness based on three sources of information: 1) the current 
experience with the illness, 2) the external social environment, and 3) previous 
experiences and cultural norms. Patients process this information to form illness 
perceptions and these perceptions elicit a coping response. When coping efforts result in 
an unsuccessful outcome, the coping strategy or the initial representation of the illness 
may be revised. The resulting feedback loop from coping to representations and back 
again makes this model self-regulatory and enables responsiveness to changes and thus 
maximizes the likelihood of a positive outcome (Figure 2).65 
Research has demonstrated the importance of illness perceptions in patients’ 
illness behaviour across various patient populations. Patients’ illness perceptions have 
been shown to be related to important health outcomes, including functioning, health 
care utilization, adherence, and mortality.66 For instance, a long-term study of patients 
with end-stage renal disease requiring hemodialysis showed that patients’ perceptions of 
treatment control predicted survival independently of survival risk factor.
67
 In addition, an 
increasing number of studies have reported a beneficial effect of illness perception 
interventions on health outcomes and treatment adherence. For instance, a text-
messaging intervention to increase adherence in patients with asthma resulted in 
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significant changes in beliefs about time line, personal control, and medication necessity 
and treatment adherence.68  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Leventhal’s Self-Regulation Model (adapted from Hagger & Orbell, 2003).
65
 
 
Studies investigating illness perceptions in SLE patients are scarce and the 
applicability is limited because their results are based on different interview techniques. 
However, general findings are that patients hold negative perceptions.69-73 One important 
study used a reliable measure of illness perceptions (e.g., the Illness Perception 
Questionnaire Revised) and showed a positive effect of a cognitive behavioural 
intervention on patients’ perceptions of treatment control and on the effect of SLE on 
their emotions.74 In addition, psychological distress and perceived stress were reduced in 
the intervention group. A new approach in the assessment of illness perceptions is the use 
of drawings to improve clinicians understanding of patients’ psychological status.
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Treatment adherence 
Treatment adherence is defined as the extent to which the amount of medical 
care patients use, corresponds with agreed recommendations from a health care 
provider.76 Treatment adherence does not only include taking medications, but also 
following-up on appointments, dietary or lifestyle advice and so on. Research into 
treatment adherence has shown that non-adherence (i.e., not following agreed 
recommendations) is very common, especially in patients with a chronic illness.77 With 
regard to medication intake, up to 50% of patients with a chronic medical condition do not 
take their medications as recommended.76 Treatment non-adherence has not only been 
found to be related to poorer health outcomes, but also to increased health care costs.
78
  
Treatment non-adherence rates in SLE patients have been found to range from 
17% up to 68%79-83 and has been associated with poor health outcomes, including a higher 
morbidity, hospitalization, and poor renal outcome.13;16 Hence, interventions aimed at 
improving adherence could contribute to better health in SLE patients. These 
interventions should be directed at the determinants of non-adherence in SLE patients. 
Treatment non-adherence can be divided in intentional and unintentional non-
adherence. Unintentional non-adherence is thought to be the result of a passive process78 
and is associated with factors such as marital status79;84, education80, side effects85;86, 
financial costs86, and doctor-patient communication.84;85 In the case of intentional non-
adherence, patients actively choose not to follow agreed treatment recommendations. An 
extension of the Common Sense Model proposes that illness perceptions and treatment 
beliefs play a major role in this decision to non-adhere (Figure 3).87 Although the majority 
of patients with varying illnesses believe that the prescribed medication is necessary for 
their health, this belief is weighed against concerns about potential side effects. Stronger 
concerns about possible adverse effects were associated with lower reported adherence. 
Hence, patients will be more motivated to use their medication as agreed if their belief in 
its necessity outweighs their concerns about taking it.
6;87
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Figure 3. Extension of the Common Sense Model by Horne (2006).
87
 
 
The majority of studies on treatment non-adherence in SLE patients do not 
distinguish between intentional and unintentional non-adherence. In addition, the focus 
has been on the determinants of unintentional non-adherence. Only one previous study 
made a distinction between intentional and unintentional non-adherence, but possible 
determinants of intentional non-adherence, such as patients’ beliefs about their illness 
and treatment, were not investigated.80 Hence, there is a need for a comprehensive 
assessment of treatment non-adherence in which intentional and unintentional non-
adherence are discerned and relationships with both medical and psychological factors 
are investigated. 
 
Aim of this thesis 
 By investigating both clinical care for patients with SLE and psychological factors, 
this thesis aims to give a behavioural medicine perspective on SLE. This perspective is in 
line with the biopsychosocial model which states that the patients’ experience and 
behaviour is the central point through which the associations between physical condition 
and well-being interact. Hence, this thesis not only addresses on-going questions about 
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optimization of diagnosis and treatment, but also the underexposed role of psychological 
determinants in disease outcome.  
 
Thesis outline 
Chapter 2 presents the results of a retrospective study on the clinical relevance of 
repeat renal biopsies in lupus nephritis. The aim of the study was to show that switches 
from proliferative to non-proliferative classes and vice versa are rare and that repeat 
biopsies are unnecessary in many cases.  
Chapter 3 provides the results of an individualized dosing regimen of MMF 
through concentration controlled treatment on MPA exposure in patients with 
proliferative lupus nephritis. This study aimed to examine the effect of therapeutic drug 
monitoring on renal outcome and the occurrence of side effects.  
The influence of two different treatment regimens for proliferative lupus 
nephritis on HRQoL is presented in chapter 4. The aim of the study was to investigate the 
effect of high versus low dose immunosuppressive treatment on HRQoL. 
 In chapter 5 sexual functioning in SLE patients is investigated. This study aimed to 
assess the influence of SLE on sexual functioning and its associations with illness 
perceptions and medical and socio-demographic characteristics.  
Chapter 6 presents the results of a study on the assessment of illness perceptions 
of SLE patients. In addition, this study investigated whether perceptions were influenced 
by type of treatment for proliferative lupus nephritis.   
Treatment non-adherence and its associations with psychological and medical 
parameters are described in chapter 7. The aim of this study was to investigate the 
determinants of non-adherence in SLE patients.  
 Chapter 8 provides a general discussion in which the results of these six studies 
are reviewed and integrated.  
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ABSTRACT 
Background The clinical utility of performing repeat biopsies during lupus nephritis flares 
is questionable and data pointing towards frequent class switches are based on the old 
WHO classification. This retrospective study investigated the hypothesis that clinically 
relevant switches from proliferative to non-proliferative lesions and vice versa as 
determined by the new ISN/RPS classification are a rare event and that repeat biopsies are 
unnecessary in many cases. Methods Thirty-five patients with lupus nephritis and one or 
more repeat renal biopsies were included. Eighty-four biopsies were blindly reassessed 
according to the ISN/RPS classification. Results Twenty-five patients had one repeat 
biopsy, six patients had two and four patients had three repeat biopsies. Forty-nine 
comparisons between reference and repeat biopsies could be made. In 25 cases (54.3%) 
there was no shift in ISN/RPS class on repeat biopsies. In 41 instances, paired biopsies 
showed proliferative lesions both on reference and repeated biopsy, whereas five of six 
cases with non-proliferative lesions on reference biopsy switched to proliferative lesions 
on repeated biopsy. Clinically significant class switches during lupus nephritis flares were 
more frequent in patients with non-proliferative lesions in their reference biopsy (p < 
0.001). Conclusion The results show that patients with proliferative lesions in the original 
biopsy rarely switch to a pure non-proliferative nephritis during a flare. Therefore, a 
repeat biopsy during a lupus nephritis flare is frequently not necessary if proliferative 
lesions were found in the reference biopsy. However, in the case of a non-proliferative 
lesion in the reference biopsy, class switches are frequently found and repeat biopsies are 
advisable. 
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INTRODUCTION 
Renal biopsy is a pivotal step in determining the nature of renal involvement in 
patients with lupus nephritis. Up to 60% of patients with SLE develop lupus nephritis.1 Six 
classes of lupus nephritis are distinguished in the current classification of the International 
Society of Nephrology and the Renal Pathology Society (ISN/RPS). Classification and 
treatment decisions strongly depend on the findings in the renal biopsy. The diagnosis 
lupus nephritis cannot be based on clinical features alone (e.g. proteinuria, rising serum 
creatinine, active sediment), since the clinical features do not permit a reliable prediction 
of the type of SLE nephritis.
2;3
 Kidney diseases due to other causes than lupus nephritis 
may also need to be excluded as a cause of renal damage.1 
 
Relapses occur frequently in patients with lupus nephritis, even after an initial 
complete remission.4 To determine the most effective treatment in the case of a lupus 
nephritis flare, a number of authors advise to perform repeat biopsies.1;5-8 Based on such 
findings it has been hospital policy at the Leiden University Medical Centre (LUMC) for 
over 25 years to perform a biopsy before treating renal flares. However, others have 
suggested that the need for repeat biopsies in renal flares may depend on the type of 
lupus nephritis in the original biopsy.4 Conversion from one proliferative form to another 
(e.g. class III to IV) will usually not influence the choice of current therapeutic regimens. 
Recent studies investigating the optimal therapy for proliferative lupus nephritis include 
class III and IV nephritis together in the treatment arms.9-13 Moreover, treatment 
guidelines usually do not differentiate between class III and IV nephritis. Therefore, 
transitions between proliferative classes have no additive value on treatment decisions. 
Similarly, the addition or disappearance of class V lesions on a second biopsy next to 
persisting proliferative lesions should not be of great influence on treatment choices, since 
the prognosis is largely determined by the associated proliferative lesions.14 Thus only a 
switch from proliferative to non-proliferative lesions (e.g. class III to V) or vice versa will 
have clear therapeutic consequences and a reasonable chance to detect such a switch will 
justify performing a repeat biopsy. 
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To determine the role of repeat biopsies, this study investigated how often a 
clinically relevant switch occurred when repeat biopsies were performed for renal flares. 
Based on the concept that the presence or absence of proliferative lesions determines 
therapy in lupus nephritis, it was hypothesized that repeat biopsies would only be helpful 
if switches between purely non-proliferative to proliferative or vice versa were detected. 
Since haemorrhage remains a concern in the face of renal biopsies, with major 
complications requiring blood transfusion or invasive intervention in 0-6.4% of biopsies1, it 
is desirable only to perform biopsies that will influence treatment. In addition, the 
discomfort for the patient and the costs of renal biopsies are important factors.  
First and successive biopsies were compared for classification according to the 
new ISN/RPS revision, therapy regimen, and clinical manifestation (e.g. proteinuria and 
serum creatinine).   
 
METHODS 
Study Population 
Patients were selected from the electronic database of the patient registration at 
the LUMC. Inclusion criteria were a diagnosis of SLE and two or more renal biopsies. 
Thirty-eight patients were included on the basis of these criteria. Thirty patients are under 
treatment at LUMC for their SLE, four are currently treated elsewhere and four patients 
are deceased (one male and three females). 
 
Materials and Procedure 
Ninety-four biopsies were retrieved from the archive and blindly reassessed by 
two renal pathologists (IMB and NNTG) by light microscopy. The Renal Biopsy Scoring 
Form of the Dutch Lupus Nephritis Study
11
 was used to record ISN/RPS-classification, 
activity index and chronicity index. After reassessment, the new classifications were 
compared with those in the old pathology reports. In the case of notable deviations 
between the former and new assessment (e.g. a class III on original diagnosis and a class 
IV on reassessment), the assessment was repeated. Hence, these second assessments 
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were not blinded. If important electron microscopy (EM) or immunofluorescence (IF) 
findings were mentioned in the reports, these were added to the classification.  
ISN/RPS-classification between first and second biopsy were compared. If 
patients had more than two biopsies, the second and third and third and fourth biopsies 
were paired. Thus, the last biopsy performed before the repeat biopsy served as the 
reference biopsy. 
Paper files and the electronic database were consulted to register clinical 
parameters. Serum creatinine and proteinuria at the time of biopsy were recorded. 
Hospital correspondence retrieved from the paper files and the electronic database were 
used to collect date of diagnosis and medical regime following biopsy.  
 
Statistical analysis 
Data were analysed using SPSS Version 15.0 software. A Fisher’s Exact Test for 
categorical variables was applied to determine if class switch occurred more often in 
patients with non-proliferative versus proliferative lesions. Two-sided P-values of less than 
.05 were considered statistically significant.  
 
RESULTS 
Ten biopsies were excluded from the study after reassessment. Four biopsy 
specimens contained no useful material (e.g. solely renal medulla) or inadequate material 
so that judgement was not possible. Two repeat biopsies were performed as protocol 
biopsies in the setting of a clinical trial and were excluded. One biopsy performed in a 
hospital other than the LUMC could not be traced. As a result, three patients and their 
original biopsies were excluded. The 84 remaining biopsies were included in the analysis.  
Material from three biopsies could not be recovered from the archives. 
Classification of these biopsies was based on careful examination of the old pathology 
reports. In six cases, IF results, as mentioned in the pathology reports, led to the addition 
of a class V to the classification. Four specimens were assessed a second time as important 
discrepancies with the original pathology reports were found. After comparing the results 
from the biopsy evaluations of the two pathologists with the original reports, 
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discrepancies were found in only four cases. These only involved minor issues, which were 
solved by plenary discussion in order to reach a final scoring. 
 
The patient group consisted of 26 females and nine males. The mean age of the 
total group was 41.5 (SD = 10.9). Patients were on average 26.0 years (SD = 9.6) when SLE 
was diagnosed and the mean disease duration at the moment of reassessment of biopsies 
was 15.5 (SD = 6.0) years. Twenty-five patients had one repeat biopsy, six patients had 
two and four patients had three repeat biopsies. The mean time period between 
reference and repeated biopsy was 4.1 years (SD = 3.6).  
 
Table 1 shows the ISN/RPS classification in the 84 biopsies that were reassessed. 
Forty-nine comparisons between reference and repeat biopsies could be made. In 25 
instances (51.0%), there was no shift in ISN/RPS class on repeated biopsy. This concerned 
19 cases of class IV (35.7%), three of class III+V (7.1%), one of class III (2.4%), one class of 
VI (2.4%), and one of class IV+V (2.4%). The most frequent transitions occurred between 
class IV and III (54.2%), with five transitions in both directions, two shifts of class III + V to 
class IV, and one from class IV+ V to class III.  
 
Table 1. ISN/RPS classifications on repeated biopsy 
               Reference Biopsy 
  I   II III IV V VI II+V III+V           IV+V 
Repeat Biopsy 
  I  0 0 0 0 0 0 0 0 0 
  II  0 0 0 0 0 0 0 0 0 
  III  0 0 1 5 0 0 0 0 1 
  IV  0 1 5 19 2 0 0 2 0 
  V  0 0 0 1 0 0 0 0 0 
  VI  0 0 0 0 0 1 0 0 0 
  II+V  0 0 0 0 0 0 0 0 0 
  III+V  0 0 0 2 1 0 1 3 0 
  IV+V  0 0 0 2 0 0 0 0 1 
  Other  0 0 0 1 0 0 0 0 0 
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Table 2 shows the changes from proliferative to non-proliferative lesions and vice 
versa between the reference and repeated biopsies. In 41 instances (84%), the reference 
biopsy as well as the repeated biopsy showed proliferative lesions. One patient with 
proliferative lesions in the reference biopsy showed extensive glomerular amyloid 
depositions in the repeat biopsy.      
 
Table 2. Proliferative versus non-proliferative  
             Reference Biopsy         
   Proliferative     Non-proliferative  
Repeat biopsy  
  Proliferative  41    5 
  Non-proliferative  1    1 
  Glomerulosclerosis   1    0 
p < .001. 
 
Figure 1 illustrates the presence of proliferative lesions in three successive 
biopsies from a representative patient. Five cases (10%) with pure non-proliferative 
lesions on reference biopsy switched to proliferative lesions on repeated biopsy. This 
indicates that clinically relevant class switches were more frequent in patients with non-
proliferative lesions in the reference biopsy (p < .001).  
 
 
   
Figure 1. Example of a patient with proliferative lesions in three successive biopsies (class IV, IV and III  
respectively).  
 
The mean renal activity index on first biopsy was 6.18 (SD = 4.43) and 5.27 (SD = 
3.84) on repeated biopsy (p = .315). The mean chronicity index for the first biopsy was 
2.62 (SD = 2.53) and 4.20 (SD = 2.39) for the repeated biopsy (p < .001).  
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Data on serum creatinine and proteinuria at the time of biopsy could be retrieved 
for 45 out of the 49 instances of reference as well as repeat biopsy. Because of the missing 
values, the presence of a high creatinine and/or the extent of proteinuria could be 
determined in 43 instances of reference biopsy and in 42 cases of the repeat biopsy. The 
most frequent clinical manifestation of nephritis at the time of biopsy consisted of 
nephrotic range proteinuria in combination with a progression of renal failure, in 20 
instances (46.5%) at the time of reference biopsy and in 19 cases (45.2%) of repeat biopsy 
(Table 3).  
Forty-one comparisons of clinical presentation on reference versus repeat biopsy 
could be made. In 24 instances (58.5%) a change in presentation was seen, whereas in 17 
(41.5%) cases the clinical manifestation at repeat biopsy had not changed.      
 
Table 3. Clinical manifestation at the time of reference versus repeated biopsy 
              Reference biopsy        Repeat biopsy 
Proteinuria > 3.5 g/24hrs    10  7 
Proteinuria > 3.5 g/24hrs + serum creatinine > 106 umol/L 20  19 
Proteinuria < 3.5 g/24hrs    10  7 
Proteinuria < 3.5 g/24hrs + serum creatinine > 106 umol/L 4  9 
Total       43  42 
 
Data on therapy could not be retrieved for six patients before biopsy, in three 
cases of reference biopsy and in eight instances of repeat biopsy. As a result, comparison 
of treatment regimen before and after reference biopsy and on reference versus repeat 
biopsy could not be made in seven and nine cases, respectively.  
Nineteen patients received an increase in immunosuppression after reference 
biopsy (Table 4). In three instances therapy remained unchanged and in one case 
immunosuppressive therapy was decreased or stopped. After repeated biopsy, a 
comparable number of patients received an increase in immunosuppression, but 
immunosuppression was decreased or stopped more often than after reference biopsy. 
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Table 4. Alterations in immunosuppressive therapy after biopsy 
             After reference          After repeat 
     biopsy    biopsy 
Increased immunosuppression   19   21 
Decreased/stopped immunosuppression  1   8 
No change     3   8 
Other     5   3 
Unknown     7   9 
Total     35   49 
 
A clear shift from single steroid use before biopsy (55.2%) to a combination of 
steroids and immunosuppression after reference biopsy (80.4%) was found (Table 5). In 
two instances of reference biopsy and in two cases of repeat biopsy no 
immunosuppressive therapy was initiated on the basis of the biopsy results. As for the 
reference biopsies this comprised two cases of class III. A repeat biopsy that was 
reassessed as a class IV in the present study was originally misdiagnosed as a lupus 
nephritis in remission. The second repeat biopsy that did not result in therapy concerned a 
class VI nephritis.  
 
Table 5. Treatment regimens 
             After reference After repeat 
   Pre-biopsy   biopsy   biopsy 
Steroids alone  16 (55.2%)   5 (10.9%)  3 (7.3%) 
Steroids + immunosuppression 5 (17.2%)   37 (80.4%)  33 (80.5%) 
  Steroids + AZA  3 (10.3%)   25 (54.3%)  15 (36.6%) 
  Steroids + AZA + Other 1 (3.4%)   2 (4.3%)  1 (2.4%)  
  Steroids + Other  1 (3.4%)   1 (2.2%)    0 (0) 
  Steroids + CYC  0 (0)  8 (17.4%)  10 (24.4%) 
  Steroids + MMF  0 (0)  0 (0)  3 (7.3%) 
  Steroids + CYC + MMF 0 (0)  1 (0)  4 (9.8%) 
Other   6 (20.7%)  1 (2.2%)  3 (7.3%)  
None   2 (6.9%)   3 (6.5%)  2 (4.9%) 
Total   29  46  41  
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DISCUSSION 
This retrospective study investigated the hypothesis that clinically relevant 
switches in lupus nephritis from proliferative to non-proliferative lesions and vice versa as 
determined by the new ISN/RPS classification are a rare event and that repeated biopsies 
during flares are unnecessary in many cases. The results show that patients with 
proliferative lesions on their original biopsy rarely switch to a pure non-proliferative 
nephritis during a flare. However, in the case of a non-proliferative lesion in the reference 
biopsy, class switches are frequently found.  
 
A number of studies report a high degree of transformation from one WHO class 
to another on repeated biopsy.5-8;15-20 Class switch is thought to be a characteristic of lupus 
nephritis.4 Studies that assessed biopsy specimens according to the old WHO-classification 
showed class switch in 26% to 50% of repeated renal biopsies.8 The present study used the 
new ISN/RPS classification in the assessment of the renal biopsies, but similar results were 
found with class switch in 49% of instances. A switch between class III and IV (with or 
without an additional class V) was the most frequent (54.2%). A predominance of 
transitions between class III and IV (with or without an additional class V) has been 
reported in several studies.8;15;17 In a study by Moroni et al. (1999)8 42.9% of transitions 
occurred between class III and IV. Another study found 4 transitions from class III to IV, 
which comprised 36.4% of all shifts.15    
Transitions in WHO class in other studies on repeat biopsies is variable, but the 
direction of the majority of transitions in five studies is remarkable. Two studies found the 
most frequent switches from class IV to a class II or V, in 50%16 and 65.2%6 of cases, and 
two other studies showed the most shifts from class III or IV to a class II or V (60.7%7 and 
61.1%).19 In a fifth study with only class IV on first biopsy, 56% of patients had switched to 
a class III on repeated biopsy.
20
 The high frequency of transitions from a class III or IV to a 
class II or III could be the result of the fact that repeat biopsies were not performed for 
clinical reasons but according to protocol
6;7;19;20
 or postmortem.
16
  As the present study 
only pertains to repeat biopsies on account of a clinical manifestation of a lupus nephritis 
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flare, we cannot address the role of protocol biopsies in the management of patients with 
lupus nephritis.  
 
Numerous authors advise serial renal biopsy in the management of lupus 
nephritis.5-8 Bajaj et al. (2000)5 reported that all therapeutic decisions were influenced by 
the repeated biopsy results, with no change in therapy in 23% of patients and either an 
increase or decrease in therapy in the remaining 77% of patients. However, repeat 
biopsies are performed because of the presence of the clinical manifestation of a lupus 
nephritis flare. Without a repeat biopsy, patients may have been treated on clinical 
grounds alone. The biopsy results could only help to choose or confirm therapy choice. 
Therapy change itself after biopsy does not prove that the therapy would not have been 
changed without a biopsy.  
 
Eighty-four percent of transitions in this study consisted of a switch from one 
proliferative form to another. The detection of these transformations within the 
proliferative group does not have clear therapeutic consequences and does not justify the 
performance of repeat biopsy during a flare. The application of similar therapeutic 
schedules for all proliferative forms of lupus nephritis is justified by recent studies 
investigating the efficacy of therapy in proliferative lupus nephritis. In these studies, no 
distinction between the different proliferative classes is made.9-13 In addition, the recent 
lupus nephritis European consensus statement does not differentiate in the treatment of 
class III and IV lupus nephritis.21 Moreover, it has been proposed that transitions from 
focal to diffuse proliferative nephritis might indicate a progression of the same type of 
nephritis rather than a true transition.15;17;22;23 Additionally, since the difference between 
class III and IV lupus nephritis is defined as less or more than 50% of the glomeruli having 
proliferative lesions, a class switch may also be explained by sampling error in borderline 
cases. Clearly more studies are necessary to define whether significant pathophysiological 
and clinical differences between class III and IV lupus nephritis exist. 
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If the majority of patients who flare remain in the same proliferative class or 
switch to another proliferative form and assuming that proliferative lesions are treated 
alike, no difference between therapy regimen after initial biopsy and after successive 
biopsy would be expected. However, in 77.5% of cases, treatment schedule differed after 
reference versus repeat biopsy in the present study. The mean time between initial and 
repeated biopsy was 4.1 years, which can explain the lack of consistency in treatment 
policy in the case of successive proliferative lesions. Pharmaceutical developments could 
have led to new insights in treatment strategy and new alternatives. Therapy schedules 
were often difficult to recover, accounting for the amount of missing data (nine 
comparisons could not be made) and could have resulted in incomplete data.  
 
Interestingly, only one case of class II nephritis was diagnosed in our group of 
patients who had repeat biopsies. This is probably the result of a conservative biopsy 
policy at LUMC. Since some mesangial abnormality is present in all patients with SLE7;15;16, 
the earlier in the course of lupus nephritis the biopsy is taken the more cases of class II 
nephritis will be found.  
Although the immediate clinical relevance of serial renal biopsy may be limited, 
repeat biopsies could have a prognostic value.6;8;11;24;25 One study allocated a good 
predictive power to systematic repeat biopsies at six months after the start of treatment 
for proliferative lupus nephritis since they provided a measure of the response to 
therapy.24 Patients who did not respond fully to treatment, as reflected by continuing 
inflammatory lesions at six months, were more likely to show a worse response on 
treatment for a lupus nephritis flare and showed more accumulation of chronic damage. 
Esdaile et al. (1993)6 state that the amount of electron-dense deposits, especially 
subendothelial deposits, at protocolized repeat biopsy two years after the start of 
treatment for all classes of lupus nephritis is the best predictor of renal outcome as well as 
mortality. In addition, a prognostic association of the chronicity index (CI) and mortality 
was found.  
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In contrast, a randomized controlled trial found that repeat biopsies were not 
predictive of outcome.11 Although the CI was significantly increased on repeat 
protocolized biopsy 2 years after initiating treatment for proliferative lupus nephritis, it 
could not predict outcome. The authors suggest that clinical parameters in patients with 
lupus nephritis are more informative than are findings on repeat renal biopsy.  
Only two known studies investigated the prognostic value of repeat biopsies in 
the face of a flare and both report a predictive association of high CI scores and poor renal 
outcome.
8;25
 Moroni et al. (1999)
8
 found an association between a CI of 5 or greater and a 
doubling plasma creatinine level in the long term. In addition, they state that the presence 
of extracapillary proliferation demands aggressive treatment to prevent irreversible renal 
failure.  
Whether repeat renal biopsies have prognostic value was not addressed in the 
present study. The two known studies do indicate an association, especially with regard to 
the CI, but data are too scarce to make a definite conclusion. Moreover, the application of 
the CI as a measure of outcome seems questionable, since the reproducibility of the CI 
remains moderate.26-28 
    
The most frequently mentioned and most important reason to perform a repeat 
biopsy is to decide on a treatment strategy in the case of a lupus nephritis flare. However, 
if evaluation of the biopsy specimen will show transition to another proliferative form in 
the majority of cases and if these forms receive the same treatment, repeated biopsy 
becomes unnecessary in these instances. This study did find a significant class switch to 
proliferative forms in patients with non-proliferative lesions in their reference biopsy. 
Based on these results, it seems that patients with a class V nephritis should be followed 
closely. If these patients flare or show a progression in renal failure a re-biopsy may be 
indicated to exclude the development of proliferative lesions. 
On choosing a policy in which repeat biopsies are only performed in patients who 
flare and had non-proliferative lesions on initial biopsy, it remains uncertain what strategy 
to follow in the case of prolonged mild deviations. When a patient maintains mild but 
substantial proteinuria, which does not improve on therapy, it can be difficult to uncover 
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whether this reflects chronic damage or activity. In these selected cases a renal biopsy 
should be considered. Although pure sclerotic lesions were only found in one repeat 
biopsy in our series, it may be difficult to clinically distinguish a mild flare from proteinuria 
and worsening renal function due to glomerulosclerosis in some patients. In these cases a 
biopsy will be necessary to guide appropriate treatment and prevent inappropriate 
immunosuppression. Similarly, a biopsy may be helpful in patients with very poor renal 
function where severe chronic damage may contribute to the decision to withhold 
aggressive treatment. 
 
It should be noted that the results of this study might not be applicable to every 
patient group. The participant group in this study consisted mostly of individuals of 
Caucasian descent. It is well known that patients with SLE of African descent have a more 
aggressive course of disease and poorer outcomes.29 A similar study with this patient 
group should be performed before a recommendation about biopsy policy can be given.  
 
In conclusion, the clinical relevance of repeat biopsy in lupus nephritis seems to 
be limited. In the case of non-proliferative lesions on reference biopsy, repeated biopsy is 
advisable in the presence of clinical deterioration since a switch to more proliferative 
lesions is often found. If a patient with proliferative lesions on a previous biopsy presents 
with a renal flare, appropriate induction treatment can be initiated without additional 
biopsies, since repeated biopsy will show similar lesions in most cases.  
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ABSTRACT 
Background Mycophenolate mofetil (MMF) has recently been established as a potent drug 
in maintenance treatment for lupus nephritis. However, there is no consensus on the 
optimal dosing regimen due to a high inter-individual variability of mycophenolic acid 
(MPA), the active metabolite of MMF. This retrospective study aimed to investigate the 
effect of an individualized dosing regimen through concentration controlled treatment on 
MPA exposure and renal outcome in patients with lupus nephritis. Methods Sixteen 
patients with lupus nephritis and treatment with low dose intravenous cyclophosphamide 
followed by MMF were included. MPA area under the plasma concentration-time curve 
from 0 to 12 hours (MPA-AUC0-12) was assessed within a month after MMF initiation. After 
determination of MPA-AUC0-12, MMF doses were titrated to achieve a target MPA-AUC0-12 
of 60-90 mg*h/l. After on average six months, MPA-AUC0-12 measures were repeated to 
assess the effect of dose adjustment. Results One month after introducing MMF, MPA-
AUC0-12 was low and showed a high inter-individual variability. Dose adjustment with a 
target MPA-AUC0-12 of 60-90 mg*h/l resulted in individualized MMF dosing, significantly 
higher MPA-AUC0-12 levels and a non-significant reduction in variability of MPA-AUC0-12. 
Adverse effects were reported by 37.5% of patients, which resulted in a switch to 
azathioprine in two patients. There was no significant relationship between the 
occurrence of adverse effects and MPA-AUC0-12. At 12 months of follow-up 87.5% of 
patients had achieved either partial (18.7%) or complete (68.8%) remission. Conclusion 
Concentration controlled dose adjustments with a target MPA-AUC0-12 of 60-90 mg*h/l 
was associated with optimized MPA exposure and an excellent renal outcome at 12 
months of follow-up in a small sample of SLE patients with lupus nephritis.  
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INTRODUCTION 
Lupus nephritis is a prevalent organ involvement in systemic lupus erythematosus 
(SLE) and affects up to 60% of patients.1 Renal involvement is strongly related to a high 
morbidity and mortality in SLE, but early and intensive treatment can greatly improve 
renal outcome.2 For decades the first choice of treatment for severe lupus nephritis 
consisted of high doses intravenous cyclophosphamide (IVC) in combination with 
corticosteroids, known as the NIH regimen.
3
 This regimen with high IVC doses has shown 
variable results as a remission induction and maintenance therapy in proliferative lupus 
nephritis.
4-6
 In addition, the high incidence and severity of IVC related adverse effects
4
 has 
resulted in a search for less toxic alternative therapies. Among these alternatives, the 
Euro-Lupus regimen with low dose IVC as remission induction followed by azathioprine 
(AZA) as maintenance therapy has been shown to be an equally effective and safe 
therapy.7 Also at a 10 years follow-up, the Euro-Lupus regimen did not differ from the NIH 
regimen in terms of clinical outcomes.8  
Another frequently studied drug for treatment of lupus nephritis is 
mycophenolate mofetil (MMF). MMF as remission induction treatment has shown to be at 
least equivalent in terms of efficacy and safety compared to high dose IVC.9 In addition, 
some studies have reported better clinical outcome and less drug related adverse events 
with MMF.10 Although both MMF and AZA have been established as effective 
maintenance treatments, contradictory results have been published on the optimal 
maintenance regimen. One recent study found MMF to be superior to AZA in preventing 
renal flares in patients with a good response after 6 months induction treatment with 
either MMF or IVC.11 However, the MAINTAIN trail in which maintenance treatment with 
MMF was compared to AZA after induction treatment with low dose IVC showed no 
difference in the incidence of renal flares.
12
  
 
The inconsistent findings in the differences in clinical outcome between MMF and 
AZA maintenance therapy may be influenced by the fact that the optimal MMF dose in 
lupus nephritis is unknown and different dosing regimens have been applied. Although 
MMF has become an important drug in the management of SLE, it is not officially 
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registered for treatment of lupus nephritis and formal dosage recommendations are 
unavailable. As a result, dosages have been based on experience in the renal 
transplantation setting. In kidney transplantation patients, doses below 1 g/d have been 
associated with a higher risk of graft rejection
13
, while doses above 3 g/d have been 
related to an increased occurrence of drug related adverse effects.14 Therefore, MMF 
trials for lupus nephritis have applied dosages between 1 to 3 g/d and adjustments were 
made based on therapeutic response and side effects.15 In current clinical practice of 
maintenance therapy for lupus nephritis, MMF is generally administrated at a fixed 
starting dose of 2 g/d. However, studies in renal transplantation patients have also shown 
that the pharmacokinetics of mycophenolic acid (MPA), the active metabolite of MMF, 
exhibit a considerable variability between individuals and over time.16;17 A high inter-
patient variability of MPA has also been found in patients with autoimmune diseases, 
including SLE18;19, and more specifically in SLE patients with lupus nephritis.20;21  
 
Because of these characteristics of MPA exposure and its associations with clinical 
outcomes, establishing individualized dosing regimens by means of therapeutic drug 
monitoring (TDM) is considered essential in MMF treatment in SLE patients.18;19;21-23 In 
addition, therapeutic target levels of MPA area under the plasma concentration time 
curve (MPA-AUC) above 35 and 45 mg*h/l have been recommended to achieve good 
response based on retrospective data.21;24 To our knowledge, no study has reported on 
the actual implementation of such therapeutic target ranges and its influence on MPA 
exposure and treatment outcome. Therefore, the aim of the present study was to report 
our experience with optimized dosing of MMF with a target MPA-AUC0-12 of 60-90 mg*h/l 
after induction treatment with low dose IVC according to a modified version of the Euro-
Lupus protocol in SLE patients with proliferative lupus nephritis.  
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METHODS 
Patients 
From 2005 onwards the patients presenting with proliferative lupus nephritis to 
the nephrology and rheumatology departments at the Leiden University Medical Centre 
(LUMC) were treated with low dose IVC (six pulses of 500 mg in three months) followed by 
MMF with a starting dose of 2 g per day. As part of local hospital policy, after 
determination of MPA-AUC0-12, MMF doses were titrated to achieve a target MPA-AUC0-12 
of 60-90 mg*h/l. All included patients had SLE according to the revised American College 
of Rheumatology criteria.25 For this retrospective cohort study 16 patients were identified 
with a total of 28 registered MPA measurements. The majority of patients were of 
Caucasian descent (75%). 
 
Pharmacokinetic analyses 
 MPA concentration measures were derived from blood samples that have been 
taken for therapeutic drug monitoring (TDM) purposes. Prior to sampling, patients had 
held a 12-hour overnight fast. Blood samples were taken before the administration of 
MMF morning dose and one, two, and three hours after intake. 
Samples were analyzed for MPA by high performance liquid chromatography 
(HPLC). TDM was performed on the basis of the limited sampling strategy and Bayesian 
estimation of the MPA clearance using MW/Pharm version 3.5 (Mediware, Groningen, The 
Netherlands) as previously described.26 MPA oral clearance was used to calculate MPA-
AUC0-12. Therapeutic dose adjustments based on MPA-AUC0-12 measurements were also 
recorded. 
 
Outcome measures 
The following disease activity parameters were recorded at the time of MPA 
exposure measurement: hemoglobuline (Hb), serum and urinary creatinine levels, serum 
albumin levels, proteinuria, and glomerular filtration rate according to the Modification of 
Diet in Renal Disease (MDRD) study equations. In addition, serum creatinine, serum 
54 
albumin and proteinuria were registered three months prior to initiation of MMF 
treatment, and 0, three, six, nine, and 12 months after the start of treatment.  
Treatment response was assessed at six and 12 months. The following three 
response categories were defined: 1) complete response: proteinuria below 0.5 g/day and 
stable serum creatinine levels or less than 25% higher than at the start of treatment, 2) 
partial response: more than 50% reduction in proteinuria and no increase in serum 
creatinine levels, and 3) failure: not reaching the criteria for partial response.  
 
Statistical analyses 
 Data were analysed using SPSS software version 17. Descriptive statistics and 
frequencies were obtained for the patient characteristics. Independent t-tests were used 
to investigate differences in MPA exposure between first and second measurements and 
to assess changes in disease activity parameters. Associations between MPA-AUC0-12 and 
disease activity parameters were explored with Pearson correlation coefficients. ANOVA 
was used to test differences in MPA-AUC0-12 between treatment response groups. An 
alpha level of .05 was used for all statistical tests.  
 
RESULTS 
Patient characteristics 
All 16 patients were treated with low dose IVC followed by MMF for an episode 
of proliferative lupus nephritis. Five patients were diagnosed with a class III, 11 with a 
class IV. This was the first episode of proliferative lupus nephritis for 10 patients and six 
patients experienced a renal flare. Previous episodes of lupus nephritis had been treated 
with IVC and corticosteroids (two), IVC and azathioprine (one), MMF and corticosteroids 
(one), or azathioprine and corticosteroids (two). 93,7% of patients used one or more anti-
hypertensive drugs at time of treatment for lupus nephritis: 73.3% ACE inhibitors, 40.0% 
AT-II antagonists, 20.0% calcium antagonists, 20.0% diuretics, and 13.3% beta blockers.  
Twelve patients had two or more measurements of MPA blood concentrations. 
The first measurement before dose adjustment was performed on average 32.6 (SD = 
27.7) days after the start of MMF maintenance treatment. The second MPA levels that 
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were assessed after dose adjustment took place on average 6.6 (SD = 7.2) months after 
the first measurement. Patient characteristics before dose adjustment are shown in Table 
1. 
 
Table 1. Patient characteristics at first MPA-AUC0-12 (before dose adjustment) (N = 16)   
Male (N, %)    1 (6.3%)   
Age in years (SD)    33.2 (12.1)  
Weight in kg (SD)    67.0 (11.5)  
Serum albumin (SD)    39.2 (5.7)   
Serum creatinine (SD)   98.6 (55.0)  
Hemoglobin (SD)    7.1 (.99)   
Proteinuria (SD)    1.3 (1.3)   
MDRD (SD)    78.3 (36.8)  
MMF dose g/day (SD)   1.9 (.29)    
 
Before the start of MMF, four patients (25.0%) had already reached complete 
remission, four patients (25.0%) showed partial remission and eight patients (50.0%) were 
labeled as failures. After six months of MMF treatment, 10 patients (62.5%) had 
completely responded, four patients (25.0%) showed a partial response, and two patients 
(12.5%) were classified as non-responders. At 12 months, one patient had switched from a 
partial to a complete response.  
 
Pharmacokinetics 
On the basis of the first MPA-AUC0-12 measurement, dose adjustments were made 
in 13 of 16 patients (81.3%). In two patients MMF dose was reduced and 11 patients 
received a dose increase. MMF dose was on average 1.9 g (SD = .29) before and 2.6  
(SD = .82) after first MPA-AUC0-12 measurement. Figure 1 depicts the dose adjustments in 
the 12 patients who had repeated MPA-AUC0-12 determinations. The dose range was 1-2 
g/24h before the first MPA-AUC0-12 and 1.5-4 g/24h before the second MPA-AUC0-12. 
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Figure 1. MMF dose/24h at first (1) and second (2) MPA-AUC0-12 (N = 12). 
 
Figure 2a shows the mean MPA levels before and after dose adjustment for four 
different time points after MMF administration in the 12 patients who had at least two 
MPA-AUC0-12 measurements. Mean MPA level after dose adjustment was significantly 
higher one hour after MMF intake (p = .023). 
 
 
Figure 2a. MPA level (mg/l) before (1) and after (2) dose adjustment.  
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The mean MPA-AUC0-12 levels before and after dose adjustment are depicted in 
Figure 2b. Mean MPA-AUC0-12 before dose adjustment was significantly lower than after 
dose adjustment (M = 46.5, SD = 24.3 vs. M = 69.3, SD = 19.4; p = .018). In addition, MPA-
AUC0-12 levels tended to be less variable after dose adjustment (SD = 24.3 versus SD = 
19.4), although the difference in variances was not significant (p = .456).   
 
 
Figure 2b. MPA-AUC0-12 before (1) and after (2) dose adjustment (N = 12). 
 
MPA-AUC0-12 was significantly correlated with levels at 0, one, two, and three 
hours after MMF administration (r = .79, .62, .60, .52, all p < .001). There was no 
significant relationship between MPA-AUC0-12 and serum albumin (r = .270, p = .212), 
proteinuria (r = -.18, p = .468), or creatinine clearance (r = -.275, p = .174).  
   
Renal outcome 
The efficacy of MMF therapy was evaluated by the follow-up of proteinuria, 
serum creatinine, and serum albumin levels. Twelve months after the start of MMF 
treatment proteinuria levels had significantly decreased (M = 2.18 g/day, SD = 1.60 vs. M = 
.72 g/day, SD = .95; p = .007) (Figure 3). Serum creatinine remained stable over time (M = 
92.38 μmol/l, SD = 68.32 vs. M = 92.00 μmol/l, SD = 50.24; p = .986). Albumin levels 
showed a marked increase from a mean value of 38 g/l (SD = 5.31) to 43.0 g/l (SD = 3. 82; 
p = .008).  
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Figure 3. Proteinuria (g/24h) at start of MMF treatment and at twelve months follow-up. 
 
Adverse events 
Adverse effects were reported by six patients (37.5%). One patient (16.7%) ended 
MMF treatment after three weeks because of ongoing nausea and vomiting and switched 
to AZA as maintenance therapy. Two patients (33.4%) also experienced gastrointestinal 
complaints such as nausea, cramps and diarrhea, but no dose adjustments were made. 
One patient (16.7%) switched to AZA after two years because of recurrent episodes of 
sinusitis. Recurrent infections were experienced by three other patients (50%) as well. 
Sleeping disturbances were reported by one patient (16.7%).  
There was no significant relationship between the occurrence of adverse effects 
and MPA-AUC0-12 (p = .293). 
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DISCUSSION 
 This is the first study to report on the effect of MPA concentration controlled 
treatment on MPA exposure and renal outcome in a cohort of SLE patients with 
proliferative lupus nephritis. The findings indicate that adjusting MMF dose aimed at a 
target MPA-AUC0-12 of 60-90 mg*h/l results in individualized MMF dosing with increased 
MPA exposure and decreased inter-individual variability. In addition, this individualized 
dosing regimen of MMF in the context of a modified version of the Euro-Lupus protocol 
was associated with a good renal outcome with 87.5% of patients showing partial or 
complete response after 12 months of MMF treatment.   
  
 MMF has recently been established as an effective drug in both the induction and 
maintenance treatment of lupus nephritis.12;27;28 However, it remains unclear whether it is 
superior to alternative therapies such as high dose IVC or the Euro-Lupus regimen with 
low dose IVC followed by AZA. In the present study, patients were treated according to a 
modified version of the Euro-Lupus regimen with low dose IVC followed by MMF instead 
of AZA. A recently published long-term study of the ALMS group found MMF to be 
superior to AZA in maintaining renal response to treatment and in preventing renal 
relapse.11 In addition, fewer patients in the MMF group withdrew due to adverse effects.11 
However, most previous studies failed to find differences in efficacy or adverse events 
between MMF and AZA maintenance therapy.12;27;29 Among these studies is the long-term 
MAINTAIN Nephritis Trial, which did find fewer renal flares in the MMF group (19% vs. 
25%), but this difference was not significant.12    
 
Studies investigating the difference in clinical outcome between MMF and AZA 
maintenance therapy administrated MMF at a fixed dose. However, studies into the 
pharmacokinetics of MMF have suggested that results with MMF may be further 
improved through concentration controlled treatment.
19;21
 Because exposure to MPA, the 
active metabolite of MMF, has been found to have a high inter-individual variability, 
concentration controlled treatment is considered to have a pivotal role in MMF therapy. 
This high inter-individual variability has been reported across various patient groups 
60 
including renal transplantation
30
, autoimmune disease in general
18;22
, and SLE
19;24
 and 
lupus nephritis in particular.20;21 Guidelines for therapeutic target ranges for MMF therapy 
in SLE patients have been proposed for MPA-AUC0-12
21;31
 and trough levels.
19;22
 MPA- 
AUC0-12 levels above 45 mg*h/l have been shown to precisely distinguish responders from 
non-responders in lupus nephritis patients who were treated with MMF and prednisone.21 
In addition, a more precise differentiation of MPA-AUC0-12 levels was associated with 
response rates of 60 and 100% for MPA-AUC0-12 levels of 30-60 mg*h/l and > 60 mg*h/l, 
respectively.
21
   
 
Although pharmacokinetic monitoring based on MPA-AUC0-12 levels is considered 
to be the golden standard to measure MPA exposure, the application in real life is 
impractical because of the numerous blood samplings. Limited sampling strategies up to 
three hours after MMF administration32 and even single point trough levels have been 
shown to be good alternatives in patients with SLE.19;22  
The present study used sampling times up to three hours after MMF intake to 
calculate MPA-AUC0-12 and showed that concentration controlled treatment with a target 
MPA-AUC0-12 of 60-90 mg*h/l resulted in exposure within the target range. Although MPA-
AUC0-12 levels were low with a mean of 46.5 mg*h/l before dose adjustment, MPA-AUC0-12 
levels increased to an average of 69.3 mg*h/l after dose adjustment. In addition, inter-
individual variability in MPA exposure tended to be lower on second measurement of 
MPA-AUC0-12 levels. But also levels at 0, one, two, and three hours after MMF 
administration showed significant associations with MPA-AUC0-12 levels. Hence, both 
limited sampling strategies in combination with population pharmacokinetics as well as 
single point trough levels are potential alternatives to the extensive MPA-AUC0-12 
measurements. The choice for one method over the other could be based on the 
availability of resources and/or personal preference of the patient or treating physician. 
Another alternative for TDM that has not been addressed in the present study, is 
the use of inosine 5’monophosphate dehydrogenase (IMPDH). IMPDH is a rate-limiting 
enzyme and inhibition by MPA results in a decreased proliferation and recruitment of 
monocytes and lymphocytes to areas of inflammation.
33
 IMPDH has been suggested as a 
 
 
 61 
promising biomarker of MPA pharmacodynamic activity in renal transplant patients and 
childhood-onset SLE patients, with an additional role in determining MMF starting dose in 
the SLE group.
34
 However, studies with less specific cohorts of SLE patients have not been 
performed and no standardized analytical protocol exists to determine IMPDH.
35
 Hence, 
more studies are needed to validate the use of IMPDH in TDM in SLE patients with lupus 
nephritis.  
 
Previous studies have indicated that the variability in MPA exposure between SLE 
patients cannot be explained by differences in MMF dose.18;19;21 Instead, associations have 
been found for creatinine clearance
18;24
, albumin levels
24
, and immunological markers (i.e., 
anti-dsDNA and complement).19;24 Although comparable determinants of variability have 
been reported in renal transplantation patients, the most important influence in this 
group has been ascribed to the use of concomitant medications.30 Especially the 
administration of calcineurin inhibitors next to MMF has been shown to influence MPA 
exposure. In lupus nephritis, MMF treatment is often combined with the use of 
prednisone. However, there does not seem to be a relationship between glucocorticoid 
dose and MPA-AUC0-12.
36  
Associations between MPA-AUC0-12 and disease parameters were also 
investigated in the present study, but the previously reported associations of MPA-AUC0-12 
with serum albumin and creatinine clearance could not be confirmed. It should be noted 
that the findings of previous studies are partly based on a cohort of SLE and ANCA-
associated small vessel vasculitis patients together.18 In addition, it is not the first time 
that these findings could not be replicated in a group of SLE patients only.19 This may 
suggest that there are other variables that influence MPA variability in SLE patients, such 
as the aforementioned immunological markers19 or genetic factors which have been 
reported in renal transplantation patients.37 Studies with larger cohorts are needed to 
assess the determinants of variability in MPA exposure in patients with lupus nephritis. 
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Pharmacokinetic monitoring in MMF therapy has not only been recommended 
because of the high inter-patient variability in MPA exposure, but also because MPA 
exposure has been related to clinical outcomes. In patients with autoimmune diseases 
(including SLE), higher exposure has been associated with lower disease activity
24
 and 
better protection from recurrence of active disease.22 One study has even suggested that 
MPA-AUC0-12 is a better predictor of renal outcome than clinical or standard laboratory 
measures in patients with lupus nephritis.21 In the present study, an individualized dosing 
regimen with a target MPA-AUC0-12 of 60-90 mg*h/l was associated with a good renal 
outcome after six and 12 months of treatment. The majority of patients were either 
partial or complete responders and only two patients (12.5%) failed to respond to MMF 
therapy. 
 
Although pharmacokinetic studies in renal transplantation patients have shown a 
relationship between high MPA concentrations and the occurrence of adverse events14, 
previous studies which have focused solely on SLE patients did not find a similar 
association.19;21 Also in the present study, adverse events were not related to MPA-AUC0-12 
levels. Two patients discontinued MMF treatment because of side effects, but one patient 
only switched after two years of treatment in which complete remission had been 
achieved. In general, the percentage of patients with adverse effects was low and side 
effects were well tolerable. This favorable outcome appears to be an additional positive 
effect of concentration controlled treatment.  
 
 Limitations of the present study are the small sample size and the lack of a 
control group. However, our patient population was homogenous in duration of MMF 
treatment and the circumstances of MMF initiation (i.e., after six pulses of low dose IVC). 
This makes the results relevant for SLE patients with proliferative lupus nephritis who are 
treated with low dose IVC followed by MMF. Of course a randomized controlled trial 
comparing fixed dose to concentration controlled treatment would be necessary to 
determine the clinical superiority of an optimized dosing regimen in patients with lupus 
nephritis with certainty. In addition, the study did not include patients with membranous 
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lupus nephritis, so that the results only pertain to patients with pure proliferative lupus 
nephritis.  
 
In conclusion, concentration controlled dose adjustments with a target MPA-
AUC0-12 of 60-90 mg*h/l resulted in optimized MPA exposure and decreased variability. 
Moreover, in the context of a modified version of the Euro-Lupus protocol this 
individualized dosing regimen was associated with an excellent renal outcome at 12 
months of follow-up. An optimized dosing regimen through concentration controlled 
treatment appears to result in a better efficacy and safety profile in lupus nephritis.  
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ABSTRACT 
Background The present study investigated the influence of two different treatments for a 
kidney inflammation (i.e., proliferative lupus nephritis) on health-related quality of life 
(HRQoL) in patients with the chronic, autoimmune disease systemic lupus erythematosus 
(SLE). One treatment protocol, the National Institutes of Health (NIH) protocol, was 
characterized by a high dose of cyclophosphamide (CYC; an immunosuppressive drug), and 
the second treatment, the Euro-Lupus protocol, involved a low dose CYC. Methods Thirty-
two SLE patients were included based on a received treatment for an episode of 
proliferative lupus nephritis according to either the Euro-Lupus or NIH protocol. The two 
groups were compared on HRQoL as measured by the Medical Outcomes Study Short 
Form 36 (SF-36) and the SLE Symptom Checklist (SSC). Results The Euro-Lupus group (N = 
16) tended to show a higher HRQoL than the NIH group (N = 16) on four of seven scales of 
the SF-36. In addition, the Euro-Lupus group experienced less burden of the symptom 
nausea/vomiting than the NIH group as assessed by the SSC. Fatigue was the most 
disturbing symptom in both groups. The most burdensome aspects of treatment were 
related to chemotherapy (55.2%) and prednisone use (34.5%). Patients with a low HRQoL 
and high levels of fatigue were more likely to have low levels of serum complement C4 
(i.e., elevated immune activity). Conclusion Patients who are treated according to the 
Euro-Lupus protocol may experience a higher HRQoL than patients who receive the NIH 
treatment. However, chemotherapy remains burdensome in the low dose treatment 
regimen. Potential interventions to further enhance HRQoL in SLE patients with 
proliferative lupus nephritis are discussed. 
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INTRODUCTION 
Few studies have investigated the effect of treatment on health-related quality of 
life (HRQoL) in patients with the chronic, autoimmune disease systemic lupus 
erythematosus (SLE). This could be due to a lack of valid and reliable disease-specific 
HRQoL measurements for SLE patients. However, over the last few years several attempts 
to develop such measurements have shown good results.
1,2,3
 The present study used one 
of those newly validated instruments to assess HRQoL in SLE patients with proliferative 
lupus nephritis.  
 
In SLE, the immune system attacks the body’s own cells, which can result in 
inflammation of multiple organ systems at the same time. SLE is most prevalent among 
women in their reproductive years with usual disease onset between ages 15 and 40.4 The 
worldwide prevalence is estimated to be about one per 1000 and the female to male ratio 
is 10:1.5 Most patients present with vague and varying symptoms including marked 
malaise, extreme fatigue and fever. Also sun over-sensitivity, painful joints, oral ulcers, 
and on the psychosocial level mild depression, are frequently reported. The course of 
disease of SLE is characterized by alternating periods of either relatively stable disease or 
high disease activity. In the face of active disease, patients may need to take high doses of 
strong immunosuppressive agents. But also when the disease is relatively stable, 
maintenance doses are often required to preserve low activity and patients are closely 
monitored for signs of flare-ups.  
 
Lupus nephritis is the most prevalent organ involvement in SLE that affects up to 
60% of patients6 and results in a substantial increase in morbidity and mortality.7 A renal 
biopsy is required to confirm a diagnosis of lupus nephritis. Six different classes of lupus 
nephritis can be distinguished.8 Most importantly, a subdivision between proliferative and 
non-proliferative lesions can be made which guides the choice of treatment regimen.
9
 This 
study will only relate to the treatment of patients with proliferative lesions in their biopsy.   
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Up to 2004, the National Institutes of Health (NIH) regimen was the standard 
treatment for proliferative lupus nephritis at Leiden University Medical Centre (LUMC) and 
involved high doses of cyclophosphamide (CYC) and corticosteroids for two years. 
Although this therapy regimen results in a complete or partial remission in more than 80% 
of patients10, it also has many severe side effects. Immediate side effects include nausea, 
vomiting, fatigue, and hair loss. In the long term cytopenias (i.e., a reduction in the 
number of blood cells), infections, infertility, and malignancy can occur.11 Since 2004, a 
modified version of the Euro-Lupus protocol has been introduced as an alternative 
treatment because it involves lower doses of CYC and corticosteroids and a large portion 
of the CYC is substituted by mycophenolate mofetil (MMF). An important advantage of 
MMF is that it can be taken orally, whereas CYC had to be given intravenously. The 
efficacy of MMF has been shown to be at least equivalent or even superior to CYC, while 
MMF has fewer side effects.11 
 
There are many factors that influence the impact of illness on quality of life, such 
as demographics, the condition itself, treatment, and psychosocial factors. It would be 
expected that less toxic treatments with fewer side effects will enhance patients’ HRQoL 
significantly. Two previous studies have investigated the effect of treatment for lupus 
nephritis on HRQoL. The first study showed that a MMF-based induction treatment for 
proliferative lupus nephritis was associated with better HRQoL than CYC.13 The second 
study found a higher self-reported treatment burden and worse mental HRQoL in a for 
proliferative lupus nephritis CYC treated patient group compared with a group treated 
with corticosteroids and azathioprine.14 
 
The present study aimed to assess HRQoL in two different treatment groups for 
proliferative lupus nephritis and to examine the associations of HRQoL with socio-
demographic and clinical characteristics. In addition, HRQoL of SLE patients was compared 
with HRQoL of patients with other chronic illnesses and with HRQoL of a reference 
population of healthy respondents. It was expected that HRQoL would be higher in 
patients who received the less toxic Euro-Lupus treatment and that HRQoL of SLE patients 
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would be lower than HRQoL of patients with other chronic illnesses and of a reference 
population of healthy respondents.  
 
METHODS 
Participants 
Patients were selected from the electronic patient registration at Leiden 
University Medical Centre (LUMC). Inclusion criteria were a diagnosis of proliferative lupus 
nephritis and a received treatment according to either the NIH or the Euro-Lupus protocol. 
Thirty-seven patients who fulfilled the inclusion criteria were approached to participate in 
the study. One patient refused to join the study without knowing its aim, two patients 
could not be contacted and two patients decided not to participate on personal grounds. 
Hence, the final participant group consisted of 32 patients (86.5% participation rate), with 
16 patients in each treatment group.  
Participants completed two self-administered paper-and-pencil questionnaires in 
a private room at LUMC. Participants filled out the questionnaires on the basis of recall 
about the first half year of treatment. Prior to the assessment, participants provided 
informed consent. The study was approved by the Committee on Medical Ethics LUMC.  
 
Materials  
Research in the area of quality of life has shown that combining generic and 
disease-specific HRQoL assessments in SLE patients results in the optimal 
measurements.15 Therefore, the Medical Outcomes Study Short Form 36 (SF-36) was used 
as a generic measurement of HRQoL.16 The questions about mood were excluded because 
memory for emotions has been shown to be especially subjective to bias from subsequent 
experiences.
17
 As a result, two of the nine scales (i.e. vitality and mental health) of the SF-
36 were not included in this study.  
The SLE Symptom Checklist (SSC) was included to assess disease-specific HRQoL.
1
 
The questions about mood were again excluded and because of this, one of the five 
components of the SSC was not assessed. The remaining four components of the SSC 
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include: (1) socio-demographic characteristics; (2) presence and burden of 38 symptoms; 
(3) influence on daily life and (4) treatment burden.  
Besides assessing HRQoL, disease activity was recorded according to the following 
parameters: proteinuria (i.e., the amount of protein in the urine), serum albumin (i.e., an 
important plasma protein), serum creatinine (i.e., a measure of kidney function), serum 
complement C3 and C4 (i.e., a measure of immune activity) and haematuria (i.e., the 
amount of blood in the urine). These parameters were registered at the start of the 
treatment, at every monthly follow-up up to six months, and at the time of assessment.  
 
Design and Procedure 
Data were analysed using SPSS Version 16.0 software. Means on measures of 
HRQoL were compared between the two patient groups with an independent t-test. One 
sample t-tests were performed to investigate differences in HRQoL between the two 
treatment groups and a reference population of healthy respondents and patients with 
other chronic illnesses (copied from Aaronson et al., 1998).18 Associations among the 
HRQoL measures, socio-demographic characteristics, and disease parameters were 
examined with Spearman’s rho correlations. Effect sizes were classified using Cohen’s d. 
G-Power 3.1.2 was used to compute post-hoc power analyses.   
 
RESULTS 
Participants 
Table 1 gives an overview of the socio-demographic characteristics. The mean age 
of the total participant group was 35.3 (SD = 10.4). Patients had been diagnosed with SLE 
on average 11.1 (SD = 5.0) years ago. The majority of patients were of Dutch origin 
(65.6%). The time since the start of treatment for patients in the NIH group was longer 
than for patients in the Euro-Lupus group (t = 4.30, df = 16.5, p = .001).  
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Table 1. Socio-demographic characteristics for the NIH, Euro-Lupus and total patient group 
    NIH
a
  Euro-Lupus
b
 Total  
    (N = 16)  (N = 16)  (N = 32) 
Female to male ratio   10:6  14:2  24:8 
Age mean (SD)   36.8 (10.3) 33.8 (10.7) 35.3 (10.4) 
Age at diagnosis of SLE mean (SD) 25.2 (7.0)  25.3 (10.3) 25.3 (8.7) 
Disease duration mean (SD)  12.4 (4.9)  9.8 (4.8)  11.1 (5.0) 
Years since start of treatment mean (SD) 8.5 (3.7)  4.5 (.82)** 6.5 (3.4) 
Origin 
  Dutch    11 (34.4%)  10 (31.3%)  21 (65.6%) 
  Surinam    3 (9.4%)  4 (12.5%)  7 (21.9%) 
  Other     2 (6.3%)  2 (6.3%)  4 (12.5%) 
Marital status   
  Living alone   7 (21.9%)  4 (12.5%)  11 (34.4%) 
  Married/cohabitating  9 (25.0%)  12 (34.4%)  21 (59.4%) 
Higher education: 
  Vocational   9 (28.1%)  10 (31.3%)  19 (59.4%) 
  University   3 (9.4%)  1 (3.1%)  4 (12.5%) 
Work status: 
  Student    1 (3.1%)  4 (12.5%)  5 (15.6%) 
  Employed   8 (25.0%)  7 (21.9%)  15 (46.8%) 
  Unemployed   7 (21.9%)  5 (15.6%)  11 (34.4%) 
a
Treatment for proliferative lupus nephritis consisted of high dose cyclophosphamide. 
b
Treatment for proliferative lupus nephritis consisted of low dose cyclophosphamide and mycophenolate 
mofetil.  
**p < .01. 
 
Disease activity parameters at the start of treatment show that the two 
treatment groups only differed in proteinuria values and level of hypoalbuminemia (see 
Table 2). Both groups showed good improvements at six months follow-up and were 
comparable on all disease parameters. Patients in general showed stable disease at the 
time of assessment. 
   
  
74 
Table 2. Disease activity parameters at the start of treatment, after six months and at time of assessment 
between the NIH and Euro-Lupus group 
    NIH  Euro-Lupus Reference 
Serum creatinin (µmol/L)      max. 106 
  Start of treatment (N = 32)  143.8 (97.5) 139.3 (133.0)  
  After six months (N = 32)  117.1 (26.6) 97.9 (59.3) 
  Assessment (N = 32)   108.4 (57.4) 85.6 (44.7) 
Proteinuria (g/24hrs)       0 – 0.15 
  Start of treatment (N = 28)  4.7 (3.0)  2.6 (1.5)*  
  After six months (N = 21)  1.1 (1.2)  1.0 (.91)  
  Assessment (N = 17)   .38 (.50)  .75 (1.4)  
Serum albumin (g/L)       40 – 50  
  Start of treatment (N = 28)  24.4 (6.3)   30.2 (6.5)* 
  After six months (N = 24)  40.9 (6.1)  41.3 (3.8)  
  Assessment (N = 16)   42.4 (7.1)  42.7 (3.7)  
Hematuria
a
        0 
  Start of treatment (N = 30)  4.0 (1.3)  3.6 (1.3)  
  After six months (N = 22)  2.4 (2.0)  1.8 (1.4)  
  Assessment (N = 27)   1.1 (1.6)  .79 (1.3)  
Serum C3
b
 (N= 21)   31.6 (13.4) 28.3 (15.3) 47 – 80  
Serum C4
b
 (N = 22)   11.5 (6.2)  9.3 (11.5)  13 – 39  
Serum C1Q
b
 (N = 20)   10.9 (4.3)  12.11 (7.9)  9 – 14  
a
Hematuria was scored as follows: 1 = trace, 2 = few, 3 = several, 4 = many, 5 = full. 
b
Values only for the start of 
treatment. 
*p < .05. 
 
Medical Outcomes Study Short Form-36 (SF-36) 
The NIH and Euro-Lupus did not show significant differences on the seven HRQoL 
scales, but effect sizes were moderate for the scales physical functioning, social 
functioning, change in health and role limitations emotional (see Table 3). Post-hoc power 
analysis suggests moderate to high power to detect differences for these four scales and 
low power for the scales pain, general health, and role limitations physical. Hence, it is 
likely that the two treatment groups differ on several HRQoL scales but that the sample 
size was too small to detect differences. 
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Table 3. Mean scores (SD) on the SF-36 for the Euro-Lupus, NIH, and total patient group in comparison with a 
reference population of healthy respondents (asterisks indicate significant differences with the reference 
population, no significant differences between the Euro-Lupus and NIH group were found) 
  Reference                   
Scale  population       SLE                       Euro-Lupus       NIH                      Cohen’s d
a
    Power
a 
Physical Functioning 81.9 (23.2)       55.3 (25.6)
***         
61.0 (20.8)
**         
50.0 (29.1)
**
       0.44              76.5% 
Social Functioning 86.9 (20.5)       44.9 (27.7)
***         
50.8 (27.2)
*** 
    39.1 (27.7)
***         
0.43              74.1% 
Role Limitations 79.4 (35.5)       55.5 (42.0)
**           
57.8 (42.5)         53.1 (42.7)
*             
0.11              9.3% 
Role Limitations  84.1 (32.3)       51.0 (44.8)
***         
58.3 (47.9)
*
       43.8 (41.7)
**           
0.32              45.6% 
Pain  79.5 (25.6)       67.2 (23.8)
**           
67.9 (25.8)         66.6 (22.4)
*             
0.05              5.9% 
General Health 72.7 (22.7)       41.4 (22.0)
***         
41.3 (23.1)
*** 
    41.6 (21.7)
***         
0.01              5.0%   
Change in Health  52.7 (19.4)       81.2 (26.9)
***         
87.5 (20.4)
**
      75.0 (31.6)
*             
0.47              83.0% 
*p < .05. **p < .01. ***p < .001. 
a
Cohen’s d and power were calculated for scores between the Euro-Lupus and NIH group.  
 
The NIH group showed a lower HRQoL than a reference population of healthy 
respondents on six scales, whereas the Euro-Lupus group had a lower functioning than 
this population on four scales. In addition, the NIH group differed at a more conservative 
significance level from the reference population than the Euro-Lupus group on the scale 
role limitations emotional. Hence, HRQoL of the NIH group could have been more affected 
by treatment as it was less comparable with that of a reference population than HRQoL of 
the Euro-Lupus Group. When HRQoL of the two treatment groups together were 
compared with HRQoL of the reference population, SLE patients showed a lower HRQoL 
on all scales, except for the scale change in health. 
To investigate whether HRQoL of SLE patients differed from that of patients with 
other chronic illnesses, the scores of the two treatment groups together were compared 
with scores for patients with migraine and cancer (derived from Aaronson et al., 1998)18. 
Table 4 shows the scores for all three groups. In general, SLE patients had a lower HRQoL 
than patients with migraine and cancer. The three patient groups did report a comparable 
level of pain and cancer patients showed a lower HRQoL on the scale role limitations 
physical than SLE patients. 
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Table 4. Mean scores (SD) on the SF-36 for SLE patients compared with migraine and cancer patients  
   SLE  Migraine
a
     Cancer
a
 
   (N = 32)  (N = )      (N = ) 
Physical Functioning  55.3 (25.6) 82.4 (21.3)***       63.6 (25.1) 
Social Functioning  44.9 (27.7) 76.2 (20.9)***         73.9 (24.1)***          
Role Limitations Physical 55.5 (42.0) 62.2 (40.8)       35.0 (40.3)* 
Role Limitations Emotional 51.0 (44.8) 74.5 (37.8)**    58.4 (43.6) 
Pain   67.2 (23.8) 64.9 (22.4)       69.3 (26.6) 
General Health  41.4 (22.0) 67.5 (20.5)***         52.5 (21.4)** 
a
Values copied from Table 4 from Aaronson et al. (1998).
18
 
*p < .05. **p < .01. ***p < .001. 
 
SLE Symptom Checklist (SSC) 
Of the 38 symptoms on the SSC, nausea/vomiting was the only symptom for 
which patients in the NIH group reported a higher burden than patients in the Euro-Lupus 
group (t = 3.39, df = 30, p = .002). Almost all patients (96.6%) mentioned the symptoms 
“fatigue” and “rounding of face”. Fatigue caused the highest burden in both treatment 
groups.  
Patients in the NIH and Euro-Lupus group reported a comparable level of 
influence of treatment on their daily lives. Physical activities were most influenced and 
especially riding the bike. As for the non-physical activities, the influence on work and 
study was the greatest.  
Level of treatment burden did not differ between the two treatment groups. 
Sixteen patients (55.2%) reported chemotherapy and/or adverse effects of chemotherapy 
as the most burdensome aspect(s) of treatment. Frequently mentioned adverse effects of 
chemotherapy were fatigue (17.3%), nausea (13.8%), hospital stay (13.8%) and hair loss 
(6.9%). Ten patients (34.5%) experienced prednisone and/or adverse effects of prednisone 
as the most disturbing effect(s) of treatment. Weight gain and joint involvement were 
stated as adverse effects of prednisone by three (10.3%) and two (6.9%) patients, 
respectively. All mentioned aspects did not show a relationship with type of treatment.   
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Correlations 
Table 5 gives an overview of the correlations between HRQoL measures, disease 
activity parameters and socio-demographic characteristics. Patients with a low HRQoL on 
the scales physical functioning, pain, and role limitations emotional of the SF-36 tended to 
report high levels of fatigue. A high HRQoL on social functioning was associated with high 
serum levels of C4 (i.e., low immune activity).   
Patients who experienced a high influence of treatment on daily life, as measured 
by the SSC, tended to be younger, to have lower serum levels of C4 (i.e., elevated immune 
activity), to have a higher proteinuria (i.e., a large amount of protein in the urine) and to 
report a higher level of fatigue. High levels of fatigue were also associated with a high self-
reported treatment burden.  
Because fatigue was experienced as the most burdensome symptom by both 
groups, its association with disease activity was investigated. Patients who had low levels 
of serum C4 (i.e., elevated immune activity) were more likely to report high levels of 
fatigue. The severity of fatigue was not related to the extent to which treatment 
influenced sleeping habit. 
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Table 5. Correlations between health-related quality of life measures and age, proteinuria, serum C4, albumin and fatigue 
  Age       Fatigue   Proteinuria
a    
Albumin
b     
Serum C4
c    
Physical         Social             Role              Role              Pain     General    Change     Total              Total         Treatment          Mean influence 
                                                                                                                                                    Functioning  Functioning  Limitations  Limitations               Health       Health       Complaints   Distress    Burden        Daily  Physical  Emotional   
Age  1.000       
Fatigue  -.195        1.000 
Proteinuria
a
  -.287        .148           1.000     
Albumin
b
  .107         -.225          -.421*   1.000      
Serum C4
c
  .610**    -.430*        .020   .177            1.000      
Physical Functioning .201        -.411*         -.405*   .123            .097             1.000       
Social Functioning .257        -.284           -.325   .139            .469*           .606**          1.000       
Role Limitations Physical -.147       -.005           .064   .222            -.099            -.156             -.145               1.000      
Role Limitations Emotional .206        -.458**      -.047   .410*          .347             .178              .047                .495**          1.000     
Pain   .085       -.498**      -.276   .208            .253             .465**          .343                -.432*           -.015   1.000    
General Health .110        -.037           -.327   -.255           .177            .218               .345                -.067             -.246   .200            1.000   
Change in Health  -.182      .434*          -.037   -.152           -.054           -.291              -.177              .011              -.142   -.273          .272           1.000  
Total Complaints  .166       .133           .050   .158            .205             -.389*           -.069              .149               .137   -.437*        -.378*        .099          1.000 
Total Distress Level  .124       .294           .090   .068            -.009           -.509**          -.193              .213              .043   -.610**      -.320          .305          .867**      1.000 
Treatment Burden  -.157      .299           .236   -.244           -.291           -.424*            -.388*            -.010            -.089   -.551**     -.268           .278         .224            .445*        1.000 
Mean Influence Daily Life  -.439*    .422*          .451*   -.090           -.544**       -.687**         -.660**          .184              -.121   -.354*        -.531**      .164         .340            .417*        .378*       1.000 
     Physical   -.331       .409*          .198   -.089           -.367           -.589**          -.347            .069              -.179   -.337          -.394*        .254          .332           .497**      .376*       .774**       1.000 
     Emotional   .169        .174            .087           .241            .012            -.299               -.552**         -.118             -.014   -.112          -.229          .143          .175           .111           .123          .368*         .116        1.000 
a
The amount of protein in the urine. 
b
An important plasma protein. 
c
An index of immune activity. 
*p < .05. **p < .01. 
 
 
 79 
DISCUSSION 
The present study aimed to assess HRQoL in SLE patients who were treated for 
proliferative lupus nephritis according to one of two treatment protocols, and to examine 
associations of HRQoL with socio-demographic and disease characteristics. The results 
seem to support the prediction that patients who were treated according to the Euro-
Lupus protocol showed a better physical and psychological functioning than patients from 
the NIH group. However, a manifest better HRQoL was not demonstrated. Chemotherapy 
remained burdensome in low dose and also prednisone use contributed to a worse HRQoL 
in both groups. All patients rated fatigue as the most disturbing symptom, which was 
frequently perceived as an adverse effect of chemotherapy. Worse HRQoL and high levels 
of fatigue were associated with low levels of serum C4 (i.e., elevated immune activity). 
 
Few studies have investigated the effect of different treatments on HRQoL in 
patients with proliferative lupus nephritis.13,14 One retrospective between-subjects study 
assessed HRQoL in 12 patients who had experienced two episodes of lupus nephritis for 
which they were treated with either CYC and prednisone or MMF and prednisone.13 
Although scores on the SF-36 did not show many significant differences, they did tend to 
be higher overall in the MMF group.  
In contrast, a randomized controlled trial (RCT) found no substantial differences 
in HRQoL as measured by the SF-36.14 Patients who were treated for proliferative lupus 
nephritis with either CYC pulses or with azathioprine (AZA) and methylprednisolone 
tablets were compared on HRQoL measures at the start of treatment and at a follow-up of 
12 and 24 months. The AZA group did show a significantly lower treatment burden as 
measured by the SSC. Such an effect was not found in the present study, which could be 
explained by the low dose CYC in the Euro-Lupus group while the AZA group in the RCT 
was completely deprived of CYC. Surprisingly, the AZA group did not report less burden of 
nausea/vomiting, whereas in the present study the Euro-Lupus group reported a 
significantly lower burden. However, it appears that the questionnaire in the RCT study 
referred to a period in which no CYC pulses were given14, which can explain the different 
findings. It seems that a low dose CYC does reduce the disturbance of a symptom like 
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nausea/vomiting, but that treatment burden as a whole may decrease only if CYC is totally 
abandoned.   
 
The finding that fatigue was the most disturbing symptom is in line with results 
from previous studies.14,19 The few studies that have investigated the relationship 
between fatigue and HRQoL, also support the finding that high levels of fatigue are 
associated with worse HRQoL.21,21 
The association between fatigue and disease activity has been examined more 
extensively, but results are inconsistent. Although SLE Disease Activity Index (SLEDAI) 
scores have not shown a relationship with fatigue
20,21
, physician’s ratings of disease 
activity have been associated with fatigue levels.22 In addition, comparable to the 
association between fatigue and serum C4 levels in the present study, low serum C3 levels 
and high lymphocyte counts have been related to high levels of fatigue.19 
 
Many studies have investigated the relation between HRQoL and disease activity, 
and although results from these studies are inconsistent, in general, HRQoL is not well 
correlated with disease activity.23 The present study did find moderate correlations for 
serum C4, proteinuria and serum albumin with some measures of HRQoL. The association 
of serum C4 with both HRQoL and fatigue suggests an important role of serum C4 level in 
physical and psychological functioning. A focus on improvements in serum level of C4 may 
contribute to an enhancement in HRQoL and a reduction in fatigue.  
 
In line with a previous study, the results showed that SLE patients have a 
significantly lower HRQoL than patients with other common chronic illnesses.24 
Interventions other than reductions in CYC and prednisone dose seem desirable to 
enhance HRQoL. A range of psychological interventions, such as self-management 
interventions, cognitive behavioral therapy, and coping skills training, have been 
successful in enhancing HRQoL and fatigue in patients with diabetes, COPD, cancer and 
cardiovascular disease.
25
 Only one known study has addressed the effect of a 
psychological intervention in SLE patients.
26
 This study investigated the application of 
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cognitive behaviour therapy to alter illness perceptions and also looked at the effects of 
therapy on psychological well-being. The beneficial effects on psychological functioning 
were limited, but levels of psychological distress did show significant reductions.
26 
Psychological interventions aimed at enhancing HRQoL are expected to be beneficial for 
SLE patients and future research should address the implementation of the available 
range of interventions.    
 
One important limitation of the present study is the retrospective reporting of 
quality of life. Patents’ reports may have been influenced by recall bias and subsequent 
experiences. In addition, the time interval between treatment and time of assessment 
varied between the two treatment groups, as patients in the NIH group were mostly 
treated before 2004 and those in the Euro-Lupus group only from or after 2004. However, 
measuring HRQoL on the basis of recall with varying time intervals between patients is 
common, as reflected in the number of studies that apply such a method.13,27,28 Moreover, 
a response shift, the re-evaluation of HRQoL in response to changing health, occurs as 
soon as six days after an event29 and time period is one of many factors that may influence 
recall bias.30 Other limitations of the present study include the small sample size and the 
non-random allocation of patients to treatment groups, which limits its power and 
generalizability. Finally, the patient group consisted mainly of patients of Dutch 
(Caucasian) origin. 
 
In conclusion, the Euro-Lupus protocol tends to result in better HRQoL outcomes 
than the NIH protocol. However, SLE patients with lupus nephritis remain having a lower 
HRQoL compared to patients with other common chronic illnesses. Chemotherapy 
remains burdensome in low dose and also prednisone use may contribute to a low HRQoL 
in both groups. Psychological interventions could be beneficial to further enhance HRQoL, 
but research is needed to find out which interventions will be the most effective. 
82 
REFERENCES 
1. Grootscholten, C., Ligtenberg, G., Derksen, R. H., Schreurs, K. M., de Glas-Vos, J. 
W., Hagen, E. C. et al. (2003). Health-related quality of life in patients with 
systemic lupus erythematosus: development and validation of a lupus specific 
symptom checklist. Quality of Life Research, 12, 635-644. 
2. Leong, K. P., Kong, K. O., Thong, B. Y., Koh, E. T., Lian, T. Y., Teh, C. L. et al. (2005). 
Development and preliminary validation of a systemic lupus erythematosus-
specific quality-of-life instrument (SLEQOL). Rheumatology, 44, 1267-1276. 
3. McElhone, K., Abbott, J., Shelmerdine, J., Bruce, I. N., Ahmad, Y., Gordon, C. et al. 
(2007). Development and validation of a disease-specific health-related quality of 
life measure, the LupusQol, for adults with systemic lupus erythematosus. 
Arthritis & Rheumatism, 57, 972-979. 
4. Simard, J. F. & Costenbader, K. H. (2007). What can epidemiology tell us about 
systemic lupus erythematosus? International Journal of Clinical Practice, 61, 
1170-1180. 
5. Manson, J. J. & Rahman, A. (2006). Systemic lupus erythematosus. Orphanet 
Journal of Rare Diseases, 1, 6. 
6. Bihl, G. R., Petri, M., & Fine, D. M. (2006). Kidney biopsy in lupus nephritis: look 
before you leap. Nephrology Dialysis Transplantation, 21, 1749-1752. 
7. Bernatsky, S., Boivin, J. F., Joseph, L., Manzi, S., Ginzler, E., Gladman, D. D. et al. 
(2006). Mortality in systemic lupus erythematosus. Arthritis & Rheumatism, 54, 
2550-2557. 
8. Weening, J. J., D'Agati, V. D., Schwartz, M. M., Seshan, S. V., Alpers, C. E., Appel, 
G. B. et al. (2004). The classification of glomerulonephritis in systemic lupus 
erythematosus revisited. Kidney International, 65, 521-530. 
9. Contreras, G., Roth, D., Pardo, V., Striker, L. G., & Schultz, D. R. (2002). Lupus 
nephritis: a clinical review for practicing nephrologists. Clinical Nephrology, 57, 
95-107. 
10. Buhaescu, I., Covic, A., & Deray, G. (2007). Treatment of proliferative lupus 
nephritis--a critical approach. Seminars in Arthritis & Rheumatism., 36, 224-237. 
11. Houssiau, F. (2007). Thirty years of cyclophosphamide: assessing the evidence. 
Lupus, 16, 212-216. 
12. Petri, M. (2004). Cyclophosphamide: new approaches for systemic lupus 
erythematosus. Lupus, 13, 366-371. 
13. Tse, K. C., Tang, C. S., Lio, W. I., Lam, M. F., & Chan, T. M. (2006). Quality of life 
comparison between corticosteroid- and-mycofenolate mofetil and 
corticosteroid- and-oral cyclophosphamide in the treatment of severe lupus 
nephritis. Lupus, 15, 371-379. 
14. Grootscholten, C., Snoek, F. J., Bijl, M., van Houwelingen, H. C., Derksen, R. H., & 
Berden, J. H. (2007). Health-related quality of life and treatment burden in 
patients with proliferative lupus nephritis treated with cyclophosphamide or 
azathioprine/ methylprednisolone in a randomized controlled trial. Journal of 
Rheumatology, 34, 1699-1707. 
 
 
 83 
15. Thumboo, J. & Strand, V. (2007). Health-related quality of life in patients with 
systemic lupus erythematosus: an update. Annals of Academic Meicine 
Singapore, 36, 115-122. 
16. Van der Zee, K. I. & Sanderman, R. (1993). Het meten van de algemene 
gezondheidstoestand met de RAND-36. Een handleiding/Measuring the general 
state of health with the RAND-36. A manual. Groningen: Noordelijk Centrum voor 
Gezondheidsvraagstukken. 
17. Levine, L.J. & Safer, M.A. (2002). Sources of bias in memories of emotions. 
Current Directions in Psychological Science, 11, 169-173. 
18. Aaronson, N. K., Muller, M., Cohen, P. D., Essink-Bot, M. L., Fekkes, M., 
Sanderman, R. et al. (1998). Translation, validation, and norming of the Dutch 
language version of the SF-36 Health Survey in community and chronic disease 
populations. Journal of Clinical Epidemiology, 51, 1055-1068. 
19. Wysenbeek, A. J., Leibovici, L., Weinberger, A., & Guedj, D. (1993). Fatigue in 
systemic lupus erythematosus. Prevalence and relation to disease expression. 
British Journal of Rheumatology, 32, 633-635. 
20. Bruce, I. N., Mak, V. C., Hallett, D. C., Gladman, D. D., & Urowitz, M. B. (1999). 
Factors associated with fatigue in patients with systemic lupus erythematosus. 
Annals of Rheumatic Diseases, 58, 379-381. 
21. Wang, B., Gladman, D. D., & Urowitz, M. B. (1998). Fatigue in lupus is not 
correlated with disease activity. Journal of Rheumatology, 25, 892-895. 
22. Krupp, L. B., LaRocca, N. G., Muir, J., & Steinberg, A. D. (1990). A study of fatigue 
in systemic lupus erythematosus. Journal of Rheumatology, 17, 1450-1452. 
23. McElhone, K., Abbott, J., & Teh, L. S. (2006). A review of health related quality of 
life in systemic lupus erythematosus. Lupus, 15, 633-643. 
24. Jolly, M. (2005). How does quality of life of patients with systemic lupus 
erythematosus compare with that of other common chronic illnesses? Journal of 
Rheumatology, 32, 1706-1708. 
25. Llewelyn, S. & Kennedy, P. (2003). Handbook of Clinical Health Psychology. West 
Sussex: John Wiley & Sons Ltd. 
26. Goodman, D., Morrissey, S., Graham, D., & Bossingham, D. (2005). The 
application of cognitive behaviour therapy in altering illness representations of 
systemic lupus erythematosus. Behaviour Change, 22, 156-171. 
27. Ito, H., Matsuno, T., Hirayama, T., Tanino, H., & Minami, A. (2007). Health-related 
quality of life in patients with systemic lupus erythematosus after medium to 
long-term follow-up of hip arthroplasty. Lupus, 16, 318-323. 
28. West, E. & Jonsson, S. W. (2005). Health-related quality of life in rheumatoid 
arthritis in Northern Sweden: a comparison between patients with early RA, 
patients with medium-term disease and controls, using SF-36. Clinical 
Rheumatology, 24, 117-122. 
29. Nieuwkerk, P. T., Tollenaar, M. S., Oort, F. J., & Sprangers, M. A. (2007). Are 
retrospective measures of change in quality of life more valid than prospective 
measures? Medical Care, 45, 199-205. 
30. Coughlin, S.S. (1990). Recall bias in epidemiologic studies. Journal of Clinical 
Epidemiology, 43(1), 87-91.  
84 
  
 
 
 85 
CHAPTER 5 
TH E I M PAC T OF  IL L NES S PERC EPT I ON S O N S EX UAL  
FUNC TI ON IN G IN  PAT IE NT S W ITH  S YS TEMI C LU PUS  
ER YTH EMAT OS US  
 
 
 
 
 
 
 
 
 
 
 
 
 
Gabriëlle M.N. Daleboudt  
Elizabeth Broadbent  
Fiona McQueen 
Ad A. Kaptein  
 
Journal of Psychosomatic Research  2012; 74(3): 260-264 
 
86 
ABSTRACT 
Background Sexual problems are common in patients with chronic illnesses. However, few 
studies have investigated problems with sexual functioning in patients with systemic lupus 
erythematosus (SLE). The present cross-sectional study assessed the influence of SLE on 
sexual functioning and its associations with illness perceptions and medical and socio-
demographic characteristics. Methods The study included 106 SLE patients who used at 
least one immunosuppressive agent to control their SLE. Sexual functioning was measured 
using the Physical Disability Sexual and Body Esteem and the Medical Impact Scale from 
the Sexual Functioning Questionnaire. Patients’ illness perceptions were assessed using 
the Brief Illness Perception Questionnaire. Results 49.1% of patients agreed that their SLE 
had a negative influence on their sexual functioning. In addition, treatment for SLE 
seemed to play an important role in the negative impact on sexual functioning. Patients’ 
illness perceptions were more important predictors of sexual functioning than medical 
and socio-demographic characteristics. SLE patients appear to report a lower sexual 
functioning than patients with other chronic illnesses. Conclusion SLE in general and 
immunosuppressive treatment for SLE specifically have a negative influence on sexual 
functioning. Patients’ illness perceptions appear to play a more important role in the 
negative impact on sexual functioning than medical characteristics such as disease activity. 
The high prevalence of sexual problems highlights the need to more frequently address 
and aim to improve sexual functioning in patients with SLE. Patients may benefit from 
methods such as illness perception modification and coping style interventions to reduce 
their sexual problems.  
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INTRODUCTION 
The impact of the chronic, rheumatic, autoimmune disease systemic lupus 
erythematosus (SLE) on health-related quality of life (HRQoL) has been addressed by 
several studies.1-3 HRQoL aims to assess both the extent to which illness and its treatment 
influences functioning on several domains (e.g., physical, mental, social, and role) and 
patients’ emotional responses to these influences.
4
 The effect of SLE on the domain of 
sexual functioning specifically has been less studied.
5;6
 There is no universal definition of 
sexual functioning and it is used interchangeably with other terms such as sexual well-
being and sexual satisfaction.
7
 In the present study, sexual functioning will refer to the 
extent to which illness interferes with one’s sexual identity (e.g., feelings of sexual 
attractiveness, sexual expression, preferences) and sex life (e.g., arousal, orgasm, 
intercourse) and patients’ emotional responses to these interferences. Sexual functioning 
may be disturbed by a variety of factors, including pain, fatigue, stiffness, functional 
impairment, depression, anxiety, negative body image, reduced libido, hormonal 
imbalance, and drug treatment.6  
 
Several disease characteristics specific for SLE may have a negative impact on 
sexual functioning. First, disease onset is commonly in the adolescent years, which is an 
important period for the development of body-image and sexual identity.8 Second, the 
clinical manifestations of SLE (e.g., skin rashes, vitiligo, painful joints) may have an adverse 
effect on interest, desire, and body image. Third, common side effects of 
immunosuppressive agents such as weight gain, hair loss, and infertility, may also 
negatively affect body image. Fourth, active SLE is associated with an increased likelihood 
of adverse pregnancy outcomes9, which could have an additional negative impact on 
sexual functioning.  
 
Although few previous studies have investigated sexual functioning in SLE 
patients, the results in general indicate a negative impact.10-15 In comparison with healthy 
women, SLE patients report lower sexual functioning and poorer body image.11 Among SLE 
patients a lower sexual functioning has been found to be associated with high levels of 
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fatigue
12
, depressive symptoms
12
, disease activity or severity
14
, menstrual cycle 
disturbances15, and the presence of vascular disease (i.e., coronary or peripheral artery 
disease).
15
 
 Apart from the association between sexual functioning and medical and a few 
psychosocial factors, no research with SLE patients has investigated the relationship with 
psychological constructs such as illness perceptions. Illness perceptions consist of 
emotional and cognitive responses to illness and can be grouped into different 
dimensions: perceived identity (illness name and symptoms), illness cause, timeline, 
consequences, how much personal control the patient has, how much treatment can help, 
how much the illness makes sense to the patient (coherence), whether the illness 
concerns the patient, and emotional responses.16  
Research with other chronic illness patients has suggested that such psychological 
parameters may be more important determinants of sexual functioning than medical 
factors.17 Therefore, the purpose of the present study was not only to expand the 
knowledge of the influence of SLE on sexual functioning, but also to investigate whether 
sexuality in these patients was more strongly associated with patients’ illness perceptions 
than medical or socio-demographic characteristics. In addition, SLE patients were 
compared with patients with other chronic illnesses on measures of sexual functioning to 
assess the presence of a disease specific influence. 
 
METHODS 
This cross-sectional study was conducted at Auckland City Hospital, Auckland, 
New Zealand and was approved by the Northern X Ethics Committee.   
  
Participants 
Patients were recruited from the rheumatology clinic at Greenlane Clinical Centre 
(the outpatient clinic of Auckland City Hospital) and from two lupus patients’ associations 
in New Zealand. This study was coupled with one investigating the association between 
treatment non-adherence and psychosocial and medical characteristics.18 Therefore, 
inclusion criteria were not only a diagnosis of SLE according to the revised American 
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College Rheumatology (ACR) criteria for SLE
19
, but also current treatment with 
corticosteroids and/or another immunosuppressive agent. Two weeks after sending out 
invitation letters to potential participants, patients were contacted by telephone. Out of 
the 141 patients who were approached, 106 patients were willing to participate (75% 
participation rate). Twenty-two patients showed no interest in joining the study, four 
patients did not attend the scheduled appointment, and nine patients stated that they 
were too busy or didn’t want to participate because of language barriers.  
Participants provided informed consent and completed four self-administered, 
paper-and-pencil questionnaires. After completion of the questionnaires, the principal 
investigator (GMND, MD and MSc in psychology) assessed disease activity according to the 
SLE Disease Activity Index (SLEDAI).20 The assessment took place in a private room at the 
clinical centre or at the patient’s home if that was more convenient for the patient.  
 
Instruments 
Socio-demographic and medical characteristics were recorded through a separate 
questionnaire and included the following parameters: age, gender, ethnic group, marital 
status, number of children (no distinction between biological or adopted) employment 
status, highest educational level achieved, religion, year of diagnosis of SLE, past and 
present organ involvement(s), and current medication use.   
Sexual functioning was measured using the Physical Disability and Sexual and 
Body Esteem scale (PDSBE)21 and the Medical Impact Scale of the Sexual Functioning 
Questionnaire (SFQ).22 Because there is no questionnaire specifically developed to 
measure sexual functioning in SLE patients, these two scales were chosen because of their 
good psychometric characteristics and because they were developed for or tested in 
several patient groups with diverse medical conditions.21;22 Both questionnaires measure 
level of sexual functioning at the time of assessment. The PDSBE has been shown to be a 
psychometrically sound instrument to assess body esteem and sexual esteem in patients 
with physical disabilities.21 The questionnaire consists of 10 items that are rated on a 5-
point scale from strongly disagree to strongly agree. The items can be subdivided in three 
subscales: 1) attractiveness, 2) sexual esteem and 3) body esteem. Examples of items of 
90 
the PDSBE are “I feel that my illness interferes with my sexual enjoyment” (subscale 
Sexual Esteem), “I feel that people are not sexually interested in me because of my illness” 
(subscale Attractiveness) and “I envy people with ‘normal’ bodies”(subscale Body Esteem). 
Mean scores are calculated for the three subscales separately and all together. In addition, 
sum scores of the three subscales were dichotomized at the scale midpoint to assess the 
strength of patients’ body and sexual esteem and feelings of attractiveness.  
The Sexual Functioning Questionnaire (SFQ) was originally developed to assess 
sexual functioning in patients with cancer, but is thought to result in equally reliable and 
valid outcome measures in patients with other medical conditions as well.22 The Medical 
Impact Scale assesses the impact of treatment on sexual functioning and contains five 
items: one rating scale item and four 5-point scale items. The rating scale item asks 
patients to rate how well they think they have adjusted to changes in their sex life since 
their treatment for SLE.  An example of a 5-point scale item is “What impact has your 
treatment had on your interest or desire for sex?”. A total score is calculated as the mean 
score on all five items. 
The Brief Illness Perception Questionnaire (B-IPQ) was used to measure illness 
perceptions. The B-IPQ contains eight items scored on a scale from 0 to 10 and one open-
ended question where the participants state what they think are the three most important 
causes of their disease. The scale items measure patients’ cognitive and emotional 
representations of their illness and correspond to eight different domains: identity, 
consequences, timeline, personal control, treatment control, coherence, concern, and 
emotion. The reported causes in the open-ended question were grouped into categories 
on the basis of common themes. The B-IPQ has been shown to be a valid and reliable 
measure to assess illness perceptions in ill populations.23 
The Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) was used to 
measure disease activity at the time of assessment.20 The SLEDAI is a reliable, valid and 
widely used instrument to assess disease activity in patients with SLE.24-26 Disease activity 
scores can range from 0 to 105. Five activity categories have been defined: 1) no activity 
(SLEDAI = 0), 2) mild activity (SLEDAI = 1-5), 3) moderate activity (SLEDAI = 6-10), 4) high 
activity (SLEDAI = 11-19), and 5) very high activity (SLEDAI ≥ 20).  
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Statistical analysis 
 Data were analysed using SPSS 17.0 software. Descriptive statistics and 
frequencies were obtained for the socio-demographic and disease related characteristics. 
One sample t-tests were used to test differences in PDSBE scores between SLE patients 
and patients with other chronic illnesses (derived from Kedde & Berlo, 2006)27 and to 
assess whether scores on the Medical Impact Scale were significantly different from 0. 
Scores on the Medical Impact Scale for the SLE group were compared with those for a 
group of cancer patients (derived from Syrjala et al., 2000).
22
 
Associations between sexual functioning and socio-demographic and disease 
related characteristics and illness perceptions were explored with correlational analysis. 
Significant relationships were investigated with multiple linear regression analyses to 
further explore the predictive associations between variables, while controlling for socio-
demographic characteristics and SLEDAI scores. In these analyses, the involved socio-
demographic characteristics were scored as follows: religion as a dichotomous variable (0 
= no religion, 1 = religion), education as an ordinal variable with five categories (1 = 
primary education, 2 = secondary education, 3 = bachelor’s degree, 4 = master’s degree, 
and 5 = doctoral degree). Five separate analyses were performed for sexual functioning in 
general (i.e., total score on the PDSBE), the three subscales of the PDSBE (i.e., sexual 
esteem, body esteem, and attractiveness), and the impact of treatment on sexual 
functioning. The stepwise method was used to select the most important predictor 
variables. An alpha level of .05 was used for all statistical tests.  
 
RESULTS 
Participants 
The mean age of the patients was 43.34 years (SD = 14.96). 94.3% of the patients 
were female, which can be explained by the higher prevalence of SLE in females. The 
largest ethnic group consisted of New Zealand Europeans (39.6%). Table 1 gives an 
overview of socio-demographic characteristics. 
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Table 1. Socio-demographic variables of the total participant group (N = 106) 
Female to male ratio    100:6 
Age mean (SD)    43.34 (14.96) 
Ethnicity 
   New Zealand European   42 (39.6%) 
   Pacific Islands    15 (14.2%) 
   Maori     13 (12.3%)    
   Middle Eastern/Latin American/African   3 (7.5%) 
   Other     3 (6.6%) 
Employment 
   Fulltime     34 (32.1%) 
   Part time    23 (21.7%) 
   Sickness benefit    20 (18.9%) 
   Housewife    9 (8.5%) 
   Retired     9 (8.5%) 
   Student     8 (7.5%) 
   Unemployed    7 (6.6%) 
Marital Status 
   Unmarried    31 (31.2%) 
   Married or living together   55 (51.9%) 
   Divorced     11 (10.4%)    
   Widow/widower    7 (6.6%) 
Education 
   Primary education    5 (4.7%) 
   Secondary education   63 (59.4%) 
   Bachelor’s degree    31 (29.2%) 
   Master’s degree    5 (4.7%) 
   Doctoral degree    2 (1.9%) 
Children (one or more)   65 (61.3%) 
Religion 
   None     60 (56.6%) 
   Christianity    37 (34.9%) 
   Other     9 (8.5%) 
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The patients had a mean disease duration of 10.2 years (SD = 9.1). Half of the 
patients (54.7%) had experienced one or more organ involvements. Nearly three quarters 
of patients (71.7%) had one or more comorbidities. An overview of disease characteristics 
is provided in Table 2.  
 
Table 2. Disease characteristics of total participant group (N = 106) 
Disease duration, mean (SD) in years  10.2 (9.1) 
SLEDAI
a
 score, mean (SD) (range 0-105)  10.2 (6.2) 
Organ involvement 
   None     48 (45.3%) 
   Lupus nephritis    31 (29.2%)  
   NPSLE
a
     17 (16.0%) 
   Pleuritis     13 (12.3%) 
   Pericarditis     10 (9.4%) 
   Hepatitis     7 (6.6%) 
   Eyes     8 (7.5%) 
Co-morbidity 
   None     30 (28.3%) 
   Other autoimmune diseases   18 (17.0%)    
   Hypertension    18 (17.0%) 
   Fibromyalgia    12 (11.3%) 
   Antiphospholipid antibody syndrome  12 (11.3%) 
   Secondary Sjögren’s syndrome   11 (10.4%) 
   Dyslipidemia    10 (9.4%) 
Medication 
   Hydroxychloroquine   89 (84.0%) 
   Prednisone    56 (52.8%) 
   Azathioprine    42 (39.6%) 
   Other immunosuppressants    15 (14.2%) 
   Psychopharmaceuticals   26 (24.5%) 
   Analgesics    30 (28.3%) 
a
Systemic lupus erythematosus disease activity index. 
b
Neuropsychiatric systemic lupus erythematosus.  
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Physical Disability and Sexual and Body Esteem (PDSBE) 
A hundred and one patients completed the PDSBE. Two patients did not want to 
complete the questionnaires, one patient had never been sexually active, and two 
patients thought the majority of the questions were not applicable to their situation. 
49.1% of the patients agreed that having SLE had a negative influence on their sexual 
functioning. This influence consisted of a lower sexual esteem and body esteem for 38.4% 
and 46.1% of the patients, respectively, and feelings of a lower attractiveness for 25.8% of 
the patients. In comparison with patients with other chronic illnesses
27
, SLE patients 
appear to have a lower sexual esteem (M = 10.11, SD = 3.91 vs. M = 12.58, SD = 4.25; t = -
6.28, df = 98, p < .001) and feel less attractive (M = 7.25, SD = 3.0 vs. M = 9.63, SD = 3.2; t = 
-7.33, df = 92, p < .001) . 
 
Medical Impact Scale (MIS) 
The impact of treatment on sexual functioning was assessed for 87 patients. 
Nineteen patients could not complete the questionnaire because they were either not 
sexually active at the time of assessment or they had not had sexual contact yet before 
they were diagnosed with SLE. The mean score on the SFQ Medical Impact Scale (M = 
2.27, SD = .97) differed significantly from 0, i.e., there is no effect of treatment on sexual 
functioning (t = 21.8, df = 86, p < .001). SLE patients appear to report a greater negative 
influence of treatment on their sexual functioning than patients who have been treated 
with bone marrow transplantation for different types of cancer (M = 2.27, SD = .97 vs. M = 
2.92, SD = .96; t = -4.97, df = 86, p < .001).22 In conclusion, SLE patients’ sexual functioning 
was negatively affected by their treatment.   
 
Brief Illness Perception Questionnaire (B-IPQ) 
Patients’ illness perception scores in general clustered around the midrange of 
the items (see Table 3). Two exceptions are the items timeline with the highest mean 
score (M = 8.43, SD = 2.53) and treatment control with the lowest mean score (M = 2.71, 
SD = 2.23)  This indicates that patients held chronic perceptions of their SLE and felt that 
treatment could not help them much. The first most important reported causes were 
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grouped into 5 broad categories: psychosocial causes (33.3%), genetics (32.0%), 
environmental causes (10.7%), previous bacterial or viral infections (13.3%), and 
pregnancy (10.7%). Causal perceptions showed no relationship with measures of sexual 
functioning.  
  
Table 3. Means and standard deviations for the Brief Illness Perception Questionnaire (B-IPQ) 
    SLE patients 
 
(N = 106)    
Identity    6.14 (2.58) 
Consequences     5.45 (2.71) 
Timeline    8.44 (2.49) 
Personal control   4.88 (3.00) 
Treatment Control   2.71 (2.23) 
Coherence   3.29 (2.47) 
Emotion    5.50 (3.03) 
Concern        6.90 (2.83) 
 
Regression analyses 
Table 4 summarizes the results for the five separate regression analyses. With 
sexual functioning in general as the dependent variable, a significant model emerged in 
which emotion and religion explained 16.7% of the variance (F (2, 100) = 11.20, p < .001). 
emotion was the strongest predictor accounting for 11.3% of the explained variance. 
Religion added a further 5.4% to the proportion of explained variance. The subscale 
attractiveness was best predicted by emotion (Adjusted R
2
 = 0.95) and coherence 
(Adjusted R2 = 0.73), which together explained 16.8% of the variance (F (2, 90) = 10.32, p < 
.001). A model with sexual esteem as the dependent variable explained 14.2% of the 
variance and included the variables emotion (Adjusted R2 = 0.11) and identity (Adjusted R2 
= 0.32; F (2, 94) = 8.94, p < .001). The variables personal control, emotion, religion, and 
education were important predictors of body esteem and explained 22.3% of the variance 
(F (4, 97) = 8.24, p < .001). Personal control was the strongest predictor accounting for 
8.2% of the explained variance. Emotion, religion, and education added a further 6.4%, 
4.7%, and 3.2% to the proportion of the explained variance, respectively. With the impact 
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of treatment on sexual functioning as dependent variable, a significant model emerged 
with consequences, coherence, SLEDAI, and treatment control as significant predictors (F 
(5, 92) = 4.97, p < .000). The model explained 31.3% of the variance in sexual functioning. 
Coherence was the strongest predictor accounting for 12.6% of the explained variance. 
Consequences, treatment control, and SLEDAI added a further 10.8%, 4.3%, and 3.6% to 
the proportion of explained variance, respectively.  
 Altogether these analyses suggest that illness perceptions are stronger predictors 
of sexual functioning than medical or socio-demographic characteristics.  
 
Table 4. Summary of regression analyses to predict sexual functioning (Physical Disability Sexual and Body 
Esteem (PDSBE) overall score, subscales and the Medical Impact Scale) 
  PDSBE Total   Sexual Esteem     Body Esteem             Attractiveness       Medical Impact Scale 
Predictor variables  Beta     P         Beta   P              Beta            P              Beta          P        Beta         P 
Socio-demographic 
    Religion
a
 -.249    .007    N/A                 -.245           .008         N/A        N/A     
    Education N/A      N/A                 -.198           .028         N/A        N/A 
Disease-related 
    SLEDAI  N/A      N/A                 N/A               N/A        .239         .015 
Illness perceptions 
    Emotion .362    .000     .251 .019        .252             .006        .333          .001       N/A 
    Coherence N/A      N/A                 N/A               .286          .003       .326            .001 
    Treatment Control N/A      N/A                 N/A                N/A        .225            .016 
    Consequences N/A      N/A                 N/A                N/A        .321            .001 
    Identity  N/A      .222 .037        N/A                N/A        N/A 
    Personal control N/A      N/A                 .232             .012         N/A        N/A 
High scores correspond with low sexual functioning. 
a
Religion was coded as 0 = not religious, 1 = religious. 
 
DISCUSSION 
 The present study assessed the influence of SLE and its treatment on patients’ 
sexual functioning. The results showed that half of the patients experienced negative 
effects of SLE in general on their sexual functioning, especially on their sexual esteem and 
body esteem. In addition, treatment for SLE specifically seemed to play an important role 
in the negative influence on sexual functioning. Patients’ illness perceptions were more 
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important predictors of sexual functioning than socio-demographic and medical 
characteristics. The influence of SLE on sexual functioning appears to be disease specific as 
SLE patients seem to report a lower sexual functioning than patients with other chronic 
illnesses. 
 
 Problems with sexual functioning are common among patients with chronic 
illnesses.28 Between one and two thirds of patients with rheumatic diseases experience 
sexual problems.
5
 However, sexual functioning in rheumatic patients, and specifically in 
patients with SLE, has not been frequently studied.5 The few previous studies that have 
addressed sexual functioning in SLE patients, in general, found a negative effect.
10-15
 This 
was also demonstrated in the present study, with nearly 50% of patients reporting a lower 
sexual functioning because of their SLE. The high prevalence of sexual problems in SLE 
patients highlights the need to address this subject during regular check-ups. Patients may 
feel reluctant to introduce the topic themselves, but if the physician inquires about sexual 
functioning this will make it more likely that patients will report problems at that time and 
in the future.29 
 
 Previous studies have found medical and socio-demographic factors to be 
important predictors of sexual functioning in SLE patients.12;14;15 Although the present 
study also found an association between sexual functioning and disease activity, religion, 
and education, patients’ illness perceptions were stronger predictors of sexual functioning 
than medical and socio-demographic characteristics. In particular, patients who were 
more emotionally affected by their SLE reported a lower sexual functioning. In addition, 
patients reported a lower sexual functioning when they perceived that SLE had a large 
impact on their lives, felt they did not understand their SLE, and believed that treatment 
could not help them much. Of interest is the finding that patients’ emotional 
representations were associated with the PDSBE subscales attractiveness, body esteem, 
and sexual esteem, whereas patients’ cognitive perceptions showed a relationship with 
the influence of treatment on SLE as measured by the Medical Impact Scale. Hence, in 
assessing sexual functioning in SLE patients it is important to differentiate between what 
98 
patients feel and think because the impact on sexual functioning may differ. Sexual 
functioning may be enhanced by interventions that are directed towards illness 
perception modification. Previous research with SLE patients has shown positive changes 
in the perceptions of identity, treatment control, and emotion and related improvements 
in distress after a onetime two-hour cognitive behavior therapy.30  
 
Although patients’ illness perceptions appear to be important predictors of the 
influence of illness on sexual functioning, the results suggest that other factors not 
included in the present study also play a role. For instance, it is likely that coping strategies 
are involved since coping acts as a mediator between illness perceptions and outcomes, as 
described by self-regulation theory.16 In addition, a recent model of coping with sexual 
dysfunction in chronic illness claims that flexibility in coping with sexual dysfunction can 
be increased by enhancing the flexibility in patients’ definitions of sexual functioning 
within their self-concept.31 A preliminary application of the model in cancer survivors with 
sexual problems has shown good results.32 The effectiveness of such an intervention to 
improve sexual functioning in SLE patients should be explored.  
  
Determinants of problems with sexual functioning have been shown to be 
multifactorial and disease specific.5 The present study illustrates this disease specificity by 
showing that SLE patients appear to experience a lower sexual functioning in general and 
as a result of treatment, compared with patients with other chronic illnesses. These 
comparison groups were derived from two separate studies. One study investigated 
sexual satisfaction and sexual self-image among men (N = 95) and women (N = 65) with 
one of seven different chronic medical conditions (e.g., arthritis related conditions, 
muscular illnesses, neurological related illnesses).27 The second study looked at sexual 
problems in 161 women and 118 men who have been successfully treated with blood or 
bone marrow transplants for leukemia or other types of cancer.22 Patients from both 
studies were comparable on socio-demographic characteristics such as age, education and 
marital status. The difference in sexual functioning between SLE patients and patients with 
other chronic illnesses could indicate that SLE has a greater impact on sexual functioning 
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than other illnesses, which would be in line with the finding that HRQoL is lower in SLE 
patients than in patients with other chronic illnesses.1;2 Sexual functioning is one of the 
domains of quality of life and because research has shown that disease specific measures 
are essential for an optimal measure of HRQoL in SLE patients
33
, future studies should be 
dedicated to the development of disease specific measures of sexual functioning in SLE 
patients.  
 
An important limitation of the present study is that it was cross-sectional and 
correlational, which limit interpretations about causality. In addition, regression analyses 
indicated that important factors in the prediction of sexual functioning were not included 
in the present study. Apart from a possible association with coping behavior, previous 
research has shown that sexual functioning was strongly related to premorbid sexual 
adjustment and relationship quality.14 These psychosocial characteristics were not 
assessed in the present study.  
    
In conclusion, SLE in general and treatment for SLE specifically have a negative 
influence on sexual functioning. Patients’ illness perceptions appear to play a more 
important role in the negative impact on sexual functioning than medical characteristics 
such as disease activity. SLE patients with sexual problems could benefit from methods 
such as illness perception modification and coping style interventions to reduce their 
sexual problems. The high prevalence of sexual problems highlights the need to more 
frequently address and aim to improve sexual functioning in SLE patients.  
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ABSTRACT 
Background This study investigated the illness perceptions of patients with systemic lupus 
erythematosus (SLE) and whether perceptions are influenced by type of treatment for 
proliferative lupus nephritis. In addition, the illness perceptions of SLE patients were 
compared with those of patients with other chronic illnesses. Methods Thirty-two patients 
who had experienced at least one episode of proliferative lupus nephritis were included. 
Patients were treated with either a high or low dose cyclophosphamide (CYC) regimen 
(National Institutes of Health (NIH) vs. Euro-Lupus protocol). Illness perceptions were 
measured with the Brief Illness Perception Questionnaire (B-IPQ) and a drawing 
assignment. Results The low dose CYC group perceived their treatment as more helpful 
than the high dose CYC group. In comparison with patients with asthma, SLE patients 
showed more negative illness perceptions on five of the eight illness perception domains. 
Drawings of the kidney provided additional information about perceptions of treatment 
effectiveness, kidney function and patients’ understanding of their illness. Drawing 
characteristics showed associations with perceptions of consequences, identity, concern 
and personal control. Conclusion These findings suggest that the type of treatment SLE 
patients with proliferative lupus nephritis receive may influence perceptions of treatment 
effectiveness. In addition, patients’ drawings reveal perceptions of damage caused by 
lupus nephritis to the kidneys and the extent of relief provided by treatment. The finding 
that SLE is experienced as a more severe illness than other chronic illnesses supports the 
need to more frequently assess and aim to improve psychological functioning in SLE 
patients.  
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INTRODUCTION 
Systemic lupus erythematosus (SLE) is a severe chronic illness with major effects 
on not only patients’ physical functioning, but also on patients’ psychological well-being. 
The importance of this latter effect is exemplified by the finding that health-related quality 
of life (HRQoL) tends to be lower in SLE patients than in patients with other chronic 
illnesses.
1
 Despite the acknowledgement that SLE is a severe disease with substantial 
impact on the patient’s life, few studies have assessed psychological functioning in SLE 
patients. The present study contributes to the need to map out psychological functioning 
in SLE patients by assessing illness perceptions and its associations with socio-
demographic and disease characteristics. In addition, the study investigated the effect of 
two different treatments for proliferative lupus nephritis on patients’ illness perceptions. 
 
Lupus nephritis is the most prevalent organ involvement in SLE. It affects up to 
60% of patients2 and results in a substantial increase in morbidity and mortality.3 Six 
different classes of lupus nephritis can be distinguished.4 Most importantly, a subdivision 
between proliferative and non-proliferative lupus nephritis can be made, which guides the 
choice of treatment regimen. At present, treatment for proliferative lupus nephritis in 
Leiden University Medical Center (LUMC) usually follows a modified version of the Euro-
Lupus protocol.5 Up to 2004, the older NIH regimen was the standard treatment which 
involved higher doses of cyclophosphamide (CYC).5 Because of the lower doses of CYC and 
substitution of a part of the CYC by mycophenolate mofetil (MMF), the modified version of 
the Euro-Lupus protocol is thought to result in less toxic side-effects.6 In addition, it would 
be expected that treatments with fewer side effects will not only form a lesser burden for 
physical health but also for psychological well-being.   
 
There are many factors that influence the impact of illness on psychological and 
physical functioning, such as demographics, the condition itself, treatment and 
psychosocial factors.7 In the realm of psychosocial factors, illness perceptions play an 
important role. Leventhal’s self-regulatory model proposes that patients are active 
problem solvers who seek to make sense of illness and form mental representations that 
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influence coping strategies.
8
 These mental representations of illness (or illness 
perceptions) are composed of cognitions about its identity (the name of the illness and its 
associated symptoms), its consequences, timeline, causes, personal control over the 
illness and the effectiveness of its treatment, as well as overall understanding. How 
individuals respond to illness is partly determined by these perceptions as well as their 
emotional responses.
9
 
 
Although the role of illness perceptions in the impact of illness is broadly 
recognized, only five studies have looked at illness perceptions in patients with SLE. In 
addition, comparison of these studies is limited because of the use of solely qualitative 
measures, such as interviews, to assess perceptions. Another important limitation is that 
no study included male patients. Three studies used semi-structured interviews based on 
Leventhal’s self-regulatory model.10-12 The first study could not support a relationship 
between illness perceptions and disease characteristics, such as disease activity and 
disease duration.11 The most important finding of the second study was that every patient 
holds unique illness perceptions12, which is also reported by two other studies.11;13 
However, such a result could be expected in studies with small sample sizes and 
uncontrolled measures, such as interviews, where the findings depend on what comes to 
mind at the time of assessment. The third study found that the illness perceptions of SLE 
patients are consistent with the self-regulatory model and that patients’ perceptions 
change over time.10 The fourth study is the only study which used a validated and reliable 
questionnaire, i.e., the Illness Perception Questionnaire Revised (IPQ-R), to investigate 
whether a cognitive behaviour therapy (CBT) intervention would influence patients’ illness 
perceptions.14 The results showed that CBT indeed had influenced patients’ perceptions of 
treatment control and the effect of SLE on their emotions. The fifth study used a relatively 
new way to measure patients’ illness perceptions by asking patients to draw their disease 
and providing comments on their drawings.13 The author states that drawings may not 
only make the individual experience more tangible and comprehensible, but it may also 
enhance patients’ feelings of understanding. However, these results were based on the 
author’s interpretation only and drawings were not analyzed to derive scores or other 
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quantitative measures. A more extensive use of drawings to assess illness perceptions has 
been applied with patients with other chronic illnesses. In these studies, quantitative 
analysis of drawings has allowed measurement of underlying perceptions in patients with 
heart disease and headache.
15-19
  
 
The present study aimed to assess illness perceptions in SLE patients and to 
examine their associations with socio-demographic and disease characteristics. It was 
hypothesized that type of treatment for lupus nephritis (i.e., NIH or Euro-Lupus) would 
influence patients’ illness perceptions and that the perceptions of SLE patients would be 
different from those of patients with other chronic illnesses. Specifically, we expected to 
find a beneficial effect of the Euro-Lupus treatment on illness perceptions and that SLE 
patients would perceive their illness as more negative than patients with other chronic 
illnesses.  
 
METHODS 
Participants 
Patients were selected from the electronic patient registration at Leiden 
University Medical Center (LUMC). This study was coupled with one investigating the 
effect of two different treatments for proliferative lupus nephritis on health-related 
quality of life (HRQoL). Therefore, inclusion criteria were a previous diagnosis of 
proliferative lupus nephritis and a received treatment according to one out of two 
protocols (i.e., either the NIH or Euro-Lupus regimen). Patients were approached by 
telephone and received an information letter when they showed interest in the study. Ten 
days after sending the information letter, patients were contacted again by telephone to 
determine their willingness to participate in the study. 
Thirty-seven patients fulfilled the criteria and were approached to participate in 
the study. One patient refused to join the study without knowing the objective, two 
patients could not be contacted and two patients decided not to participate on personal 
grounds. Hence, the final participant group consisted of 32 patients (86.5% participation 
rate), with 16 patients in each treatment group. One patient was excluded from the 
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analysis of the B-IPQ because this patient developed a chemotherapy induced SLE and 
proliferative lupus nephritis, which completely resolved after completion of the 
chemotherapeutic treatment.  
 
Materials  
The Brief Illness Perception Questionnaire (B-IPQ)
20
 and patients’ drawing of their 
kidneys were used to assess illness perceptions. The B-IPQ contains eight items to score 
on a scale from 0 to 10 and one open-ended question where the participants have to state 
the three most important causes for their disease. A mean score is calculated for every 
scale and the reported causes can be grouped into categories on the basis of common 
themes. The B-IPQ has been shown to be a valid and reliable measure to assess illness 
perceptions in ill populations, including patients with renal disease20, but no validation for 
patients with SLE has been done. The Dutch version of the B-IPQ has been used in several 
studies with varying chronic patient populations.21-24 
In the drawing assignment, participants were asked to make two drawings: 1) a 
drawing of their kidneys at the time of the diagnosis of lupus nephritis and 2) a drawing of 
their kidneys after the treatment for lupus nephritis. It was stressed that the drawing 
should represent what they thought their kidneys looked like. Participants were ensured 
that the assignment had no purpose of judging their drawing abilities according to the 
drawing instructions protocol.18  
Besides assessing illness perceptions, parameters of kidney function were 
retrieved from the electronic patient registration at LUMC to assess the effect of both 
treatments on renal outcome. The following parameters were recorded: proteinuria, 
serum creatinine, serum albumin, and hematuria. These parameters were registered at 
the start of treatment, at six months follow-up, and at the time of assessment.   
Participants completed the B-IPQ and drawing assignment in a private room at 
LUMC in the presence of the principal investigator (GMND). Because this assessment was 
combined with another questionnaire based study, time between completion of the first 
and second drawing could be stretched out with 20 up to 30 minutes. So, patients started 
with the first drawing, continued with several questionnaires including the B-IPQ, and 
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finished with the second drawing. Prior to the assessment, participants provided informed 
consent. The study was approved by the Committee on Medical Ethics LUMC.  
 
Design and Procedure 
Data were analysed using SPSS Version 16.0 software. An alpha level of .05 was 
used for all statistical tests. Descriptive statistics and frequencies were obtained for the 
socio-demographic and disease characteristics and kidney function parameters. An 
independent t-test was used to test differences in illness perceptions and measures of 
kidney function between the two treatment groups. Percent reductions in serum levels of 
proteinuria and creatinine and percent increases in serum albumin levels between the 
start of treatment and six months follow-up were calculated and compared between the 
two groups with independent t-tests. One sample t-tests were performed to compare the 
illness perceptions of patients with SLE with those of patients with asthma. Scores for the 
latter group were derived from the study of Broadbent et al. (2006).20 Associations 
between illness perceptions and kidney function, and socio-demographic, disease and 
drawing characteristics were examined with Pearson’s r or Spearman’s rho correlations.  
The drawings were analysed by means of ImageJ software.25 The drawings were 
analysed for the area of the kidneys, the way in which infection or damage was 
represented in the drawing, and the location in the kidney of the representation of 
infection or damage. Moreover, the drawings were rated for the patients’ perceived 
efficacy of treatment and kidney function. Patients’ perceived efficacy was assessed by 
comparing the drawing before treatment with the drawing after treatment. For instance, 
when the first drawing contained many dots to represent damage and the second drawing 
contained no dots, this was regarded as indicating a high perceived efficacy of treatment. 
Patients’ perceived kidney function was assessed on the basis of the second drawing of 
the kidney after treatment. For instance, if the kidney in the second drawing contained no 
representations of damage, this was seen as demonstrating good perceived kidney 
function.  
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RESULTS 
Participants  
The participant group consisted of 24 females and eight males. The majority of 
patients (62.5%) were of Dutch origin. Patients in the NIH group began their treatment for 
proliferative lupus nephritis on average 8.6 (SD = 3.7) years ago, whereas the time since 
the start of treatment for patients in the Euro-Lupus group was on average 4.5 (SD = .82) 
years ago (t = 4.30, df = 16.5, p = .001). There were no other significant differences on 
socio-demographic or disease characteristics between the two treatment groups (see 
Table 1).  
 
Table 2 shows kidney function parameters for the two treatment groups at the 
start of treatment, at six months follow-up and at the time of assessment. At the start of 
treatment, patients from the NIH group showed higher levels of proteinuria (t = 2.48, df = 
21.4, p = .022) and lower serum albumin levels (t = -2.47, df = 25, p = .021) than Euro-
Lupus patients. Both groups showed good improvements at six months follow-up and 
were comparable on all disease parameters. With regard to percent reductions or 
increases between start of treatment and six months follow-up, only the percent increase 
in serum albumin was greater in the NIH group than in the Euro-Lupus group, 41.6% and 
22.6%, respectively (t = 2.07, df = 18, p = .053). Patients in general showed stable disease 
at the time of assessment. Hence, even though patients from the NIH group showed a 
worse protein loss at the start of treatment, renal outcome in general was comparable 
between both treatment groups. 
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Table 1. Socio-demographic and disease characteristics for the NIH and Euro-Lupus group 
    NIH
1
  Euro-Lupus
2
 Total  
    (N = 16)  (N = 16)  (N = 32) 
Percentage females   62.5%  87.5%  75.0% 
Age mean (SD)   36.8 (10.3) 33.8 (10.7) 35.3 (10.4) 
Age at diagnosis of SLE mean (SD) 25.2 (7.0)  25.3 (10.3) 25.3 (8.7) 
Disease duration mean (SD)  12.4 (4.9)  9.8 (4.8)  11.1 (5.0) 
Years since start of treatment mean (SD) 8.5 (3.7)  4.5 (.82)** 6.5 (3.4) 
Number of lupus nephritis episodes:      
  First episode   11  9  20 
  Second or third episode  5  7  12 
Ethnicity: 
  Dutch    11 (34.4%)  10 (31.3%)  21 (65.6%) 
  Surinam    3 (9.4%)  4 (12.5%)  7 (21.9%) 
  Other     2 (6.3%)  2 (6.3%)  4 (12.5%) 
Marital status:   
  Living alone   7 (21.9%)  4 (12.5%)  11 (34.4%) 
  Married/cohabitating  9 (25.0%)  12 (34.4%)  21 (59.4%) 
Higher education: 
  Vocational   9 (28.1%)  10 (31.3%)  19 (59.4%) 
  University   3 (9.4%)  1 (3.1%)  4 (12.5%) 
Work status: 
  Student    1 (3.1%)  4 (12.5%)  5 (15.6%) 
  Employed   8 (25.0%)  7 (21.9%)  15 (46.8%) 
  Unemployed   7 (21.9%)  5 (15.6%)  12(37.5%) 
1
Treatment for proliferative lupus nephritis consisted of high dose cyclophosphamide.  
2
Treatment for proliferative lupus nephritis consisted of low dose cyclophosphamide and mycophenolate mofetil.  
**p < .01. 
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Table 2. Kidney function parameters at the start of treatment, after six months, and at time of assessment 
    NIH  Euro-Lupus Reference ranges 
    Mean (SD)  Mean (SD) 
Serum creatinine (µmol/L)      max. 106 
  Start of treatment (N = 32)  143.8 (97.5) 139.3 (133.0)  
  After six months (N = 32)  117.1 (26.6) 97.9 (59.3) 
  Assessment (N= 32)    108.4 (57.4) 85.6 (44.7) 
Proteinuria (g/24hrs)       0 – 0.15 
  Start of treatment (N = 28)  4.7 (3.0)  2.6 (1.5)*  
  After six months (N = 21)  1.1 (1.2)  1.0 (.91)  
  Assessment (N = 17)   .38 (.50)  .75 (1.4)  
Serum albumin (g/L)       40 – 50  
  Start of treatment (N = 28)  24.4 (6.3)   30.2 (6.5)* 
  After six months (N = 24)  40.9 (6.1)  41.3 (3.8)  
  Assessment (N = 16)   42.4 (7.1)  42.7 (3.7)  
Hematuria
a
        0 
  Start of treatment (N = 30)  4.0 (1.3)  3.6 (1.3)  
  After six months (N = 22)  2.4 (2.0)  1.8 (1.4)  
  Assessment (N = 27)   1.1 (1.6)  .79 (1.3)  
a
Hematuria was scored as follows: 1 = trace, 2 = few, 3 = several, 4 = many, 5 = full.  
*p < .05. 
 
Brief Illness Perception Questionnaire (B-IPQ) 
Table 3 shows the mean scores on the eight B-IPQ items for the total patient 
group. Patients held the strongest perceptions about timeline and treatment control. 
Hence, they perceived their illness as chronic and experienced benefits from their 
treatment. The other illness perception scores clustered around the midrange of the 
items. Patients’ perceptions about the most important cause for their SLE were grouped in 
five categories: stressful events (28.9%), no idea (20.0%), genetics (17.8%), immune 
system defaults (11.1%), environment (11.1%), and bad luck (11.1%).  
The two treatment groups only differed in their perception of treatment control. 
Patients from the Euro-Lupus group thought that treatment had helped them more than 
patients from the NIH group (t = -2.26, df = 29, p = .035). 
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Table 3. Mean scores (SD) on the B-IPQ dimensions of SLE patients versus patients with asthma  
   SLE  Asthma
1 
 
Dimension  (N = 31)  (N = 309) 
Consequences
2
  6.5 (2.3)  3.5 (2.3)***  
Timeline   9.2 (1.8)   8.8 (2.2)  
Personal control  5.6 (2.7)  6.7 (2.4)*  
Treatment control  8.4 (1.6)  7.9 (2.0)  
Identity
2
   6.0 (2.6)  4.5 (2.3)**  
Concern
2
   5.8 (2.7)  4.6 (2.8)*  
Understanding  6.8 (1.9)  6.5 (2.6)  
Emotional response
2  
5.8 (2.7)  3.3 (2.9)***   
1
Values from Broadbent et al. (2006). 
2
Higher scores indicate more negative perceptions. 
*p < .05. **p < .01. ***p < .001. 
  
To investigate whether the illness perceptions of SLE patients differed from the 
perceptions of patients with another chronic illness, the scores of the total patient group 
were compared with scores of patients with asthma (scores were derived from Broadbent 
et al. (2006).20 This sample of asthma patients from the UK had a mean age of 39.8 (SD = 
10.1) and 58.9% of patients was female. Table 3 shows that the illness perceptions of SLE 
patients were more negative on five of the eight items in comparison with asthma 
patients.  
 
Associations between illness perceptions, kidney function and socio-demographic and 
disease characteristics 
None of the kidney function parameters were associated with illness perceptions, 
but several socio-demographic and disease characteristics did show an association with 
illness perceptions. Patients’ illness perceptions of emotion and identity showed a 
relationship with ethnicity and employment status, respectively. Emotional responses to 
SLE were higher for patients from Surinam than for patients of Dutch origin (F = 4.40, df = 
2, p = .021). Patients who were unemployed or received sick benefit reported more 
symptoms than patients with a job or students (t = 2.28, df = 24, p = .032).  
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Two disease characteristics were associated with the illness perception concern. 
Patients with longer disease durations tended to be less concerned about their SLE (r = -
.55, p = .001). In addition, patients who have had two or more episodes of lupus nephritis 
were less concerned than patients with just one experienced episode (t = 3.58, df = 29, p = 
.001).  
 
Drawing assignment  
Thirty patients fulfilled the drawing assignment (see Figure 1 for examples of 
drawings from three patients). Twenty-one patients (70.0%) drew two kidneys and nine 
patients (30.0%) drew just one kidney. The area of the kidneys did not differ between the 
time of diagnosis and after treatment. 
Twenty-two patients (73.3%) showed a clear difference between their drawings 
at diagnosis and after treatment. This difference could consist of 1) a change in the 
amount of damage that was drawn on the kidney, 2) a change in the distribution of this 
damage across the kidney, or 3) a change in the meaning of the drawn damage.  
 
A  
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Figure 1. Drawings of three patients representing their kidneys at the start of treatment and after treatment. A. 
Word in the left drawing means “proteins” and in the right drawing “proteins (highly decreased compared to 
before treatment)”. 
 
Amount of drawn damage 
Sixteen patients (53.3%) used dots to represent damage to the kidney. The 
number of dots that were drawn at diagnosis was larger than the number drawn after 
treatment (t = 3.66, df = 15, p = .002). Six patients (20.0%) represented damage by 
colouring parts of the kidney. 83.3% of the second drawings of these patients showed less 
colouring. Seven patients (23.3%) left their kidneys blank both before and after treatment.  
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Distribution of damage 
In some cases, another noticeable difference between two drawings was the 
position of the damage, which changed in seven occasions (31.8%). For instance, the first 
drawing showed dots globally distributed over the kidney and the second drawing located 
the dots in a circumscribed portion of the kidney (e.g., Figure 1B).  
 
Meaning of the drawn damage 
Fifteen patients (50.0%) wrote down the meaning of the depicted damage, which 
changed in four instances (26.7%) in the second drawing. The most frequently mentioned 
representations were infection, protein leakage and holes.    
 
Perceived efficacy of treatment 
The sets of drawings were categorized into three groups based on the patients’ 
perceived efficacy of treatment. Group 1 was defined as “no change to kidneys”, group 2 
as “kidneys better” and group 3 as “kidneys much better”. For instance, a patient’s 
drawings were put into group 3 when the first drawing contained many dots to represent 
damage and the second drawing contained no dots. According to this classification, eight 
patients (26.7%) believed that their kidneys had not improved after treatment, eleven 
patients (36.7%) thought that their kidneys were better, and another eleven patients 
(36.7%) depicted their kidneys as much better after treatment.  
 
Perceived current kidney function 
The after-treatment drawings were assessed for the patient’s depiction of the 
kidneys’ current function. Three groups were distinguished: 1) poor function, 2) moderate 
function, and 3) good function. For instance, a second drawing with many dots or 
colouring was categorized as group 1. Two patients (6.7%) viewed their kidney function as 
poor, 14 patients (46.7%) as moderate, and 14 patients (46.7%) as good. 
 
  
 
 
 117 
Associations between drawing characteristics, illness perceptions, kidney function and 
socio-demographic and disease characteristics 
None of the socio-demographic characteristics and kidney function measures 
were related to the drawing characteristics, but several drawing characteristics did show 
associations with illness perceptions and disease characteristics. 
The illness perception identity was associated with the number of kidneys that 
were drawn. Patients who drew two kidneys experienced more physical symptoms than 
patients who drew just one kidney (t = -3.12, df = 27, p = .004). 
Reporting the meaning of the drawn damage on the kidneys was associated with 
the illness perceptions concern and personal control. Patients who stated the meaning of 
the dots or colouring in their drawings tended to be more concerned than patients who 
did not explain their drawing (t = 2.11, df = 27, p = .044). In addition, patients who wrote 
down the meaning also experienced less control over their illness than patients who did 
not write down the meaning (t = -2.38, df = 27, p = .025).  
There was also a relationship between reporting the meaning of damage and the 
number of experienced episodes of lupus nephritis. Within the group of patients who had 
experienced one episode of lupus nephritis, the majority (80%) stated the meaning of 
their drawings, whereas in the group of patients who have experienced two or more 
episodes, only a minority (20%) explained what they had drawn (Χ2(1, N = 30) = 5.0, p = 
.025).  
Perceived efficacy of treatment was associated with the illness perceptions 
identity and consequences. Patients who depicted their kidneys as much better after 
treatment experienced fewer physical symptoms and a smaller influence of SLE on their 
lives than patients who depicted their kidneys unchanged after treatment (F = 7.50, df = 2, 
p = .003; F = 6.45, df = 2, p = .005).  
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DISCUSSION 
The present study assessed illness perceptions in SLE patients and its associations 
with socio-demographic and disease characteristics. In addition, the study investigated the 
influence of two different treatments for proliferative lupus nephritis on illness 
perceptions and differences in illness perceptions between SLE patients and patients with 
another chronic illness. Patients who were treated with the less aggressive Euro-Lupus 
regimen rated their treatment as more helpful than patients who had received the heavier 
NIH treatment. SLE patients perceived their illness more negatively than patients with 
asthma on most illness perception dimensions. Patients with longer disease duration or 
those who had experienced more than one episode of lupus nephritis, reported lower 
concern about their condition. Patients’ drawings of their kidneys provided additional 
information on patients’ perceptions of damage to their kidneys due to lupus nephritis 
and the extent of improvement due to treatment.  
 
The finding that the two treatment groups differed in their perception of 
treatment effectiveness is consistent with self-regulation theory. Self-regulation theory 
states that patients are active problem solvers who form mental models about their 
treatment based on their experiences.8 That patients see the Euro-Lupus treatment as 
more effective suggests that this regimen may have more positive effects for patients.  
The more negative illness perceptions of SLE patients compared with patients 
with another chronic illness may indicate that SLE is a more severe illness, which has been 
suggested previously.1 This higher impact of SLE stresses the necessity to investigate 
patients’ psychological functioning more fully and to develop methods to improve it when 
desirable.  
 
 The notion that illness perceptions are susceptible to change, was demonstrated 
by an effect of time and illness experience on the extent to which patients were 
concerned about their SLE. The longer patients had lived with SLE and the more episodes 
of lupus nephritis they had experienced, the less concern they expressed. One of the 
previous studies on illness perceptions in SLE patients also found beneficial changes in 
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illness perceptions over time.
10
 However, these changes were self-reported and no 
associations with socio-demographic or disease characteristics were investigated.   
In addition to these naturally occurring changes, previous work has shown 
positive changes in the perceptions of identity, treatment control, and emotional 
representations after an onetime CBT intervention of two hours.14 The study does show 
some important limitations (small sample size (N = 22), self-selection of treatment 
condition, and participant differences across conditions), which may explain that the 
effects were rather small. However, the positive results suggest that it would be 
worthwhile to perform randomized controlled studies with larger samples and varying 
types of interventions.  
 
Two previous semi-structured interview studies found that patients’ illness 
perceptions often conflicted with medical information and recommendations.11;12 A 
comparable finding in the present study is that few patients named autoimmunity as an 
important causational mechanism of their SLE symptoms. Instead, the most frequently 
stated causal factors were related to experiencing stress. In addition, a considerable 
percentage of patients had no idea what played a role in the origin of their SLE symptoms. 
This finding does not really support the presence of perceptions that conflict medical 
information, but rather a lack of adequate medical knowledge. Improving patients’ 
understanding of the mechanisms of SLE may contribute to a better adjustment to living 
with their illness.  
 
Few studies have used drawings as a research method for assessing illness 
perceptions.13;15-18 Among these studies is one that asked 38 SLE patients to draw their 
disease and comment on what they had drawn.13 The author recommends the use of 
drawings in clinical practice to improve clinicians’ understanding of patients’ psychological 
status. However, information from the drawings could not be extended beyond the 
individual patient and there were no attempts to investigate associations with other 
measures of illness perceptions or disease parameters. Previous work with cardiac 
patients has shown that drawing characteristics are associated with outcome 
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measures.
15;16;18
 For instance, myocardial infarction (MI) patients who drew a larger 
amount of damage at discharge18 and a bigger heart at 3 months follow-up15 showed a 
slower recovery and more heart-focused anxiety.  
 
In the present study, all patients were surprised by the drawing assignment and 
many patients showed some initial reluctance. Many patients reported that they had 
never thought about what their kidneys looked like and that they had never seen their 
kidneys. However, after a moment of reflection almost every patient successfully 
completed both drawings. Several patients who gave explanations for their drawings 
named protein leakage or some kind of filters that were leaking. Thus, some patients were 
aware of at least one of the most important clinical manifestations of lupus nephritis and 
could represent it in a drawing. The observation that the majority of patients (70%) drew 
less damage in their second drawing, seems to indicate that patients perceived an 
improvement in their kidney function because of treatment, but recovery was not 
complete or without damage. More detailed drawings and the inclusion of comments 
were associated with poorer perceptions, and these drawing features may indicate 
greater cognitive focus on the illness. Patients’ drawings added important information to 
the questionnaire assessment, showing details about how patients understood the illness, 
their perceptions of its effects on the kidneys, the effects of treatment, as well as their 
perception of how well their kidneys were currently functioning. 
 
Although the influence of type of treatment on patients’ illness perceptions was 
small, the possible effects on perceptions of treatment effectiveness may have important 
implications. For instance, patients are more likely to adhere to treatment that is 
perceived as effective. In addition, when aggressive treatments are necessary any 
adjustment that can reduce the burden of treatment is worth considering.  
The more positive illness perceptions reported by patients with longer disease 
duration and those who had experienced more episodes of lupus nephritis, suggests that 
patients in the early phases of their SLE may especially benefit from interventions aimed 
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to modify patients’ illness perceptions. A combination of questionnaire and visual based 
assessment is likely to capture the broadest range of patients’ perceptions.  
 
 Some limitations of the present study include the small sample size, the non-
random allocation of patients to treatment groups, and the lack of ethnic diversity in the 
sample, which limits its power and generalizability. In addition, the study was cross-
sectional, which limits its ability to draw conclusions about changes in perceptions over 
time. Finally, it should be mentioned that the sample of SLE patients was not matched for 
age and sex with the referent sample of asthma patients.  
 
In conclusion, SLE may have a higher impact on the patients’ life than other 
chronic illnesses and the level of impact may be influenced by type of treatment. Patients’ 
drawings provide additional information on the physical and psychological burden of SLE.   
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ABSTRACT 
Background Patients may be defined as non-adherent if they don’t take their medications 
as prescribed by their physicians. Determinants of non-adherence may vary between and 
within patient groups. This study investigated the extent to which patients with systemic 
lupus erythematosus (SLE) show intentional and unintentional non-adherence, and the 
associations of non-adherence with psychological and medical parameters. Methods The 
study included 106 patients who were on at least one immunosuppressive agent to 
control their SLE. Level of self-reported adherence and a measure of both intentional and 
unintentional non-adherence were obtained. Questionnaires were completed to assess 
associations between adherence and problems with cognitive functioning, beliefs about 
medicines, illness perceptions, emotional health, and disease characteristics. Results The 
mean self-reported adherence rate for the total patient group was 86.7%. At least 
occasional intentional non-adherence was reported by 46.2% of patients and 58.5% of 
patients were at least occasionally unintentionally non-adherent. Problems with cognitive 
functioning, concerns about adverse effects of medication and younger age were the 
strongest predictors of (non-)adherence. Patients who were emotionally affected by their 
SLE were more likely to report low adherence, but this was not a significant predictor after 
accounting for other variables. Disease characteristics showed no relationship with 
measures of adherence. Conclusion Although SLE patients reported high levels of 
adherence on average, they commonly reported intentional and unintentional non-
adherence. Adherence was associated with both cognitions and emotions. Non-adherence 
may be reduced by targeting emotional and cognitive functioning and by fine-tuning 
doctor-patient communication to address patients’ individual concerns about their 
medications.   
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INTRODUCTION 
Treatment adherence in patients with systemic lupus erythematosus (SLE) has 
been shown to be low, with around 30% never failing to take their medications1-3, 
between 20% and 40% stopping their medication on their own2 and between 14.0% and 
42.6% missing one or more clinic visits.1;4-6 Non-adherence may pose a severe problem as 
it has been associated with higher morbidity
5
, hospitalization
6
 and poor renal outcome.
7
 
Few studies have investigated treatment adherence in SLE patients and generalization of 
the results is often limited because rheumatic arthritis (RA) and SLE patients were treated 
as one patient group
2;8;9
 or differences between specific ethnic groups were 
investigated.1;2;8-10 Moreover, psychosocial factors that may predict treatment adherence 
in SLE patients have not been sufficiently investigated.11 The present study aimed at 
assessing treatment adherence in a representative cohort of SLE patients and investigating 
associations with psychosocial and medical factors.  
 
SLE is an autoimmune disease that can result in inflammation of multiple organ 
systems at the same time. The worldwide prevalence is estimated to be about 1 per 1000 
and the female to male ratio is 10:1.12 The course of disease is characterized by alternating 
periods of either relatively stable disease or high disease activity. In the face of an 
exacerbation, patients may need to take high doses of immunosuppressive agents. But 
also when the disease is relatively stable, maintenance doses are often required to 
preserve low activity and patients are closely monitored for signs of flare-ups. Hence, 
treatment adherence is important to control the course of disease.  
 
A comprehensive assessment of treatment non-adherence should involve both 
intentional and unintentional non-adherence.
13
 In the case of intentional non-adherence, 
patients actively choose not to follow treatment recommendations. A social cognition 
model that aims to explain intentional non-adherent behavior was developed by Horne 
(1997)14 and is based on the Health Belief Model (HBM)15 and the illness perceptions 
model.16 According to Horne’s model, adherence to medication is based on a combination 
of a range of beliefs concerning perceived severity, susceptibility, benefits and barriers 
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and patients’ illness perceptions, i.e., their understandings of the nature of the illness, its 
severity, cause, timeframe, likely prognosis and treatability.  
In contrast to intentional non-adherence, unintentional non-adherence is thought 
to be the result of a passive process which is less strongly associated with individuals’ 
beliefs and perceptions.13 Factors associated with unintentional non-adherence can be 
categorized according to the following three groups: 1) patient factors (e.g., age), 2) 
treatment factors (e.g., side effects), and 3) patient-health care provider factors (e.g., 
doctor-patient interaction).
13
  
 
 Problems with cognitive functioning are frequently reported in SLE patients. The 
prevalence of cognitive dysfunctions is not only high (i.e., 27-52%) in patients with past or 
present neuropsychiatric manifestations of SLE, but also 20-42% of patients without 
neuropsychiatric lupus show cognitive impairments.17 Two previous studies have looked at 
the association between medication adherence and cognitive functioning in SLE 
patients.1;3 In both studies, the assessment of cognitive impairments was based on 
patients’ performance on ability tests: reading ability and short-term memory in one 
study1 and verbal learning and memory in the second study.3 Poor performance on short-
term memory was associated with low adherence in African-American patients, but not in 
White patients.1 However, the authors propose that this difference between ethnic groups 
is a result of socioeconomic disparity and it may not reflect a real barrier to adherence.  
Problems with verbal learning and memory did show a relation with poor adherence, but 
were not important predictors after accounting for other variables.3 Contrary to 
measuring performance, the present study aimed to assess patients’ self-reported 
problems in doing several cognitive functions and activities of daily life. From a clinical 
perspective, it is more informative to know which problems patients actually experience 
and how these real problems relate to non-adherent behavior.  
 
 The present study assessed intentional and unintentional treatment non-
adherence in SLE patients. Moreover, we examined the associations between treatment 
non-adherence and socio-demographic and disease characteristics, cognitive functioning 
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and several psychosocial factors, including beliefs about medicines, illness perceptions, 
and emotional well-being.  
 
METHODS 
Participants 
Patients were recruited from the rheumatology clinic at Greenlane Clinical Centre 
(i.e., the outpatient clinic of Auckland City Hospital) and from two lupus patients’ 
associations. Patients were included when a diagnosis of SLE according to the revised 
American College Rheumatology (ACR) criteria for SLE
18
 was well documented in the 
electronic patient records, and when they received a current treatment with prednisone 
and/or another immunosuppressive agent. Two weeks after sending out invitation letters 
to potential participants, patients were contacted by telephone. Out of 141 patients who 
were approached, 106 patients participated (75% participation rate). Twenty-two patients 
indicated no interest in joining the study, four patients did not attend their scheduled 
study appointment, and nine patients stated they were either too busy or did not want to 
participate due to language barriers.  
Participants provided informed consent prior to the assessment and completed 
six self-administered, paper-and-pencil questionnaires. After completion of the 
questionnaires, the principal investigator (GMND) assessed disease activity according to 
the SLE Disease Activity Index (SLEDAI).19 Assessment took place in a private room at 
Greenlane Clinical Center or at the patient’s home. The study was approved by the 
Northern X Ethics Committee (Auckland region, New Zealand).  
 
Materials 
Treatment adherence was measured using part A of the Medication Adherence 
Self-Report Inventory (MASRI).20 Part A of the MASRI has been shown to be a reliable 
(Cronbach’s a = .70 and ICC = .93) and valid (rs ≥ .55) measure of medication adherence in 
SLE patients. Part A of the MASRI is 87% sensitive and 86% specific for identifying patients 
who were non-adherent.21 Part A consists of five 4-point scale items and one visual 
analogue scale (VAS) item.  
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As a measure of adherence to clinic visits, hospital records were consulted to 
determine the number of visits that were missed in the past 12 months as a percentage of 
the total scheduled appointments in that period.  
The distinction between intentional and unintentional non-adherence was made 
using the Medication Adherence Report Scale (MARS).22 This self-report scale consists of 
one statement to measure unintentional non-adherence and four statements to obtain a 
measure of intentional non-adherence. Two different variables were derived for both non-
adherence measures: a continuous variable (mean score) and a dummy variable (mean 
score 1 is never unintentionally or intentionally non-adherent; mean score > 1 is at least 
occasionally unintentional or intentionally non-adherent).  
The Cognitive Symptoms Inventory (CSI) was used to measure cognitive 
functioning.23 The CSI has been demonstrated to be a good screening measure of cognitive 
impairment in SLE patients in research settings.24 The CSI contains 21 questions to assess 
difficulties in daily activities that relate to: 1) concentration, 2) recognition/planning, 3) 
intermediate memory, and 4) executive function.  
The Beliefs about Medicines Questionnaire (BMQ) was used as a measure of 
commonly-held beliefs about medicine.25 The BMQ consists of 18 items divided over four 
scales: 1) the Specific Necessity scale assesses the perceived necessity of the prescribed 
medication, 2) the Specific Concern scale addresses concerns about the potential adverse 
effects of prescribed medication, 3) the General Harm scale measures the perceived level 
of harm and addiction caused by medications in general, and 4) the General Overuse scale 
assesses beliefs about the use of medicines by doctors. An extended version of the BMQ 
also contains four single items about complementary or alternative medication use.  
 The Brief Illness Perception Questionnaire (B-IPQ) was used to measure illness 
perceptions.26 The B-IPQ contains eight items to score on a scale from 0 to 10 and one 
open-ended question where the participants have to state the three most important 
causes for their disease. The reported causes were grouped into categories on the basis of 
common themes.  
 The subscale emotional health of the LupusQol was used as a measure of the 
emotional domain of health-related quality of life (HRQoL).
27
 The LupusQol is a validated 
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SLE-specific HRQoL instrument. The subscale emotional health consists of six items with a 
5-point scale response format.  
 The Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) was used to 
measure disease activity at the time of assessment.
19
 The SLEDAI is a reliable, valid and 
widely used instrument to assess disease activity in SLE patients.28-30  
 
Design and procedure 
Data were analysed using SPSS 17.0 software. Descriptive statistics and 
frequencies were obtained for the socio-demographic and disease characteristics. 
Associations between measures of adherence and other variables were explored with 
Pearson’s r or Spearman’s rho correlation coefficients. In the presence of significant 
correlations, regression analyses were performed to further study the predictive 
associations between variables. Independent t-tests or Chi-square tests were used to test 
differences on predictor variables between patients who were at least occasionally non-
adherent and patients who were never non-adherent (i.e., dichotomized intentional and 
unintentional adherence variables). In the case of not normally distributed data, non-
parametric t-tests (Mann-Whitney U tests) were performed. To test differences in 
adherence levels between more than two groups (e.g., ethnicity), ANOVA or non-
parametric ANOVA (Kruskal-Wallis test) with Bonferroni correction were used. An alpha 
level of .05 was used for all statistical tests.  
  
RESULTS 
Patients 
 The participant group consisted of 100 females and six males, and had a mean 
age of 43.4 (SD = 15.0). New Zealand Europeans formed the largest ethnic group (39.6%). 
The distribution of ethnicities in the current sample is a good representation of the 
general Auckland population.
31
 Table 1 gives an overview of socio-demographic 
characteristics. 
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Table 1. Demographic variables (N = 106) 
Female:male   100:6 
Age mean (SD)   43.34 (14.96) 
Ethnicity 
   New Zealand European  42 (39.6%) 
   Pacific Islands   15 (14.2%) 
   Maori    13 (12.3%)    
   Indian    11 (10.4%) 
   Asian    14 (7.5%) 
   Other    11 (6.6%) 
Employment 
   Fulltime    34 (32.1%) 
   Part time   23 (21.7%) 
   Sickness benefit   20 (18.9%) 
   Housewife   9 (8.5%) 
   Retired    9 (8.5%) 
   Student    8 (7.5%) 
   Unemployed   7 (6.6%) 
Marital Status 
   Unmarried   31 (31.2%) 
   Married or living together  55 (51.9%) 
   Divorced    11 (10.4%)    
   Widow/widower   7 (6.6%) 
Education 
   Primary education   5 (4.7%) 
   Secondary education  63 (59.4%) 
   Bachelor degree   31 (29.2%) 
   Master degree   5 (4.7%) 
   Doctoral degree   2 (1.9%) 
Children (one or more)  65 (61.3%) 
Religion 
   None    60 (56.6%) 
   Christianity   37 (34.9%) 
   Other    9 (8.5%) 
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Two-thirds of patients were on two or more immunosuppressive agents (62.3%). 
The majority of patients (54.7%) had experienced one or more organ involvements. Nearly 
three quarters of patients (71.7%) had one or more comorbidities. An overview of disease 
characteristics is provided in Table 2. 
 
Table 2. Disease characteristics (N = 106) 
Disease duration mean (SD) in years  10.2 (9.1) 
SLEDAI
a
 score (range 0-105)   10.2 (6.2) 
Organ involvement 
   None     48 (45.3%) 
   Lupus nephritis    31 (29.2%)  
   NPSLE     17 (16.0%) 
   Pleuritis     13 (12.3%) 
   Pericarditis     10 (9.4%) 
   Hepatitis     7 (6.6%) 
   Eyes     8 (7.5%) 
Co-morbidity 
   None     30 (28.3%) 
   Other autoimmune disease   18 (17.0%)    
   Hypertension    18 (17.0%) 
   Fibromyalgia    12 (11.3%) 
   Antiphospholipid antibody syndrome  12 (11.3%) 
   Secondary Sjögren’s syndrome   11 (10.4%) 
   Dyslipidemia    10 (9.4%) 
Medication 
   Hydroxychloroquine   89 (84.0%) 
   Prednisone    56 (52.8%) 
   Azathioprine    42 (39.6%) 
   Other immunosuppressants    15 (14.2%) 
   Psychopharmaceuticals   26 (24.5%) 
   Analgesics    30 (28.3%) 
a
Systemic lupus erythematosus disease activity index. 
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Adherence measures 
The mean self-reported adherence rate for the total patient group was 86.7%. 
Hence, on average patients reported they had taken 86.7% of their medication in the past 
month. The dichotomous distinction between intentional and unintentional non-
adherence showed that 46.2% of patients were at least occasionally intentionally non-
adherent, 58.5% of patients were at least occasionally unintentionally non-adherent, and 
25.5% of patients stated never to be either intentionally or unintentionally non-adherent. 
Unintentional non-adherence was significantly more common than intentional non-
adherence (t = 7.47, df = 105, p < .001). The most common form of intentional non-
adherence was altering the dose of the medications (35.8%).  
Twenty-three patients (22.8%) did not attend one or more clinic visits in the past 
year. On average, 5.2% of scheduled visits were not attended. The more visits patients did 
not attend, the lower the self-reported adherence levels (r = -.28, p = .004). In addition, 
patients who reported frequent unintentional non-adherence tended to miss more clinic 
visits (rs= .24, p = .018).  
 
Associations between adherence measures and socio-demographic characteristics 
Adherence measures were associated with some socio-demographic 
characteristics. Older patients were more likely to report high adherence levels (r = .23,  
p = .017) and unintentional non-adherers were younger than patients who were never 
unintentionally non-adherent (Z = -2.68, p = .007). Ethnicity showed a relationship with 
self-reported adherence level, non-attendance at clinic visits and unintentional non-
adherence. Patients from the Pacific Islands missed out on more clinic visits than patients 
from all other ethnicities (X2 = 10.02, df = 4, p = .040, two-sided) and reported lower 
adherence levels than patients from Asian countries (X2 = 10.15, df = 4, p = .038, two-
sided). Patients from the Pacific showed more unintentional non-adherence than patients 
from New Zealand European or Asian ethnicity (X2 = 16.72, df = 4, p = .002, two-sided).  
Disease characteristics (e.g., SLEDAI scores, disease duration, number of 
comorbidities, number of organ involvements, number of medications) showed no 
relationship with measures of (non-)adherence.  
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Associations between adherence measures and cognitive functioning  
Patients who reported low adherence rates were more likely to experience 
problems with cognitive functioning in general (rs = -.24, p = .013) and specifically with 
concentration (rs = -.24, p = .014) and recognition/planning (rs = -.30, p = .002). Problems in 
these three domains were more common in unintentional non-adherers than in patients 
who did not show unintentional non-adherence (see Table 3). There was no effect for 
intentional non-adherence. Age was not associated with problems with cognitive 
functioning. 
 
Table 3. Means and standard deviations for the Cognitive Symptoms Inventory (CSI) for the total patient group 
and for unintentional versus never unintentional non-adherers 
   Total patient Unintentional Never unintentional    P 
group     non-adherent  non-adherent  
(N = 106)  (N= 62)  (N=44) 
Concentration  14.3 (4.2)  15.2 (4.3)  13.0 (3.6)                       .005** 
Recognition/Planning  4.9 (1.3)  5.2 (1.5)  4.5 (.90)                       <.001*** 
Intermediate Memory 3.4 (1.3)  3.5 (1.2)  3.2 (1.3)                       .181 
Executive Function    2.6 (1.0)  2.5 (.80)  2.7 (1.3)                       .785 
Total CSI score  30.9 (8.0)  32.2 (8.3)  28.9 (7.2)                       .017* 
*p < .05. **p < .01. ***p < .001. 
 
Relations between adherence measures and psychological variables 
Beliefs about Medicines Questionnaire (BMQ) 
80.2% of patients supported the necessity of taking SLE medications to maintain 
good health. However, the majority of patients (63.2%) also expressed concerns about the 
possible negative effects of SLE medications.  
The extent to which patients expressed concerns about their SLE medications was 
associated with all measures of adherence. The more concerned patients were about 
taking SLE medications, the lower their mean self-reported adherence rate (rs = -.23,  
p = .019). Table 4 shows the scores on all 4 subscales for patients who reported intentional 
or unintentional non-adherence versus those who did not. Intentional and unintentional 
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non-adherers were more concerned about the possible side effects of their medications 
than patients who reported no intentional or unintentional non-adherence.  
With regard to medicines in general, 24.5% of patients regarded them as harmful 
and 40.6% of patients thought doctors overuse medicines. Intentional non-adherers held 
stronger beliefs about overuse than patients who were not intentionally non-adherent 
(see Table 4). 
Alternative or complementary medicines were used by 50.9% of patients to 
relieve symptoms, but only a minority of patients agreed that these medicines could 
control their lupus between acute episodes (36.8%). The belief that alternative medicines 
were more natural and less damaging was supported by 24.5% of patients and one-third 
of patients agreed that Western medicines should be substituted by alternative medicines. 
Beliefs about alternative or complementary medicines were not associated with 
adherence measures. 
 
Table 4. Mean scores on the Beliefs about Medicines Questionnaire (BMQ) for intentional versus never 
intentional non-adherers and unintentional versus never unintentional non-adherers  
   Intentional  Never intentional    p                    Unintentional        Never unintentional    p 
   non-adherent non-adherent                     non-adherent        non-adherent 
   (N = 49)  (N = 57)                     (N = 62)             (N = 44) 
Necessity    20.1 (4.1) 19.5 (3.9)                  .389               20.1 (3.9)               19.3 (4.0)                       .192 
Concern    18.0 (3.5) 15.2 (3.9)                  .001***        17.5 (3.4)              14.2 (4.2)                       .003** 
Harm    10.7 (3.2) 10.6 (2.9)                  .896               10.8 (2.9)               10.4 (3.1)                       .439 
Overuse    12.6 (2.8) 11.4(2.7)                   .023*             12.3 (2.9)             11.5 (2.0)                       .145 
*p < .05. **p < .01. ***p < .001. 
 
Brief Illness Perception Questionnaire (B-IPQ) 
Patients’ illness perception scores in general clustered around the midrange of 
the items. An exception is the item timeline with the highest mean score (M = 8.43, SD = 
2.53). This indicates that patients held chronic perceptions of their SLE. Patients who 
experienced strong emotional effects from their SLE showed lower self-reported 
adherence levels (rs = -.25, p = .012). The first most important reported causes were 
grouped into 5 broad categories: psychosocial causes (33.3%), genetics (32.0%), 
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environmental causes (10.7%), previous bacterial or viral infections (13.3%), and 
pregnancy (10.7%). There were no associations with adherence measures.  
 
LupusQol 
 Emotional Health for the total patient group was moderate (M = 72.2, SD = 2.2; 
range 0-100). Patients who were at least occasionally intentionally non-adherent showed 
a worse emotional health than patients who were never intentionally non-adherent (M = 
66.6, SD = 25.3 vs. M = 77, SD = 18.1; Z = -2.09, p = .036). There was no effect for 
unintentional non-adherence.  
 
Regression analyses 
Stepwise linear regression analysis was used to test whether problems with 
cognitive functioning, concerns about medication (i.e., concern), and emotions were 
stronger predictors of self-reported adherence level than demographic variables (age and 
ethnicity). A significant model emerged in which recognition/planning and age explained 
35.9% of the variance in self-reported adherence levels (F (3, 101) = 20.45, p < .001). 
Recognition/planning was the strongest predictor, accounting for 18.8% of the explained 
variance. Age added a further 8.3% to the proportion of explained variance. Table 5 shows 
the regression coefficients. 
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Table 5. Summary of regression analyses to predict treatment non-adherence 
VAS level
a
             Unintentional    Intentional  
        non-adherence  non-adherence 
Predictor variables  Beta  P          B        P  B P 
Cognitive Functioning 
    Recognition/Planning -1.342  .001***         .632        .015*  N/A 
    Concentration  -.003  .976         .069        .332  N/A 
Beliefs about Medicines 
    Concern   -.046  .631         .173        .006** .204           .001** 
    Overuse   -.005  .959         .035        .696  .063           .463 
Socio-demographic 
    Age   -1.089  .001***         -.039        .014*  N/A 
    Ethnicity  -.043  .627         N/A   N/A 
    Religion   N/A          N/A   .130           .694 
Psychosocial 
    Emotional Health   N/A          N/A   -.012          .240 
    B-IPQ
b
 Emotions  -.050  .592         N/A   N/A 
a
VAS = Visual analogue scale. 
b
B-IPQ = Brief Illness Perception Questionnaire. 
*p < .05. **p < .01. ***p < .001. 
 
Logistic regression analyses were performed to assess the strongest predictors of 
intentional and unintentional non-adherence as dummy variables. The Forward:LR 
method was used to test whether intentional non-adherence could be predicted by 
concern, beliefs about medication overuse, and emotional health. A significant model 
emerged with concern as the only significant predictor of intentional non-adherence 
(omnibus X2 = 13.56, df = 1, p < .001). The model accounted for between 12.0% and 16.0% 
of the variance in intentional non-adherence (see Table 5). Using a similar analysis to 
predict unintentional non-adherence, showed that a model with the predictors 
recognition/planning, age, and concern was significant (omnibus X
2 
= 24.56, df = 3,  
p < .001). The model accounted for between 20.7% and 27.8% of the variance in 
unintentional non-adherence (see Table 5).  
 In conclusion, regression analyses showed that problems with 
recognition/planning, concerns about medication use, and age were the strongest 
predictors of non-adherence.  
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DISCUSSION 
This study assessed the prevalence and predictors of intentional and 
unintentional treatment non-adherence in SLE patients. The high mean self-reported 
adherence level indicates good adherence, but patients also commonly report intentional 
or unintentional non-adherence. Unintentional non-adherence was more common than 
intentional non-adherence and was associated with non-attendance of clinic visits. 
Problems with cognitive functioning, concerns about potential adverse effects of 
medication, and age were the best predictors of non-adherence. 
 
Treatment non-adherence has been identified as a substantial problem in 
patients with chronic inflammatory rheumatic diseases.32 However, few studies have 
focused on treatment non-adherence in SLE patients specifically and no prior studies have 
included self-report adherence questionnaires that have been validated for use in SLE 
patients. Previous studies that have assessed adherence in SLE patients report levels 
between 69.1% and 83%.2;6;10;33;34 Even though every study used a different measure to 
assess adherence, the mean adherence level of 86.7% found in the present study seems to 
lie at the high end of the range. This may be partly explained by a difference in the 
regulation of the healthcare system. Three of the previous studies have been conducted in 
the United States or Mexico where costs for medication may be a barrier to 
adherence.2;6;33 This is less likely to be a problem for patients in New Zealand due to the 
publicly funded health care system. Health care costs have indeed been identified as 
potential threats to adherence for SLE patients in the United States and developing 
countries.8;35 Higher health care costs may also explain the difference in percentage of 
missed clinic visits: 5.2% in the present study versus rates between 14% and 42.6% in 
previous studies.1;4-6  
 
Only one known study, in which RA and SLE patients were assessed together, has 
made the distinction between intentional and unintentional non-adherence.
2
 Two third of 
patients reported forgetting their medication at least occasionally and between 20% and 
40% of patients said they intentionally did not take their medication at least occasionally.2 
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These results are comparable to the findings in the present study that both intentional 
and unintentional non-adherence were frequently reported and unintentional non-
adherence seems to be more common.  
 
Problems with cognitive functioning, more specifically with recognition/planning, 
were the strongest predictors of self-reported adherence level and unintentional non-
adherence. Activities that pertain to recognition/planning are managing money and 
paying bills, remembering to take medication and recognizing people. As mentioned 
before, two previous studies have looked at the association of cognitive functioning with 
adherence measures in SLE patients
1;3
 and both could not support a predictive effect of 
cognitive impairments. A study that looked at the relationship between adherence and 
cognitive impairments in three different patient groups does propose that cognitive 
dysfunctions may identify patients at risk of poor adherence regardless of diagnosis or 
regimen.36   
 
Concern about potential adverse effects of medication was the second most 
important predictor of unintentional non-adherence and the only predictor of intentional 
non-adherence. Although most studies on treatment adherence in SLE patients have also 
looked at associations with socio-demographic and psychological factors, only few have 
used validated questionnaires to measure these variables.1;2;33 Despite this limitation, fear 
of side effects of medication was an important barrier to adherence in five out of six 
studies.1;2;8;10;35  
 
Age was a third significant predictor of self-reported adherence level and 
unintentional non-adherence. One other study has examined the relationship between 
age and adherence in SLE and found a non-significant tendency for adherent patients to 
be older than non-adherent patients.33 A similar effect of age on adherence has been 
reported in a study investigating predictors of adherence in four chronic illnesses.37  
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Adherence measures did tend to differ between ethnic groups, with patients 
from the Pacific Islands reporting lower adherence and missing more clinic visits than 
patients from the other ethnicities. However, ethnicity was not a significant predictor on 
the basis of regression analyses. Previous studies have reported mixed results on the 
relationship between ethnicity and adherence levels and comparison with the present 
study is limited because prior research involved different ethnic groups. Three studies 
report a lower self-reported adherence in African-Americans compared with Whites2;5;33, 
but one study used a physician’s assessment of adherence
5
 and another study only found 
an effect for hydroxychloroquine, and not for prednisone or other immunosuppressants.33 
Studies that involved the same ethnic groups as the present study, but looked at 
medication adherence in diabetes patients, support a poorer medication self-care38 and 
lower adherence rates39 in Pacific Islanders compared with Europeans.  
 
Although three previous studies have found a relationship between adherence 
and education2;33;34 and two between adherence and marital status2;33, the present study 
could not confirm these results. Similarly, none of the disease characteristics (disease 
activity, disease duration, number of comorbidities, number of organ involvements, 
number of medications) were related to measures of adherence. However, the disease 
activity index that was used in the present study, the SLEDAI, may have failed to detect a 
relationship with adherence because of a lack of the inclusion of subjective symptoms. For 
instance, the assessment of fatigue is not part of the SLEDAI but has been identified as a 
highly prevalent and disturbing symptom.40 Other indices, such as the European 
Consensus Lupus Activity Management (ECLAM)41, do include these subjective measures 
and may be better correlated with adherence measures.  
 
  The high prevalence of unintentional non-adherence and its association with 
missing clinic visits, suggests that a primary focus on reducing unintentional non-
adherence would greatly improve treatment adherence. This approach is supported by 
findings from a previous study that the main self-reported barriers to adherence among 
SLE patients were examples of unintentional non-adherence (e.g., “just having forgotten” 
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or “being busy at work”).
33
 In addition, suggestions by these patients on how to improve 
adherence all referred to actions that are related to preventing unintentional non-
adherence (e.g., pill boxes or task lists). Apart from these direct methods to reduce 
unintentional non-adherence, adherence can be further improved indirectly by resolving 
problems with cognitive functioning and concerns about adverse effects of medication. A 
recent study found a significant improvement in cognitive functioning of SLE patients after 
an eight-week psycho-educational intervention.42 With regard to concerns about possible 
side effects, addressing a patient’s specific concerns may not only reduce fear of adverse 
effects and thereby improve adherence, but it may also improve the doctor-patient 
relationship. Problems with communication and trust have been identified as important 
barriers to adherence in SLE patients.1;8;10;33  
  
A limitation of this study is that it was cross-sectional and correlational, which 
limits interpretations about causality. In addition, several potential barriers to adherence 
were not investigated. For instance, assessment of the patient-doctor relationship1;10;33, 
perceived costs and evaluation of the healthcare system8;10, and frequent dosing of 
medication8;33 have been identified as a threat to adherence but were not assessed in the 
present study. Lastly, the majority of patients were of New Zealand European origin, 
which limits comparisons between different ethnic groups. A substantial proportion of SLE 
patients of Asian origin could not be included in the study because of language barriers.  
 
In conclusion, intentional and unintentional non-adherence are common in SLE 
patients. Adherence measures were associated with age, cognitive functioning, and 
illness-related emotions. Non-adherence may be reduced by targeting cognitive 
functioning and by fine-tuning doctor-patient communication to address patients’ 
individual concerns about their medications.   
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CHAPTER 8 
GEN ERA L DI S CU SS IO N
148 
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The overall aim of this thesis was to provide a behavioural medicine perspective 
on SLE by investigating both clinical care for patients with SLE and their well-being. 
Therefore, this thesis included studies which described optimization of SLE diagnosis and 
treatment and studies investigating the impact of SLE on patients’ psychological 
functioning. The five main results of this thesis are:  
1. Repeat renal biopsies during a lupus nephritis flare are only advisable in the case of a 
non-proliferative lesion in the original biopsy (chapter 2). The majority of patients with 
proliferative lesions in the reference biopsy have proliferative lesions in a repeat biopsy of 
either the same or a closely related class, which has no therapeutic consequences and 
frequently makes repeat biopsies unnecessary.  
2. Concentration controlled dose adjustments with a target MPA-AUC0-12 of 60-90 mg*h/l 
appears to result in optimized drug exposure and an optimal renal outcome in patients 
with proliferative lupus nephritis (chapter 3). 
3. Type of treatment for proliferative lupus nephritis may not only influence HRQoL 
(chapter 4), but also patients’ perceptions of treatment effectiveness (chapter 6). In 
addition, SLE in general and immunosuppressive treatment for SLE specifically have a 
negative influence on sexual functioning (chapter 5).  
4. Specific illness-related cognitions and emotions which are not assessed by 
questionnaires may be revealed by patients’ drawings (chapter 6).   
5. Intentional and unintentional non-adherence is common in SLE patients and associated 
with both cognitions and emotions (chapter 7).  
 
These main results show that a selective repeat renal biopsy policy and 
therapeutic drug monitoring do not hamper renal outcome and may even reduce 
treatment burden. However, also low dose immunosuppressive treatment remains 
burdensome. This burden is reflected by a lowered HRQoL and lowered sexual 
functioning. In view of limitations in the extent to which immunosuppressive treatment 
can be further lowered, patients' illness perceptions may be targeted to enhance 
psychological functioning. In addition, treatment outcome may benefit from illness 
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perception modification through a beneficial effect of positive (i.e. more adaptive) 
treatment perceptions on level of treatment adherence.  
 
Disease outcome is generally regarded as an important determinant of good 
patient care. One could argue that the correct diagnosis and treatment are essential steps 
in achieving a good disease outcome and therefore important for good patient care. In the 
case of SLE patients with lupus nephritis, classification of lupus nephritis and the 
subsequent treatment are indeed important parameters of disease outcome and good 
patient care. However, good patient care includes more than the management of disease 
parameters. It also comprises consideration of the patient’s management of the illness 
itself and how illness influences everyday functioning and feelings of well-being. In 
addition, there is a reciprocal relationship between disease characteristics and patients’ 
well-being. This perspective is in line with the biopsychosocial model which states that the 
relationship between disease characteristics and patients’ well-being is reciprocal and 
multifactorial and that therefore the patient and not the disease should be the centre of 
focus.1 The studies included in this thesis aimed to derive at a patient centered 
perspective on SLE.  
 
Repeat renal biopsies in the classification of lupus nephritis 
Although a renal biopsy can be necessary to decide on the optimal treatment for 
lupus nephritis, this procedure is risky and burdensome for patients. Hence, it would be 
desirable to keep the number of biopsies to a minimum. However, numerous authors 
advise serial renal biopsy in the management of lupus nephritis.2-6 This advice is based on 
the finding that transformations from one WHO class to another are frequent, i.e. 
between 26-75%.
2-7
 Chapter 2 reports on a study that also found a frequent class switch of 
49%. However, 84% consisted of a switch from one proliferative form to another. A switch 
between class III and IV (with or without an additional class V) was the most frequent 
(54.2%). A predominance of transitions between class III and IV (with or without an 
additional class V) has been reported in several studies.3;4;8;9 The detection of these 
transformations within the proliferative group does not have clear therapeutic 
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consequences and does not justify the performance of repeat biopsy during a flare. On the 
contrary, this thesis does report a significant class switch to proliferative forms in patients 
with non-proliferative lesions in their reference biopsy. Hence, repeat renal biopsy may be 
preserved for patients with non-proliferative lesions in their original biopsy. In these cases 
it remains uncertain which treatment strategy to follow and a biopsy should be 
considered. 
 
Therapeutic drug monitoring in lupus nephritis 
Several treatments have been shown to be effective in achieving a good renal 
outcome in lupus nephritis, but treatment for lupus nephritis in general is burdensome 
because of frequent and serious side effects. Mycophenolate mofetil (MMF) has recently 
been established as an effective drug in both the induction and maintenance treatment of 
lupus nephritis.10-12 However, studies into the pharmacokinetics of MMF have suggested 
that results with MMF may be further improved through therapeutic drug monitoring.13;14 
Although several studies have proposed guidelines for therapeutic target ranges for MMF 
therapy in SLE patients13-16, no study reports on the application of these guidelines in a 
concentration controlled treatment. Chapter 3 describes a study where concentration 
controlled treatment with a target MPA-AUC0-12 of 60-90 mg*h/l resulted in exposure 
within the target range in a sample of SLE patient with proliferative lupus nephritis. 
Although MPA-AUC0-12 levels were low with a mean of 46.5 mg*h/l before dose 
adjustment, MPA-AUC0-12 levels increased to an average of 69.3 mg*h/l after dose 
adjustment. In addition, the individualized dosing regimen was associated with a good 
renal outcome with 87.5% of patients showing a partial or complete response after 12 
months of treatment.  
 
Health-related quality of life (HRQoL) 
A negative effect of pharmacological therapy for SLE on HRQoL has been reported 
previously, but mostly for medication groups only (e.g., immunosuppressants or 
glucocorticosteroids).17-19 Differences between certain variants within medication groups 
or differences in treatment schedules have only been investigated by two previous 
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studies.
20;21
 Comparison of CYC with MMF
20
 and CYC with AZA
22
 showed a lower physical 
and social functioning and higher treatment burden in the CYC groups. Chapter 4 shows 
that patients who were treated according to a low dose CYC and MMF protocol showed a 
non-significant improvement in physical and psychological functioning compared with 
patients in a high dose CYC only group. Hence, with regard to immunosuppressants CYC 
appears to have a more negative effect on HRQoL than other cytotoxic drugs and remains 
burdensome when low dosages are given.  
 
Sexual functioning 
Sexual functioning is a subdomain of HRQoL that has been shown to be important 
for patients with SLE, but which has been studied infrequently. Chapter 5 shows that 
nearly 50% of SLE patients reported a lower sexual functioning because of their SLE. This is 
consistent with a general negative effect found in previous studies that have addressed 
sexual functioning in SLE patients.23-29 The focus in previous studies with regard to 
predictors of sexual functioning has been on medical and socio-demographic factors, 
which have been shown to have associations with sexual functioning in patients with 
SLE.23;26;28 However, this thesis showed that when also psychological factors are included, 
patients’ illness perceptions appear to play a more important role in the negative impact 
on sexual functioning than disease or socio-demographic characteristics. This is consistent 
with comparable research in patients with other chronic medical illnesses30, strengthening 
the relevance of Engel’s biopsychosocial model1 which forms the theoretical basis of this 
thesis.  
 
Illness perceptions 
The findings in chapter 6 suggest that type of treatment for proliferative lupus 
nephritis influences perceptions of treatment effectiveness. Patients who were treated 
with low dose CYC rated their treatment as more helpful than patients with a high dose 
CYC treatment. An effect of  treatment on illness perceptions has not been studied 
previously in patients with SLE. Moreover, illness perception assessment in SLE patients in 
general has been scarce. Although previous studies are difficult to compare because of the 
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use of non-standardized measures, general findings are that patients hold negative 
perceptions31-35 and that their perceptions are susceptible to change.36;37 The results of 
this thesis are in line with these previous findings.    
 
Drawings  
Patients’ drawings of their illness have been shown to uncover additional 
information on illness perceptions in various patient populations
38-40
, including patients 
with SLE.
41
 More importantly, drawing characteristics have been shown to predict physical 
recovery better than medical parameters (e.g. recovery after myocardial infarction).
42
 Also 
in this thesis, SLE patients’ drawings of their kidneys provided additional information on 
their perceptions of damage to their kidneys due to lupus nephritis and the extent of 
improvement due to treatment. Drawing characteristics were not associated with 
measures of renal outcome.    
 
Treatment adherence 
 Adherence to treatment is an important factor in achieving successful treatment 
outcomes. Although the mean self-reported adherence level in chapter 7 of 86.7% implies 
good adherence, patients' also reported frequent intentional and unintentional non-
adherence. Non-adherence has been reported frequently in studies with SLE patients43-49, 
but a distinction between intentional and unintentional non-adherence has been only 
made once.
43
 The previous finding that unintentional non-adherence was more common 
than intentional non-adherence43 is also supported by the findings in chapter 7. In 
contrast to the earlier study43, this thesis also investigated predictors of unintentional 
non-adherence. Problems with cognitive functioning, concerns about potential side effects 
and age were the best predictors of unintentional non-adherence.  
 
Clinical implications and future research 
In studies with patients with SLE, the focus has mainly been on improving disease 
characteristics such as renal outcome and disease activity. Although research into 
patients’ well-being is increasing over the last few decades, this thesis also showed that 
154 
several aspects of psychological functioning for patients with SLE are only beginning to be 
uncovered. The studies included in this thesis aimed to give more insight in the reciprocal 
relationship between disease characteristics and well-being in patients with SLE. The 
results point in the direction of several recommendations to influence this relationship in 
a positive way and for the focus of future research.  
First of all, a restrictive repeat renal biopsy policy may reduce the number of 
repeat renal biopsies and therefore reduce treatment burden. Current renal biopsy 
policies are often based on results from studies existing of protocol renal biopsies. 
However, in clinical practice biopsies are performed on account of a clinical manifestation 
of a lupus nephritis flare. Chapter 2 describes one of the few studies that performed 
repeat biopsies based on clinical characteristics. Given this study’s results and its 
implications, more such studies are needed to confirm the results. In addition, the 
participant group in chapter 2 consisted mostly of individuals of Caucasian descent, so 
that a similar study with patients of other ethnicities should be performed. For example, 
patients with SLE of African descent have a more aggressive course of disease and poorer 
outcomes which may influence preferred biopsy policy. 
Secondly, therapeutic drug monitoring allows making early adjustments in 
medication dosages in order to minimize the occurrence of adverse and toxic effects and 
to maximize renal outcome. Although therapeutic drug monitoring requires frequent 
blood sampling, the early detection of too high or too low drug concentrations may result 
in an overall reduction of treatment burden. Future studies are needed to investigate the 
actual effects on patient experience. In addition, randomized controlled trials comparing 
fixed dose to therapeutic drug monitoring would be necessary to confirm the superiority 
of an individualized dosing regimen.   
Thirdly, the finding that SLE has a great impact on patients’ HRQoL highlights the 
need to address this issue regularly. Patients may feel hesitant to introduce problems with 
psychological functioning themselves, especially when the focus is on medical aspects. 
Moreover, it has been shown that patients are more likely to report problems with sexual 
functioning if physicians inquire about such problems.
50
 But besides making problems with 
psychological functioning open to discussion, disease specific measures of HRQoL can be 
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useful to assess the most important problems and their impact. Although several 
measures of HRQoL have been developed for use with SLE patients, cross-cultural 
validation is often missing and these measures in general do not include an adequate 
assessment of sexual functioning. Future studies are needed to address these issues.  
Furthermore, besides discussing psychological problems, the results of this thesis 
highlight the importance of adequate doctor-patient communication. Chapter 6 showed 
that patients with SLE in general hold negative illness perceptions. Such negative emotions 
and cognitions have been associated with poor outcomes, such as a lowered sexual 
functioning (chapter 5) and low adherence levels (chapter 7). Therefore, improving 
psychological functioning in patients with SLE starts with uncovering patients’ specific 
emotional and cognitive perceptions about their illness. Besides the use of short 
questionnaires, drawings have been shown to be a successful tool to reveal patients’ 
unique illness perceptions (chapter 6). Knowing these perceptions will enable doctors to 
fine-tune their communication to address patients’ specific needs and concerns.  
Lastly, this thesis showed a negative influence of treatment on both HRQoL and 
illness perceptions. Not only adjustments in pharmacological treatment should be sought 
to lower this burden, but also non-pharmacological methods to improve HRQoL and illness 
perceptions should be applied. Psychological interventions aimed at enhancing HRQoL 
have been shown to be successful in patients with different chronic diseases, but 
implementation in SLE patients and its effect on HRQoL have not been studied. A previous 
study did find a positive effect of cognitive behavioural therapy on patients’ illness 
perceptions.36 More positive illness perceptions may not only have a beneficial effect on 
psychological functioning, but also on treatment adherence. Illness perceptions 
modification in SLE patients should therefore be addressed in future studies. 
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CHAPTER 9 
SUM MAR Y  
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Systemic lupus erythematosus (SLE) is a chronic autoimmune disease in which 
autoantibodies can cause inflammation throughout the whole body. Intensive 
immunosuppressive therapy is often necessary to suppress this inflammation and to 
prevent organ damage. The optimal treatment for one of the most serious and prevalent 
manifestations of SLE, lupus nephritis, is a matter of debate. Although several treatment 
regimens have been compared in many different studies, it is unclear which treatment 
regimen results in the best renal outcome and the least adverse effects. Type and 
intensity of treatment are based on the results of a kidney biopsy, which is a burdensome 
procedure for patients and gives risk of haemorrhages and infections. Therefore, it would 
be desirable to be able to keep the frequency of biopsies to a minimum. However, lupus 
nephritis tends to relapse, which results in the question whether repeated biopsies are 
necessary in recurrent episodes of lupus nephritis.  
 Previous studies investigating the relevance of repeated biopsies and optimal 
treatment for lupus nephritis have focused on the effects on renal outcome. The impact of 
diagnosis and treatment on patients’ well-being has been given less attention. Engel’s 
biopsychosocial model describes the relationship between disease characteristics and 
patients’ well-being. This model states that there is a reciprocal relationship between 
disease and well-being and many factors can influence this relationship. This thesis aimed 
to produce a biopsychosocial perspective on SLE by investigating both medical care and 
psychological functioning in patients with SLE. Therefore, the studies included in this 
thesis did not only look at the diagnosis and treatment of lupus nephritis, but also at the 
influence of psychological factors on disease outcome.  
 
 Chapter 1 provides a general introduction on the studies in this thesis and 
outlines the theoretical background of the biopsychosocial perspective. This chapter 
describes Leventhal’s process model of quality of life, the Self-Regulatory Model and 
Horne’s extension of the Common Sense Model. The concepts of quality of life, illness 
perceptions and treatment adherence are defined and reviewed in relation to previous 
research.  
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Chapter 2 describes the relevance of repeated biopsies in the choice of treatment 
for lupus nephritis flares. This retrospective study included 35 patients with lupus 
nephritis and one or more repeat renal biopsies. A total of 84 biopsies were blindly 
reassessed by two pathologists according to the new ISN/RPS criteria. The results showed 
that patients with proliferative lesions in their original biopsy rarely switch to a pure non-
proliferative nephritis during a flare. Therefore, a repeat renal biopsy during a lupus 
nephritis flare appears not to be necessary if proliferative lesions were found in the 
reference biopsy. However, transformation to another class of lupus nephritis during a 
flare was frequently found in patients with a non-proliferative lesion in the original biopsy. 
For these patients, a repeat renal biopsy during a recurrent episode of lupus nephritis is 
advisable. 
 
Chapter 3 presents a retrospective study on the effect of an individualized dosing 
regimen of mycophenolate mofetil (MMF) on the concentration of the active metabolite 
of MMF (mycophenolic acid, i.e. MPA) and renal outcome. A total of 16 patients with 
proliferative lupus nephritis were treated with low dose intravenous cyclophosphamide 
followed by MMF. MPA area under the plasma concentration-time curve (AUC) was 
assessed within one month after the start of MMF therapy. After the determination of 
MPA-AUC, MMF dosages were adjusted to reach a target MPA-AUC of 60-90 mg*h/l. One 
month after the start of MMF treatment mean MPA-AUC was low and showed a high 
inter-individual variability. Dose adjustments of MMF to reach a target MPA-AUC of 60-90 
mg*h/l resulted in a significant higher MPA-AUC and a non-significant reduction in 
variability. At 12 months of follow-up 87.5% of patients had a good renal outcome. An 
individualized dosing regimen appears to result in optimal MPA concentrations, which 
may result in the best renal outcome and least adverse effects. 
 
In chapter 4, the effect of two different treatments for proliferative lupus 
nephritis on quality of life is discussed. The study consisted of 32 patients with 
proliferative lupus nephritis who were treated with cyclophosphamide in a low or high 
dose, the Euro-Lupus and National Institutes of Health (NIH) group, respectively. The two 
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treatment groups were compared on health-related quality of life (HRQoL), as measured 
by the SF-36 and the SLE Symptom Checklist (SSC). Patients in the Euro-Lupus group 
reported a higher HRQoL than patients in the NIH group. The most burdensome aspects of 
treatment were related to chemotherapy and corticosteroids. Hence, also low dose 
treatment for proliferative lupus nephritis remains burdensome. The application of 
psychological interventions, such as self-management and coping skills training, seem 
desirable to try to improve HRQoL in patients with SLE.  
 
Chapter 5 describes the extent to which sexual functioning of patients with SLE is 
influenced by their illness. The Physical Disability Sexual and Body Esteem (PDSBE) and the 
Medical Impact Scale of the Sexual Functioning Questionnaire were used to assess sexual 
functioning in 106 patients who were treated with at least one immunosuppressive drug. 
In addition, patients’ illness perceptions were measured with the Brief Illness Perception 
Questionnaire (B-IPQ). The results showed that 49.1% of patients experienced a negative 
influence of SLE on their sexual functioning. In addition, treatment for SLE seemed to play 
an important role in this negative impact. Patients’ illness perceptions were more 
important predictors of sexual functioning than medical or socio-demographic 
characteristics. The high prevalence of sexual problems highlights the need to more 
frequently address this subject. Illness perception modification and coping style 
interventions may be beneficial in improving sexual functioning.  
 
Chapter 6 discusses the illness perceptions of patients with SLE and the influence 
of pharmacological treatment for SLE on these perceptions. The patient group consisted of 
32 patients who were treated for lupus nephritis with cyclophosphamide in a low or high 
dose, the Euro-Lupus and NIH group, respectively. Illness perceptions were assessed with 
the Brief Illness Perception Questionnaire (B-IPQ) and a drawing assignment. Patients in 
the Euro-Lupus group perceived their treatment as more helpful than patients in the NIH 
group. Patients’ drawings of the kidney provided additional information about perceptions 
of treatment effectiveness, kidney function and patients’ understanding of their illness. 
The results indicate that type of treatment may influence perceptions of treatment 
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effectiveness. In addition to the use of questionnaires, a drawing assignment can provide 
an important contribution to an extensive assessment of patients’ illness perceptions.  
 
In chapter 7, intentional and unintentional treatment non-adherence in patients 
with SLE is investigated. Self-reported adherence and a measure of intentional and 
unintentional non-adherence were assessed for 106 SLE patients who were treated with 
at least one immunosuppressive drug. In addition, patients completed questionnaires to 
measure cognitive functioning, beliefs about medication, illness perceptions, and 
emotional health. This study investigated whether these psychological factors and medical 
parameters had a relationship with the extent to which patients were non-adherent. 
Although the mean self-reported adherence was high (86.7%), patients also reported to 
be regularly intentional and unintentional non-adherent, 46.2% versus 58.5%. Problems 
with cognitive functioning, concerns about side effects and younger age were the 
strongest predictors of non-adherence, whereas no relationship with medical parameters 
was found. Non-adherence may be reduced by targeting problems with cognitive 
functioning and by addressing patients’ individual concerns.   
 
Chapter 8 presents the main conclusions of this thesis. In addition, several 
implications for clinical practice and suggestions for future research are given. A selective 
biopsy policy and individualized treatment regimen do not have a negative influence on 
renal outcome and may even result in a reduction of treatment burden. However, even 
low dose immunosuppressive treatment for SLE remains burdensome, as reflected in a 
lowered quality of life and sexual functioning in patients with SLE. Although there are 
limits to the extent to which immunosuppressive medication can be further adjusted, 
illness perceptions modification may help in improving psychological functioning. In 
addition, renal outcome can benefit from this modification because of a positive effect of 
more favourable perceptions about treatment on level of adherence. In conclusion, the 
assessment, and if necessary adjustment of patients’ perceptions about their illness, is an 
essential step in achieving a good psychological and medical treatment outcome. 
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CHAPTER 10 
NED ER LAN DS E  SA M EN VAT TI N G  
168 
  
 
 
 169 
Systemische lupus erythematosus (SLE) is een chronische auto-immuunziekte 
waarbij auto-antilichamen een ontstekingsreactie door het gehele lichaam kunnen 
veroorzaken. Intensieve immunosuppressieve therapie is vaak nodig om deze ontsteking 
te onderdrukken en schade aan organen te voorkomen. De optimale behandeling van een 
van de meest voorkomende manifestaties van SLE, lupus nefritis, is onderwerp van 
discussie. Alhoewel verschillende behandelschema’s in veel studies met elkaar zijn 
vergeleken, blijft het onduidelijk welke behandeling de beste uitkomst en de minste 
bijwerkingen geeft. Het type en de intensiteit van de behandeling worden gebaseerd op 
de uitkomst van een nierbiopt, een voor de patiënt belastend onderzoek dat risico’s geeft 
op bloedingen en infecties. Gezien de belasting van het onderzoek, is het wenselijk om zo 
min mogelijk biopsieën te verrichten. Lupus nefritis heeft echter veelal een recidiverend 
karakter, waardoor de vraag bestaat of herhaalde biopten noodzakelijk zijn bij 
terugkerende episodes van lupus nefritis.    
Eerdere studies naar het nut van herhaald biopteren en de optimale behandeling 
van lupus nefritis, hebben zich gefocust op het effect hiervan op de nierfunctie. De impact 
van diagnose en behandeling op het welzijn van patiënten komt veel minder vaak aan 
bod. Het biopsychosociale model van Engel beschrijft de relatie tussen ziektekenmerken 
en het welzijn van patiënten. Volgens dit model is er sprake van een wisselwerking tussen 
de ziekte en welzijn en zijn er velerlei factoren die deze wisselwerking beïnvloeden. Door 
zowel de medische zorg als het psychologisch functioneren van patiënten met SLE te 
onderzoeken beoogde dit proefschrift om een biopsychosociaal perspectief op SLE te 
verwezenlijken. De studies in dit proefschrift hebben dan ook niet alleen gekeken naar het 
optimaliseren van de diagnose en behandeling van lupus nefritis, maar ook naar de rol van 
psychologische factoren hierin. 
 
Hoofdstuk 1 geeft een algemene introductie op dit proefschrift en schetst de 
theoretische achtergrond van het biopsychosociale perspectief. In dit hoofdstuk komen 
Leventhal’s process model of quality of life, het Self-Regulatory Model en Horne’s 
uitbreiding van het Common Sense Model aan de orde. De begrippen kwaliteit van leven, 
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ziektepercepties en therapietrouw worden geïntroduceerd en beschreven aan de hand 
van eerder onderzoek.  
 
Hoofdstuk 2 beschrijft de relevantie van herhaald biopteren in de keuze voor 
behandeling van recidiverende lupus nefritis. Deze retrospectieve studie bevatte 35 
patiënten met lupus nefritis waarvan één of meer herhalingsbiopten beschikbaar waren. 
In totaal werden 84 biopten opnieuw beoordeeld door twee pathologen volgens de 
nieuwe ISN/RPS criteria. Uit de resultaten blijkt dat patiënten bij wie in het originele biopt 
een proliferatieve lupus nefritis werd vastgesteld, zelden een overgang naar een niet-
proliferatieve lupus nefritis vertoonden. Herhalingsbiopten lijken dus niet noodzakelijk bij 
een recidiverende nefritis als er sprake was van proliferatieve laesies in het voorafgaande 
biopt. Echter, bij patiënten met een niet-proliferatieve nefritis in het eerste biopt, bleek bij 
een recidiverende nefritis vaak sprake te zijn van een overgang naar een andere klasse 
nefritis. Voor deze groep patiënten wordt geadviseerd om bij een recidief wel opnieuw 
een nierbiopt uit te voeren.   
 
Hoofdstuk 3 behandelt een retrospectieve studie naar het effect van een 
geïndividualiseerde behandeling met mycofenolaatmofetil (MMF) op de concentratie van 
de werkzame stof van MMF (mycofenolzuur) en de nierfunctie. In totaal werden 16 
patiënten met proliferatieve lupus nefritis behandeld met een lage dosis intraveneuze 
cyclofosfamide gevolgd door MMF oraal. Binnen één maand na de start van MMF werd bij 
alle patiënten de concentratie onder de curve (AUC) van mycofenolzuur gemeten. Op 
basis van de gemeten AUC werd de MMF dosis aangepast opdat een streef AUC van  
60-90 mg*h/l zou worden bereikt. De resultaten van deze studie toonden dat de 
gemiddelde AUC van mycofenolzuur één maand na de start van de behandeling met MMF 
laag was en dat er sprake was van een hoge interindividuele variabiliteit. 
Dosisaanpassingen van MMF om een streef AUC van 60-90 mg*h/l te bereiken resulteerde 
na 6 maanden in een significant hogere AUC en een niet-significante afname in de 
variabiliteit. Na 12 maanden behandeling met MMF had 87.5% van de patiënten een 
goede uitkomst met betrekking tot de nierfunctie. Met een geïndividualiseerde 
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behandeling van MMF lijkt het dus mogelijk om een optimale concentratie te bereiken, 
waardoor het optreden van bijwerkingen zo beperkt mogelijk blijft en de 
behandeluitkomst zo optimaal mogelijk gemaakt kan worden.   
 
In hoofdstuk 4 wordt gekeken naar het effect van twee verschillende 
behandelingen voor proliferatieve lupus nefritis op kwaliteit van leven. De studie omvatte 
32 patiënten met proliferatieve lupus nefritis die waren behandeld met cyclofosfamide in 
een lage of hoge dosis, respectievelijk de Euro-Lupus en National Institutes of Health (NIH) 
groep. De twee behandelingsgroepen werden met elkaar vergeleken op ziekte gerelateerd 
kwaliteit van leven, gemeten met de Medical Outcomes Study Short Form 36 en SLE 
Symptom Checklist (SSC). Patiënten in de Euro-Lupus groep rapporteerden een hogere 
kwaliteit van leven dan patiënten in de National Institutes of Health (NIH) groep. De meest 
belastende aspecten van de behandeling waren gerelateerd aan chemotherapie en het 
gebruik van corticosteroïden. Dus ook in lage dosis blijft de behandeling voor 
proliferatieve lupus nefritis belastend. Het introduceren van psychologische interventies 
voor patiënten met SLE, zoals zelfmanagement of coping vaardigheden training, is 
wenselijk om de kwaliteit van leven te kunnen verbeteren.   
 
Hoofdstuk 5 beschrijft de mate waarin het seksueel functioneren van patiënten 
met SLE beïnvloed wordt door hun ziekte. Bij 106 patiënten die tenminste één 
immunosuppressivum gebruikten werd seksueel functioneren gemeten met de Physical 
Disability Sexual and Body Esteem (PDSBE) en de Medical Impact Scale van de Sexual 
Functioning Questionnaire. Ook ziektepercepties werden gemeten met de Brief Illness 
Perception Questionnaire (B-IPQ). De resultaten lieten zien dat de 49.1% van de patiënten 
een negatieve invloed ervoer van SLE op hun seksueel functioneren, waarin de invloed van 
de behandeling voor SLE een belangrijke rol speelde. De ziektepercepties van patiënten 
waren belangrijkere voorspellers van hun seksueel functioneren dan medische en sociaal 
demografische kenmerken. De hoge prevalentie van seksuele problemen benadrukt het 
belang om dit thema bespreekbaar te maken. Het aanpassen van ziektepercepties en 
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copingstijl interventies lijken goede methoden om te proberen het seksueel functioneren 
te verbeteren.   
 
Hoofdstuk 6 behandelt de ziektepercepties van patiënten met SLE en de invloed 
van medicamenteuze behandeling voor SLE op de aard van deze percepties. De 
patiëntengroep bestond uit 32 patiënten die waren behandeld voor lupus nefritis met een 
lage of hoge dosis cyclofosfamide, respectievelijk de Euro-Lupus en NIH groep. De 
ziektepercepties werden gemeten met de B-IPQ en een tekenopdracht. Patiënten uit de 
Euro-Lupus groep beschouwden hun behandeling als meer behulpzaam dan patiënten uit 
de NIH groep. Tekeningen die patiënten maakten van hun nieren leverden extra 
informatie op over hoe patiënten dachten over de effectiviteit van hun behandeling, de 
functie van de nieren en het begrip van hun ziekte. De resultaten geven aan dat type 
behandeling kan bepalen hoe patiënten de werkzaamheid van hun behandeling 
beoordelen. Naast het invullen van vragenlijsten lijkt het maken van een tekening een 
belangrijke bijdrage te leveren aan een zorgvuldige beoordeling van de ziektepercepties 
van patiënten.  
 
In hoofdstuk 7 wordt beschreven in hoeverre patiënten met SLE 
therapieadviezen bewust en onbewust niet opvolgen. Van 106 SLE patiënten die 
tenminste één immunosuppressivum gebruikten werd de zelf gerapporteerde 
therapietrouw en een meting van bewuste en onbewuste therapieontrouw vastgelegd. 
Daarnaast vulden alle patiënten vragenlijsten in voor het meten van cognitief 
functioneren, opvattingen over medicatie, ziektepercepties en emotionele gezondheid. Er 
werd gekeken of deze psychologische metingen en medische parameters een relatie 
hadden met de mate waarin patiënten therapieontrouw waren. Alhoewel de gemiddelde 
zelf-gerapporteerde therapietrouw hoog was (86.7%), gaven patiënten ook aan regelmatig 
bewust en onbewust therapieontrouw te zijn, 46.2% versus 58.5%. Problemen met 
cognitief functioneren, zorgen over medicatiebijwerkingen en een jonge leeftijd waren de 
sterkste voorspellers van therapieontrouw, terwijl er geen relatie met medische 
parameters werd gevonden. Om therapieontrouw te kunnen verminderen, is het nodig 
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om mogelijke problemen met cognitief functioneren aan te pakken en om de specifieke 
zorgen van de patiënt bespreekbaar te maken.      
 
In hoofdstuk 8 worden de belangrijkste conclusies van dit proefschrift besproken. 
Daarnaast worden enkele implicaties voor de klinische praktijk en suggesties voor 
toekomstig onderzoek gegeven. Een beleid van selectief herhaald biopteren en 
geïndividualiseerde behandeling hebben geen nadelige invloed op de uitkomst voor de 
nierfunctie en kunnen zelfs tot een vermindering van de therapielast zorgen. Maar 
immunosuppressieve therapie blijft ook in lage doseringen belastend, wat blijkt uit een 
verminderde kwaliteit van leven en seksueel functioneren bij patiënten met SLE. Alhoewel 
er een grens is aan de mate waarin immunosuppressieve medicatie verder verlaagd kan 
worden, lijkt het aanpassen van de ziektepercepties van patiënten een manier om het 
psychologisch functioneren te verbeteren. De uitkomst voor de nierfunctie kan hiervan 
profiteren vanwege een positief effect van gunstige percepties over de behandeling op 
therapietrouw. Concluderend, het achterhalen en zo nodig aanpassen van de percepties 
van patiënten over hun ziekte is een essentiële stap in het bereiken van een goede 
psychologische én medische behandeluitkomst. 
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Vele mooie, maar gevoelsmatig soms ook lange jaren, heeft het voltooien van 
mijn proefschrift in beslag genomen. Het ene jaar maakte ik grote sprongen vooruit, het 
andere jaar lag het project nagenoeg stil. Ik vond het niet altijd makkelijk om naast studie 
en werk door te gaan met mijn proefschrift. De hulp en steun van onderstaande personen 
hebben me in staat gesteld om het tot een mooi resultaat te volbrengen!     
 
 Mijn eerste kennismaking met het wetenschappelijk onderzoek verliep via dr. 
Ingeborg Bajema. Zij heeft mij geïntroduceerd in haar onderzoeksgroep waar ik me zeer 
welkom voelde en veel inspiratie heb opgedaan. Ik ben haar dankbaar voor de 
mogelijkheden die ze me geboden heeft om kennis te maken met het wetenschappelijk 
onderzoek en haar deelnemers, waaronder in het bijzonder mijn co-promotor, dr. Stefan 
Berger.  
 
 Stefan Berger heeft mij geïntroduceerd in de wereld van de SLE en lupus nefritis. 
Ik was plezierig verrast door de vanzelfsprekendheid en het vertrouwen waarmee hij me 
in zijn onderzoek betrok. Ik heb van hem veel geleerd over SLE, lupus nefritis en het 
wetenschappelijk onderzoek. Ik ben hem zeer dankbaar voor de deuren die hij voor me 
geopend heeft om mijn onderzoeken zo goed mogelijk uit te kunnen voeren. Daarnaast 
waardeer ik het zeer dat hij heeft willen meedenken en het mede mogelijk heeft gemaakt 
om mijn onderzoek uit te bouwen tot een proefschrift.  
 
 Het was mijn droom om de psychologie en geneeskunde in één proefschrift te 
verenigen en mijn promotor prof. dr. Ad Kaptein heeft het mogelijk gemaakt om deze 
droom te verwezenlijken! Ik heb genoten van zijn enthousiasme, zijn onuitputtelijke bron 
van ideeën en zijn werkijver. Ik ben hem zeer dankbaar voor zijn begeleiding die ik als zeer 
warm, motiverend en behulpzaam heb ervaren. Zonder zijn vertrouwen en geduld was het 
me niet gelukt om mijn proefschrift te voltooien. Meerdere keren heb ik het gevoel gehad 
dat een voltooid proefschrift een niet te bereiken doel was geworden, maar een e-mail of 
gesprek met Ad was altijd in staat me weer te inspireren en te motiveren om door te gaan.  
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 De medewerkers van de afdelingen nierziekten en pathologie van het LUMC, 
Rheumatology van het Auckland City Hospital en Psychological Medicine van de University 
of Auckland ben ik zeer dankbaar voor hun hulp bij het werven van de patiënten en de 
dataverzameling. In het bijzonder wil ik dr. Elizabeth Broadbent bedanken. Ik ben haar 
zeer dankbaar voor de mogelijkheden die ze me geboden heeft om mijn onderzoek in 
Nieuw-Zeeland uit te voeren. De voorafgaande gesprekken en de samenwerking aldaar 
hebben me veel inspiratie en werkplezier opgeleverd. Haar gastvrijheid en professionele 
begeleiding hebben veel voor mij betekend.  
I am grateful for all the help from the colleagues from the departments of 
Nephrology and Pathology from the LUMC, Rheumatology of Auckland City Hospital and 
Psychological Medicine from the University of Auckland with patient recruitment and data 
collection. In particular, I would like to thank dr. Elizabeth Broadbent. I am very thankful 
for the opportunities she has given me to do my research in New Zealand. The preceding 
discussions and team work have given me much inspiration and job satisfaction. Her 
hospitality and professional support have meant a lot to me.  
 
  En natuurlijk wil ik alle patiënten bedanken die hebben willen deelnemen aan het 
onderzoek. Ik ben hun dankbaar voor hun toewijding en enthousiasme. Het directe 
contact heeft een belangrijke bijdrage geleverd aan mijn inzicht in hun ziekte.  
And of course I would like to thank all the patients who participated in my studies. 
I am thankful for their dedication and enthusiasm. The direct contact has played an 
important role in my understanding of their illness.  
 
 De aanmoedigende woorden vanuit velerlei hoeken hebben me de afgelopen 
jaren enorm gesteund. In de laatste maanden zijn in het bijzonder Hanneke Gouma en Rob 
de Vries belangrijk voor mij geweest. Zonder Hanneke’s advies om mezelf tijd te gunnen 
om mijn proefschrift af te maken, was het nu misschien nog steeds niet af geweest! En 
Rob maakte het mede mogelijk om deze tijd ook te nemen, waarvoor ik erg dankbaar ben.  
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Een laatste woord van dank is voor mijn lieve vrienden, vriendinnen en mijn 
ouders. Jullie niet-aflatende interesse in de vooruitgang van mijn proefschrift en 
bemoedigende woorden hebben veel voor mij betekend. In het bijzonder wil ik mijn steun 
en toeverlaat in het hele leven, mijn aanstaande echtgenoot, bedanken. Arjen, het was op 
jouw advies dat ik contact zocht met Ad, wat een van de belangrijkste stappen voor mijn 
proefschrift is geweest! Maar juist ook daarna zijn je adviezen, vertrouwen en steun van 
een onschatbare waarde geweest. Zonder jou aan mijn zijde was mijn proefschrift nooit 
geworden wat het nu is! 
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Gabriëlle Daleboudt was born on October 17
th
 1983 in Delft. She completed 
secondary education at the Erasmiaans Gymnasium in Rotterdam in June 2002 and in 
September of that same year she started studying Psychology at Leiden University. In 2004 
she decided to switch her full-time studies to medical school, also at Leiden University. 
She completed Psychology in the following years in part-time. Her first research activities 
in 2006 at the departments of Pathology and Nephrology at LUMC were supervised by 
Ingeborg Bajema and Stefan Berger. She contacted Ad Kaptein in 2007 for guidance of the 
psychological aspects of her research. She completed part of her research in Auckland, 
New Zealand, where she worked for 6 months under supervision of Elizabeth Broadbent.  
In 2010, she obtained her master’s degree in Psychology and in 2012 she received her 
Medical Degree. In March 2013 she started her training as a general physician at the 
department of Public Health and Eerstelijnsgeneeskunde at LUMC. At the annual patient 
conference of the NVLE and Lupus Nederland in May 2014, Gabriëlle received the Lupus 
Award for her PhD research. 
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Gabriëlle Daleboudt werd op 17 oktober 1983 geboren te Delft. Zij behaalde haar 
eindexamen VWO aan het Erasmiaans Gymnasium te Rotterdam in juni 2002 en in 
september van dat jaar begon zij met de studie Psychologie aan de Universiteit Leiden. In 
2004 besloot zij over te stappen naar de voltijd opleiding Geneeskunde aan de Universiteit 
Leiden. Haar studie Psychologie heeft zij in de daarop volgende jaren in deeltijd afgerond. 
Haar eerste onderzoeksactiviteiten vonden plaats in 2006 op de afdelingen Pathologie en 
Nefrologie van het LUMC onder begeleiding van Ingeborg Bajema en Stefan Berger. In 
2007 benaderde zij Ad Kaptein voor begeleiding van het psychologische deel van haar 
onderzoek. Een deel van haar onderzoek voltooide ze in Auckland, Nieuw Zeeland, waar zij 
6 maanden verbleef en werd begeleid door Elizabeth Broadbent. In 2010 behaalde ze haar 
doctoraal Psychologie en in 2012 deed ze haar artsexamen. Sinds maart 2013 is zij bezig 
met de huisartsenopleiding  op de afdeling Public Health en Eerstelijnsgeneeskunde in het 
LUMC. Op het jaarlijkse patiënten congres van de NVLE en Lupus Nederland in mei 2014 
ontving Gabriëlle de Lupus Award voor haar promotieonderzoek.  
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